WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, October 14, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L23	(L19 AND olfactory)	62
☐	L22	(L19 AND inhale)	7
☐	L21	L19 AND nasal administration	23
☐	L20	L19 AND inhalation therapy	8
☐	L19	L18 AND coronary artery disease	805
☐	L18	FGF-1 OR FGF-2 OR aFGF OR bFGF OR VEGF	12449
☐	L17	L16 NOT Ashkenazi-Avi-J.IN.	173
☐	L16	L15 NOT Ashkenazi-Avi.IN.	173
☐	L15	L14 NOT Rosen-Craig.IN.	245
☐	L14	L13 NOT Rosen-Craig-A.IN.	245
☐	L13	L12 AND nasal	281
☐	L12	L11 AND inhalation	345
☐	L11	(L7 AND coronary artery disease)	540
☐	L10	L9 AND coronary artery disease	26
☐	L9	L8 AND inhalation	532
☐	L8	L6 AND growth factor	2460
☐	L7	530/300,350,399.CCLS.	18515
☐	L6	514/2.CCLS.	6335
☐	L5	Franco.IN.	6556
☐	L4	Franco-W.IN.	4
☐	L3	Franco-W-P.IN.	3
☐	L2	Franco-Wayne.IN.	0
☐	L1	(Franco-Wayne-P.IN.)	7

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20040167070 A1

Using default format because multiple data bases are involved.

L24: Entry 1 of 6 File: PGPB Aug 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040167070
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040167070 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20040116349 A1

L24: Entry 2 of 6 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040116349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040116349 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising

the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 3. Document ID: US 20040023863 A1

L24: Entry 3 of 6 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023863
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023863 A1

TITLE: Methods of use growth factors for treating heart disease

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 4. Document ID: US 20020058612 A1

L24: Entry 4 of 6 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des.

☐ 5. Document ID: US 6759386 B2

L24: Entry 5 of 6 File: USPT Jul 6, 2004

US-PAT-NO: 6759386
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des.

☐ 6. Document ID: US 20040167070 A1, WO 200177328 A1, AU 200155237 A, US 20020058612 A1, US 20040023863 A1, US 20040116349 A1, US 6759386 B2

L24: Entry 6 of 6 File: DWPI Aug 26, 2004

DERWENT-ACC-NO: 2002-049148

DERWENT-WEEK: 200457

TITLE: Treatment of heart disease brought on by e.g. myocardial infarction, unstable angina, thrombolytic therapy, bypass surgery or angioplasty, comprises multi-tiered administration of growth factors

INVENTOR: FRANCO, W P

PRIORITY-DATA: 2000US-195624P (April 6, 2000), 2001US-0828330 (April 6, 2001), 2003US-0730831 (December 9, 2003), 2003US-0731197 (December 9, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040167070 A1	August 26, 2004		000	A61K038/18
WO 200177328 A1	October 18, 2001	E	089	C12N015/12
AU 200155237 A	October 23, 2001		000	
US 20020058612 A1	May 16, 2002		000	A61L009/04
US 20040023863 A1	February 5, 2004		000	A61K038/18
US 20040116349 A1	June 17, 2004		000	A61K038/18
US 6759386 B2	July 6, 2004		000	A61K038/18

INT-CL (IPC): A61 K 38/18; A61 L 9/04; C07 K 5/00; C07 K 14/52; C12 N 15/12

ABSTRACTED-PUB-NO: US20020058612A
BASIC-ABSTRACT:

NOVELTY - Treatment of heart disease comprising multi-tiered administration of growth factors.

DETAILED DESCRIPTION - Systematic multi-tiered treatment of heart disease comprises delivery of therapeutic growth factor proteins (GFP) by:

(a) oral inhalation of at least one dose of an effective amount of a first therapeutic GFP formulation in a patient displaying symptoms of heart disease;

(b) monitoring levels of CPK-MB in the patient;

(c) determining whether administration of the GFP formulation was effective in treating the symptoms;

(d) administering one or ore additional doses of a second GFP formulation by a delivery method more invasive than oral inhalation; and

(e) repeating steps (b)-(d) until there is a clinical indication of amelioration of the symptoms of heart disease in the patient, or until there is a contraindication to continued treatment.

INDEPENDENT CLAIMS are also included for the following:

(1) administration of therapeutic amounts of GFP formulation for treatment of heart disease by inhalation;

(2) monitoring clinical effectiveness of administration of a GFP formulation in the treatment of heart disease comprising:

(i) performing an assay on a sample of biological fluid from a patient displaying symptoms of heart disease to determine the amount of CPK-MB present in the fluid;

(ii) administering a therapeutic amount of GFP formulation to the patient; and

(iii) repeating steps (i) and (ii) until the assayed amount of CPK-MB in the biological fluid has decreased by an amount sufficient to indicate the clinical effectiveness of the administration of the GFP formulation.

ACTIVITY - Cardiant. Pellets containing 10 or 100 micro g basic fibroblast growth factor (bFGF) or placebo were placed on the epicardial surface in patients with a viable and ischemic myocardial area that could not be revascularized, during coronary artery bypass surgery. After 16 months patients were angina free with the exception of 3 people in the placebo group and 1 patient who received the 10 micro g pellet.

MECHANISM OF ACTION - Angiogenesis stimulator.

USE - The method is used for the treatment of heart disease, where the symptoms are chronic or acute, especially where the symptoms are brought on by myocardial infarction, unstable angina, acute anginal attack or reperfusion injury, preferably induced by thrombolytic therapy, bypass surgery or angioplasty (claimed).

ADVANTAGE - Inhalation is the least invasive method of delivering the growth factors to the lungs. Prior are invasive approaches have not been successful in promoting angiogenesis. The pericardial space serves as a drug delivery reservoir for delivery of therapeutic agents to the heart. Use of a catheter avoids the need for open chest surgery. Intravenous infusions are practical, low cost and can be used in a broad group of patients. Treatment can be repeated easily and may not require any special facilities.
ABSTRACTED-PUB-NO:

WO 200177328A EQUIVALENT-ABSTRACTS:

NOVELTY - Treatment of heart disease comprising multi-tiered administration of growth factors.

DETAILED DESCRIPTION - Systematic multi-tiered treatment of heart disease comprises delivery of therapeutic growth factor proteins (GFP) by:

(a) oral inhalation of at least one dose of an effective amount of a first therapeutic GFP formulation in a patient displaying symptoms of heart disease;

(b) monitoring levels of CPK-MB in the patient;

(c) determining whether administration of the GFP formulation was effective in treating the symptoms;

(d) administering one or ore additional doses of a second GFP formulation by a delivery method more invasive than oral inhalation; and

(e) repeating steps (b)-(d) until there is a clinical indication of amelioration of the symptoms of heart disease in the patient, or until there is a contraindication to continued treatment.

INDEPENDENT CLAIMS are also included for the following:

(1) administration of therapeutic amounts of GFP formulation for treatment of heart disease by inhalation;

(2) monitoring clinical effectiveness of administration of a GFP formulation in the treatment of heart disease comprising:

(i) performing an assay on a sample of biological fluid from a patient displaying symptoms of heart disease to determine the amount of CPK-MB present in the fluid;

(ii) administering a therapeutic amount of GFP formulation to the patient; and

(iii) repeating steps (i) and (ii) until the assayed amount of CPK-MB in the biological fluid has decreased by an amount sufficient to indicate the clinical effectiveness of the administration of the GFP formulation.

ACTIVITY - Cardiant. Pellets containing 10 or 100 micro g basic fibroblast growth factor (bFGF) or placebo were placed on the epicardial surface in patients with a viable and ischemic myocardial area that could not be revascularized, during coronary artery bypass surgery. After 16 months patients were angina free with the exception of 3 people in the placebo group and 1 patient who received the 10 micro g pellet.

MECHANISM OF ACTION - Angiogenesis stimulator.

USE - The method is used for the treatment of heart disease, where the symptoms are chronic or acute, especially where the symptoms are brought on by myocardial infarction, unstable angina, acute anginal attack or reperfusion injury, preferably induced by thrombolytic therapy, bypass surgery or angioplasty (claimed).

ADVANTAGE - Inhalation is the least invasive method of delivering the growth factors to the lungs. Prior are invasive approaches have not been successful in promoting angiogenesis. The pericardial space serves as a drug delivery reservoir for delivery of therapeutic agents to the heart. Use of a catheter avoids the need for open chest surgery. Intravenous infusions are practical, low cost and can be used in a broad group of patients. Treatment can be repeated easily and may not require any special facilities.

Terms	Documents
L23 AND L10	6

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 20040167070 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 7 File: PGPB Aug 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040167070
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040167070 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 2. Document ID: US 20040116349 A1

L1: Entry 2 of 7 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040116349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040116349 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising

the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 3. Document ID: US 20040023863 A1

L1: Entry 3 of 7 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023863
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023863 A1

TITLE: Methods of use growth factors for treating heart disease

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 4. Document ID: US 20020058612 A1

L1: Entry 4 of 7 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 5. Document ID: US 6759386 B2

L1: Entry 5 of 7 File: USPT Jul 6, 2004

US-PAT-NO: 6759386
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 6. Document ID: US 4378347 A

L1: Entry 6 of 7 File: USPT Mar 29, 1983

US-PAT-NO: 4378347
DOCUMENT-IDENTIFIER: US 4378347 A

TITLE: Composition for treating the heart for myocardial infarction

DATE-ISSUED: March 29, 1983

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Wethersfield	CT	06109	

US-CL-CURRENT: 424/565; 514/21, 514/777

ABSTRACT:

An effective dose of FGF for treatment of the heart is suspended in a slow release carrier and used in treatment of ischemic heart disease.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1,2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 7. Document ID: US 4296100 A

L1: Entry 7 of 7 File: USPT Oct 20, 1981

US-PAT-NO: 4296100
DOCUMENT-IDENTIFIER: US 4296100 A
**** See image for Certificate of Correction ****

TITLE: Method of treating the heart for myocardial infarction

DATE-ISSUED: October 20, 1981

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Wethersfield	CT	06109	

US-CL-CURRENT: 424/565; 514/21

ABSTRACT:

The heart is treated with fibroblast growth factor to alleviate conditions caused by myocardial infarctions as by reducing the size of damaged heart areas. An effective dose of fibroblast growth factor when applied to the heart is found to increase blood flow in affected areas for a period of at least 4 hours and often more.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(Franco-Wayne-P.IN.)	7

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20040167070 A1, WO 200177328 A1, AU 200155237 A, US 20020058612 A1, US 20040023863 A1, US 20040116349 A1, US 6759386 B2

Using default format because multiple data bases are involved.

L2: Entry 1 of 3 File: DWPI Aug 26, 2004

DERWENT-ACC-NO: 2002-049148
DERWENT-WEEK: 200457
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Treatment of heart disease brought on by e.g. myocardial infarction, unstable angina, thrombolytic therapy, bypass surgery or angioplasty, comprises multi-tiered administration of growth factors

INVENTOR: FRANCO, W P

PRIORITY-DATA: 2000US-195624P (April 6, 2000), 2001US-0828330 (April 6, 2001), 2003US-0730831 (December 9, 2003), 2003US-0731197 (December 9, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040167070 A1	August 26, 2004		000	A61K038/18
WO 200177328 A1	October 18, 2001	E	089	C12N015/12
AU 200155237 A	October 23, 2001		000	
US 20020058612 A1	May 16, 2002		000	A61L009/04
US 20040023863 A1	February 5, 2004		000	A61K038/18
US 20040116349 A1	June 17, 2004		000	A61K038/18
US 6759386 B2	July 6, 2004		000	A61K038/18

INT-CL (IPC): A61 K 38/18; A61 L 9/04; C07 K 5/00; C07 K 14/52; C12 N 15/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | [illegible] | Claims | KWIC | Draw. Des

☐ 2. Document ID: US 4378347 A

L2: Entry 2 of 3 File: DWPI Mar 29, 1983

DERWENT-ACC-NO: 1983-36768K
DERWENT-WEEK: 198315
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Fibroblast growth factor in slow-release carrier - for treating ischaemic heart disease

INVENTOR: FRANCO, W P

PRIORITY-DATA: 1981US-0274722 (June 18, 1981), 1980US-0164074 (June 30, 1980)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4378347 A	March 29, 1983		005	

INT-CL (IPC): A61K 35/55

ABSTRACTED-PUB-NO: US 4378347A
BASIC-ABSTRACT:

A dose of fibroblast growth factor (FGF) effective for treating the heart, suspended in a slow-release carrier for use in treatment of ischaemic heart disease is claimed. The carrier pref. comprises dextran beads. Admin. is pref. by direct injection into the heart, the dosage being 0.01-1000 mg per 100 g of heart. Intravenous, subcutaneous or oral admin. is also possible.

Admin. of the dose after myocardial infarction produces a sustained increase in blood flow in and around the damaged areas of myocardium and reduces the extent of damage.

☐ 3. Document ID: US 4296100 A, GB 2090528 A, GB 2090528 B, JP 57500878 W, WO 8200098 A

L2: Entry 3 of 3 File: DWPI Oct 20, 1981

DERWENT-ACC-NO: 1981-83435D
DERWENT-WEEK: 198145

TITLE: Treating the heart with fibroblast growth factor - to alleviate conditions caused by myocardial infarction(s)

INVENTOR: FRANCO, W P

PRIORITY-DATA: 1980US-0164074 (June 30, 1980), 1981US-0274722 (June 18, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4296100 A	October 20, 1981		005	
GB 2090528 A	July 14, 1982		000	
GB 2090528 B	August 15, 1984		000	
JP 57500878 W	May 20, 1982		000	
WO 8200098 A	January 21, 1982	E	000	

INT-CL (IPC): A61K 9/00; A61K 35/55

ABSTRACTED-PUB-NO: GB 2090528B
BASIC-ABSTRACT:

Treatment of an area in the heart of a patient subjected to ischemic heart disease comprises admin. of fibroblast growth factor (FGF) to the heart.

After the treatment blood flow is increased for sustained periods after myocardial infarction. The treatment is useful after myocardial infarction (or when there is an indication of impeding myocardial infarction), when blood flow is increased in the treatment area and in surrounding areas. It is also useful with heart surgery procedures e.g. coronary by-pass operations, to reduce the quantity of myocardium

damage due to ischemic disease. FGF is a known mitogenic agent for a variety of mesodermal cells in vitro and it has been used to increase vascularisation in the cornea of laboratory animals. Dose is 10 micrograms-1g.100g heart by direct injection, esp. intravenously. The treatment is useful in man, cats, dogs, cows, etc.

ABSTRACTED-PUB-NO:

US 4296100A EQUIVALENT-ABSTRACTS:

A composition for use in the treatment of ischemic heart disease, comprising fibroblast growth factor (FGF) in association with a carrier material which ensures a slow release of the FGF therefrom, the carrier material being dextran or an albumin macro-aggregate.

Terms	Documents
Franco-W-P.IN.	3

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: WO 2003033917 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 4 File: DWPI Apr 24, 2003

DERWENT-ACC-NO: 2003-343371
DERWENT-WEEK: 200332
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: A double acting actuator for exerting tensile and thrust forces comprise a flexible annular cylinder with top and bottom end caps forming two chambers each with an inlet for a pressurizing fluid

INVENTOR: FERRARESI, C; FRANCO, W ; QUAGLIA, G

PRIORITY-DATA: 2001IT-TO00984 (October 17, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2003033917 A1	April 24, 2003	E	017	F15B015/10

INT-CL (IPC): F15 B 15/10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 2. Document ID: IT 1292335 B

L4: Entry 2 of 4 File: DWPI Jan 29, 1999

DERWENT-ACC-NO: 2001-467388
DERWENT-WEEK: 200151
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Muscular actuator using fluid with straight fibers - NoAbstract

INVENTOR: FERRARESI, C; FRANCO, W ; MANUELLO BERTETTO, A

PRIORITY-DATA: 1997IT-TO00499 (June 9, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
IT 1292335 B	January 29, 1999		000	F15B000/00

INT-CL (IPC): F15 B 0/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 3. Document ID: BE 1010130 A4

L4: Entry 3 of 4 File: DWPI Jan 6, 1998

DERWENT-ACC-NO: 1998-077674
DERWENT-WEEK: 199808

TITLE: Aeration of polluted earth for biological purification - using cutting and lifting rotors with efficient displacement for good aeration and subsequent purification

INVENTOR: FRANCO, E; FRANCO, W

PRIORITY-DATA: 1996BE-0000265 (March 25, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
BE 1010130 A4	January 6, 1998	F	012	B09C000/00

INT-CL (IPC): B09 C 0/00; C05 F 0/00

ABSTRACTED-PUB-NO: BE 1010130A
BASIC-ABSTRACT:

A machine for aerating earth consists of a hollow structure, mounted on wheels, supporting adjacent and non-vertically mounted rotors. Also claimed is a method of treating earth using the machine described above, in particular to aerate for biological purification purposes, where the earth is treated in a long heap and redeposited behind the machine.

ADVANTAGE - The earth is displaced efficiently for good aeration and subsequent purification.

☐ 4. Document ID: WO 9211439 A1, AU 9190804 A, BE 1004106 A3, EP 561936 A1

L4: Entry 4 of 4 File: DWPI Jul 9, 1992

DERWENT-ACC-NO: 1992-250145
DERWENT-WEEK: 199230

TITLE: Handling long elements such as pipes - involves upper frame carried by machine and connected to power take=off and intermediate frame which can be inclined to upper frame

INVENTOR: FRANCO, E; FRANCO, W

PRIORITY-DATA: 1990BE-0001238 (December 20, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9211439 A1	July 9, 1992	E	022	E21B019/14
AU 9190804 A	July 22, 1992		000	E21B019/14

BE 1004106 A3	September 22, 1992	F	016	E21B000/00
EP 561936 A1	September 29, 1993	E	022	E21B019/14

INT-CL (IPC): E02F 3/96; E21B 19/14; E21B 19/15

ABSTRACTED-PUB-NO: WO 9211439A
BASIC-ABSTRACT:

The device for handling long elements has an upper frame (10) carried by a mobile machine (1) and an intermediate frame (20) is mounted on the upper frame. This intermediate frame can perform a movement of inclination with respect to the upper frame. In its turn the intermediate frame supports a lower frame (30) which can move in a longitudinal direction.

On the lower frame is a grip (40) capable of lifting the long elements and holding them. The power take off is a hydraulic power take-off.

USE/ADVANTAGE - Gives independent control to grip and hold long elements such as pipes.

Terms	Documents
Franco-W.IN.	4

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20020058612 A1

Using default format because multiple data bases are involved.

L15: Entry 1 of 2 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 2. Document ID: US 6759386 B2

L15: Entry 2 of 2 File: USPT Jul 6, 2004

US-PAT-NO: 6759386
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart

disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Terms	Documents
L14 AND CPK-MB	2

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6759386 B2

Using default format because multiple data bases are involved.

L20: Entry 1 of 1 File: USPT Jul 6, 2004

US-PAT-NO: 6759386
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L19 AND CPK-MB	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 26 of 26 returned.

☐ 1. Document ID: US 20040185440 A9

Using default format because multiple data bases are involved.

L10: Entry 1 of 26 File: PGPB Sep 23, 2004

PGPUB-DOCUMENT-NUMBER: 20040185440
PGPUB-FILING-TYPE: corrected
DOCUMENT-IDENTIFIER: US 20040185440 A9

TITLE: 125 human secreted proteins

PUBLICATION-DATE: September 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Feng, Ping	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Ni, Jian	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Soppet, Daniel R.	Centreville	VA	US	
Moore, Paul A.	Germantown	MD	US	
Kyaw, Hla	Frederick	MD	US	
LaFleur, David W.	Washington	DC	US	
Shi, Yanggu	Gaithersburg	MD	US	
Janat, Fouad	Westerly	RI	US	
Endress, Gregory A.	Potomac	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20040097401 A1

L10: Entry 2 of 26 File: PGPB May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Datta, Debatosh	Kolkata		IN	

US-CL-CURRENT: 514/2; 514/564, 514/565

ABSTRACT:

Present invention features methods for induction of angiogenesis by administration of lysine (l-&d-) or lysine oligomers (molecular weight approx between 500 and 2500), both homo and hetero-oligomers, consisting of either l-or d- or both enantiomers.

Induction of Angiogenesis by the methods of the invention can be use in therapeutic angiogenesis, in, for example, treatment of ischaemic conditions and syndromes, such as chronic wounds (e.g diabetic wounds and ulcers, bed sores and other pressure sores, burns of various degrees and extents etc.) as well as coronary and cerebral ischaemia and peripheral vascular ischaemic conditions. Induction of angiogenesis by the described methods also will be useful in inducing/enhancing radiosesitivity in some solid tumors.

☐ 3. Document ID: US 20040033971 A1

L10: Entry 3 of 26 File: PGPB Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033971
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040033971 A1

TITLE: Polypeptides and nucleic acids encoding same

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gangolli, Esha A.	Madison	CT	US	
Patturajan, Meera	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Stone, David J.	Guilford	CT	US	
Anderson, David	Branford	CT	US	

Shimkets, Richard A.	Guilford	CT	US
Burgess, Catherine E.	Wethersfield	CT	US
Zerhusen, Bryan D.	Branford	CT	US
Liu, Xiaohong	Branford	CT	US
Spytek, Kimberly A.	New Haven	CT	US
Casman, Stacie J.	North Haven	CT	US
Boldog, Ference L.	North Haven	CT	US
Smithson, Glennda	Guilford	CT	US
Li, Li	Branford	CT	US
Ji, Weizhen	Branford	CT	US
MacDougall, John R.	Hamden	CT	US

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/7.1, 514/2, 530/387.1, 536/23.1

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention farther discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

☐ 4. Document ID: US 20030215840 A1

L10: Entry 4 of 26 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	

Acton, Susan L.	Lexington	MA	US
Donoghue, Mary A.	West Roxbury	MA	US
Stagliano, Nancy	North Reading	MA	US
Perodin, Jacqueline	Arlington	MA	US
Rodrigue-Way, Amelie	Malden	MA	US

US-CL-CURRENT: 435/6; 424/146.1, 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

☐ 5. Document ID: US 20030215452 A1

L10: Entry 5 of 26 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215452
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215452 A1

TITLE: Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carroll, Joseph M.	Cambridge	MA	US	
Healy, Aileen	Medford	MA	US	
Weich, Nadine S.	Brookline	MA	US	
Kelly, Louise M.	Brookline	MA	US	

US-CL-CURRENT: 424/146.1; 435/6, 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

☐ 6. Document ID: US 20030211472 A1

L10: Entry 6 of 26 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211472
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211472 A1

TITLE: 125 human secreted proteins

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Feng, Ping	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Ni, Jian	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Soppet, Daniel R.	Centreville	VA	US	
Moore, Paul A.	Germantown	MD	US	
Kyaw, Hla	Frederick	MD	US	
LaFleur, David W.	Washington	DC	US	
Shi, Yanggu	Gaithersburg	MD	US	
Janat, Fouad	Westerly	RI	US	
Endress, Gregory A.	Potomac	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

☐ 7. Document ID: US 20030199425 A1

L10: Entry 7 of 26 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199425
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030199425 A1

TITLE: Compositions and methods for treatment of hyperplasia

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Desai, Neil P.	Los Angeles	CA	US	
Soon-Shiong, Patrick	Los Angeles	CA	US	

US-CL-CURRENT: 514/2; 424/45, 514/291, 514/365, 514/449

ABSTRACT:

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

☐ 8. Document ID: US 20030154504 A1

L10: Entry 8 of 26 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030154504
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030154504 A1

TITLE: Methods and compositions for modulating carbohydrate metabolism

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Farese, Robert V. JR.	San Francisco	CA	US	
Chen, Hubert C.	San Francisco	CA	US	

US-CL-CURRENT: 800/18; 514/2, 514/3

ABSTRACT:

Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake into cells and assimilation into glycogen. Also provided are pharmaceutical compositions for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering conditions associated with abnormal carbohydrate metabolism, such as obesity or diabetes.

☐ 9. Document ID: US 20030152574 A1

L10: Entry 9 of 26 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas Joseph	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	

US-CL-CURRENT: 424/146.1; 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential

expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

☐ 10. Document ID: US 20030092658 A1

L10: Entry 10 of 26 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092658
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092658 A1

TITLE: Novel human enzyme family members and uses thereof

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyers, Rachel E.	Newton	MA	US	
Glucksmann, Maria Alexandra	Lexington	MA	US	
Rudolph-Owen, Laura A.	Jamaica Plain	MA	US	

US-CL-CURRENT: 514/44; 424/130.1, 435/6, 514/2

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

☐ 11. Document ID: US 20030083231 A1

L10: Entry 11 of 26 File: PGPB May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030083231 A1

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D- -glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17- -one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost- -4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandros- tane that can be used in the treatment method.

☐ 12. Document ID: US 20030073118 A1

L10: Entry 12 of 26 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073118
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073118 A1

TITLE: MID 9002, a human sulfatase family member and uses therefor

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Williamson, Mark W.	Saugus	MA	US	

US-CL-CURRENT: 435/6; 424/130.1, 514/1, 514/2, 514/44

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated MID 9002 nucleic acid molecules, which encode novel sulfatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MID 9002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MID 9002 gene has been introduced or disrupted. The invention still further provides isolated MID 9002 proteins, fusion proteins, antigenic peptides and anti-MID 9002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

☐ 13. Document ID: US 20020151046 A1

L10: Entry 13 of 26 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151046
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151046 A1

TITLE: 52871, a novel human G protein coupled receptor and uses thereof

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glucksmann, Maria Alexandra	Lexington	MA	US	
Silos-Santiago, Inmaculada	Cambridge	MA	US	

US-CL-CURRENT: 435/320.1; 435/325, 435/6, 435/69.1, 435/7.1, 514/2, 530/324, 530/387.7, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 52871 nucleic acid molecules, which encode novel G-Protein Coupled Receptor molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52871 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52871 gene has been introduced or disrupted. The invention still further provides isolated 52871 proteins, fusion proteins, antigenic peptides and anti-52871 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 14. Document ID: US 20020119913 A1

L10: Entry 14 of 26 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119913
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020119913 A1

TITLE: 61833, a novel human pyridoxyl-dependent decarboxylase family member and uses thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glucksmann, Maria Alexandra	Lexington	MA	US	

US-CL-CURRENT: 514/2; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.2, 530/324, 530/387.9, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 61833 nucleic acid molecules, which encode novel pyridoxyl-dependent decarboxylase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 61833 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 61833 gene has been introduced or disrupted. The invention still further provides isolated 61833 proteins, fusion proteins, antigenic peptides and anti-61833 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 15. Document ID: US 20020061521 A1

L10: Entry 15 of 26 File: PGPB May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	

Ruben, Steven M.	Olney	MD	US
Barash, Steven C.	Rockville	MD	US

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

☐ 16. Document ID: US 20020058612 A1

L10: Entry 16 of 26 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment

with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

☐ 17. Document ID: US 20020037832 A1

L10: Entry 17 of 26 File: PGPB Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037832
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Soren	Abyhoj		DK	
Frokiaer, Jorgen	Abyhoj		DK	
Jonassen, Thomas Engelbrecht Norkild	Frederiksberg		DK	
Bjerke, Thorbjorn	Fredensborg		DK	

US-CL-CURRENT: 514/2; 514/169

ABSTRACT:

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

☐ 18. Document ID: US 6787519 B2

L10: Entry 18 of 26 File: USPT Sep 7, 2004

US-PAT-NO: 6787519
DOCUMENT-IDENTIFIER: US 6787519 B2

TITLE: Methods of treating disorders related to apoE

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Huang; Yadong	San Francisco	CA		

Mahley; Robert W. San Francisco CA

US-CL-CURRENT: 514/2; 514/17, 514/18, 530/300, 530/329

ABSTRACT:

The present invention provides methods inhibiting formation of neurofibrillary tangles; and methods for treating disorders relating to apolipoprotein E (apoE) in a subject. The methods generally involve reducing the level of a carboxyl-terminal truncated form of apoE in a neuronal cell of a subject. The invention further provides isolated cells comprising a nucleic acid molecule encoding a carboxyl-terminal truncated form of apoE; and methods of screening compounds using the cells. The invention further provides compounds that inhibit an apoE cleavage enzyme, and that reduce the formation of neurofibrillary tangles in a neuronal cell. The invention further provides transgenic non-human animals that include as a transgene a nucleic acid that encodes a carboxyl-terminal truncated form of apoE; as well as methods of screening compounds using transgenic animals.

16 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 19. Document ID: US 6759386 B2

L10: Entry 19 of 26 File: USPT Jul 6, 2004

US-PAT-NO: 6759386
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D

☐ 20. Document ID: US 6737404 B2

L10: Entry 20 of 26 File: USPT May 18, 2004

US-PAT-NO: 6737404
DOCUMENT-IDENTIFIER: US 6737404 B2

TITLE: Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Springer; Barry A.	Wilmington	DE		
Pantoliano; Michael W.	Boxford	PA		
Sharp; Celia M.	Doylestown	PA		

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

30 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D

☐ 21. Document ID: US 6605592 B2

L10: Entry 21 of 26 File: USPT Aug 12, 2003

US-PAT-NO: 6605592
DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		
Komatsoulis; George A.	Silver Spring	MD		
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Soppet; Daniel R.	Centreville	VA		
Young; Paul E.	Gaithersburg	MD		
Wei; Ping	Brookeville	MD		
Florence; Kimberly A.	Rockville	MD		

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1, 435/71.1, 435/71.2, 514/12, 514/8, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

☐ 22. Document ID: US 6541224 B2

L10: Entry 22 of 26 File: USPT Apr 1, 2003

US-PAT-NO: 6541224
DOCUMENT-IDENTIFIER: US 6541224 B2
**** See image for Certificate of Correction ****

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2, 530/350, 530/351

ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 23. Document ID: US 6521211 B1

L10: Entry 23 of 26 File: USPT Feb 18, 2003

US-PAT-NO: 6521211
DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51, 514/18, 514/2, 600/431, 600/437

ABSTRACT:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or

receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 24. Document ID: US 6475796 B1

L10: Entry 24 of 26 File: USPT Nov 5, 2002

US-PAT-NO: 6475796
DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothelial growth factor variants

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollitt; N. Stephen	Los Altos	CA		
Abraham; Judith A.	San Jose	CA		

US-CL-CURRENT: 435/455; 424/198.1, 514/2, 530/350

ABSTRACT:

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

17 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17

☐ 25. Document ID: US 6407135 B1

L10: Entry 25 of 26 File: USPT Jun 18, 2002

US-PAT-NO: 6407135
DOCUMENT-IDENTIFIER: US 6407135 B1

TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		
Wang; Tingmin	San Marcos	CA		

US-CL-CURRENT: 514/423; 514/2, 514/514, 530/402, 548/565, 548/573

ABSTRACT:

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

21 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 26. Document ID: US 6403552 B1

L10: Entry 26 of 26 File: USPT Jun 11, 2002

US-PAT-NO: 6403552
DOCUMENT-IDENTIFIER: US 6403552 B1

TITLE: Ob receptor and methods for the diagnosis and treatment of body weight disorders

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tartaglia; Louis A.	Watertown	MA		
Tepper; Robert I.	Weston	MA		
Culpepper; Janice A.	Brookline	MA		
White; David W.	Holbrook	MA		

US-CL-CURRENT: 514/2; 424/143.1, 435/69.7, 536/23.4

ABSTRACT:

The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.

41 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 34

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 20040167070 A1

Using default format because multiple data bases are involved.

L20: Entry 1 of 8 File: PGPB Aug 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040167070
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040167070 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20040116349 A1

L20: Entry 2 of 8 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040116349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040116349 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

☐ 3. Document ID: US 20040023863 A1

L20: Entry 3 of 8 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023863
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023863 A1

TITLE: Methods of use growth factors for treating heart disease

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/12

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

☐ 4. Document ID: US 20030036773 A1

L20: Entry 4 of 8 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036773
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036773 A1

TITLE: Systems and methods for treatment of coronary artery disease

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Whitehurst, Todd K.	Frazier Park	CA	US	
McGivern, James P.	Stevenson Ranch	CA	US	
McClure, Kelly H.	Simi Valley	CA	US	
Stultz, Mark R.	Maple Grove	MN	US	

US-CL-CURRENT: 607/3; 607/120

ABSTRACT:

Methods and systems for treatment of coronary artery disease (CAD) include implantation of the discharge portion(s) of a catheter and, optionally, electrodes on a lead, near the tissue(s) to be stimulated. Stimulation pulses, i.e., drug infusion pulses and optional electrical pulses, are supplied by a stimulator implanted remotely, and through the catheter or lead, which is tunneled subcutaneously between the stimulator and stimulation site. Stimulation sites include the coronary arteries, the aorta, the left ventricle, the left atrium, and/or the pulmonary veins, among other locations. Disclosed treatments include drugs used for acute treatment of CAD, for chronic treatment of CAD, to promote angiogenesis, and/or as AGE Crosslink Breakers, among other drugs. For instance, the systems and methods reduce or eliminate the incidence of CAD and related morbidities, improve symptoms resulting from CAD, and/or improve cardiac blood flow, cardiac function, and patient quality of life.

☐ 5. Document ID: US 20020103454 A1

L20: Entry 5 of 8 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020103454
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020103454 A1

TITLE: External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sackner, Marvin A.	Miami Beach	FL	US	
Inman, D. Michael	Miami	FL	US	

US-CL-CURRENT: 604/19

ABSTRACT:

Methods of medical treatment and diagnosis using mediators released by endothelial cells stimulated by external addition of pulses to the circulation are disclosed. The external pulses produce circumferential shear stress in body fluid channels

that subsequently stimulates the endothelial cells to produce mediators that become available for therapeutic and diagnostic purposes. The preferred means of adding external pulses is the mechanical inducement of periodic acceleration of the body or parts of the body by a reciprocating motion platform.

☐ 6. Document ID: US 20020058612 A1

L20: Entry 6 of 8 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

☐ 7. Document ID: US 6759386 B2

L20: Entry 7 of 8 File: USPT Jul 6, 2004

US-PAT-NO: 6759386
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 8. Document ID: US 6673908 B1

L20: Entry 8 of 8 File: USPT Jan 6, 2004

US-PAT-NO: 6673908
DOCUMENT-IDENTIFIER: US 6673908 B1

TITLE: Tumor necrosis factor receptor 2

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stanton, Jr.; Vincent P.	Belmont	MA		

US-CL-CURRENT: 536/22.1; 435/6, 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

10 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L19 AND inhalation therapy	8

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 23 of 23 returned.

☐ 1. Document ID: US 20040185507 A1

Using default format because multiple data bases are involved.

L21: Entry 1 of 23 File: PGPB Sep 23, 2004

PGPUB-DOCUMENT-NUMBER: 20040185507
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040185507 A1

TITLE: Anti-integrin antibodies, compositions, methods and uses

PUBLICATION-DATE: September 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Giles-Komar, Jill	Downingtown	PA	US	
Snyder, Linda	Pottstown	PA	US	
Trikha, Mohit	Paoli	PA	US	
Nakada, Marian T.	Malvern	PA	US	

US-CL-CURRENT: 435/7.2; 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20040120952 A1

L21: Entry 2 of 23 File: PGPB Jun 24, 2004

PGPUB-DOCUMENT-NUMBER: 20040120952
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040120952 A1

TITLE: Anti-TNF antibodies and peptides of human tumor necrosis factor

PUBLICATION-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knight, David M.	Berwin	PA	US	
Shealy, David J.	Downingtown	PA	US	

US-CL-CURRENT: 424/145.1

ABSTRACT:

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20040077648 A1

L21: Entry 3 of 23 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077648
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077648 A1

TITLE: Methods and compositions of novel triazine compounds

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Timmer, Richard T.	Decatur	GA	US	
Alexander, Christopher W.	Norcross	GA	US	
Pillarisetti, Sivaram	Norcross	GA	US	
Saxena, Uday	Atlanta	GA	US	
Campbell, Karen A.	Durham	NC	US	

US-CL-CURRENT: 514/241; 544/212, 544/223

ABSTRACT:

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20040058412 A1

L21: Entry 4 of 23 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058412
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058412 A1

TITLE: Cell populations which co-express CD49c and CD90

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ho, Tony W.	Berwyn	PA	US	
Kopen, Gene C.	Wynnewood	PA	US	
Righter, William F.	Ridley Park	PA	US	
Rutkowski, J. Lynn	Wynnewood	PA	US	
Wagner, Joseph	West Chester	PA	US	
Herring, W. Joseph	Valley Forge	PA	US	
Ragaglia, Vanessa	Newtown Square	PA	US	

US-CL-CURRENT: 435/69.1; 424/93.7, 435/320.1, 435/325, 435/366

ABSTRACT:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous populaton of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.

☐ 5. Document ID: US 20030198954 A1

L21: Entry 5 of 23 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198954
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198954 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 536/23.2

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 6. Document ID: US 20030181379 A1

L21: Entry 6 of 23 File: PGPB Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030181379
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030181379 A1

TITLE: Novel fibroblast growth factor (FGF23) and methods for use

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Econs, Michael	Indianapolis	IN	US	
White, Ken	Carmel	IN	US	
Strom, Tim Matthias	Munchen		DE	
Meitinger, Thomas	Munchen		DE	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.4, 530/399, 536/23.5

ABSTRACT:

The invention relates to novel nucleic acids encoding a fibroblast growth factor-23 (FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 20030176317 A1

L21: Entry 7 of 23 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030176317
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030176317 A1

TITLE: Stabilization of hypoxia inducible factor (HIF) alpha

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guenzler-Pukall, Volkmar	San Leandro	CA	US	
Neff, Thomas B.	Atherton	CA	US	
Wang, Qingjian	Davis	CA	US	
Arend, Michael P.	San Mateo	CA	US	
Flippin, Lee A.	Woodside	CA	US	
Melekhov, Alex	San Mateo	CA	US	

US-CL-CURRENT: 514/1

ABSTRACT:

The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 8. Document ID: US 20030170628 A1

L21: Entry 8 of 23 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170628
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170628 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Bejanin, Stephane	Paris	FR
Tanaka, Hiroaki	Antony	FR

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 530/388.1, 536/23.5

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

9. Document ID: US 20030162186 A1

L21: Entry 9 of 23 File: PGPB Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030162186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030162186 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

10. Document ID: US 20030157485 A1

L21: Entry 10 of 23 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157485
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157485 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 435/7.2, 530/388.26, 536/23.2, 800/8

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 11. Document ID: US 20030152921 A1

L21: Entry 11 of 23 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152921
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152921 A1

TITLE: Full-length human cDNAs encoding potentially secreted proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dumas Milne Edwards, Jean-Baptiste	Paris		FR	
Bougueleret, Lydie	Petit Lancy		CH	
Jobert, Severin	Paris		FR	

US-CL-CURRENT: 435/6; 435/183, 536/23.2

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET

products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 12. Document ID: US 20030096247 A1

L21: Entry 12 of 23 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096247
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096247 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2, 800/8

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 13. Document ID: US 20030092011 A1

L21: Entry 13 of 23 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092011
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092011 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.9, 536/23.2, 800/3

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 14. Document ID: US 20030072737 A1

L21: Entry 14 of 23 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030072737
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030072737 A1

TITLE: Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brines, Michael	Woodbridge	CT	US	
Cerami, Antony	Croton On Hudson	NY	US	
Cerami, Carla	Sleepy Hollow	NY	US	

US-CL-CURRENT: 424/85.1; 530/351

ABSTRACT:

Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of a tissue protective cytokine.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 15. Document ID: US 20030040044 A1

L21: Entry 15 of 23 File: PGPB Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040044
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040044 A1

TITLE: Anti-dual integrin antibodies, compositions, methods and uses

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Heavner, George	Malvern	PA	US	
Giles-Komar, Jill	Downingtown	PA	US	
Snyder, Linda	Pottstown	PA	US	
Trikha, Mohit	Paoli	PA	US	

US-CL-CURRENT: 435/69.1; 424/146.1, 435/320.1, 435/326, 530/387.2, 530/388.26, 536/23.53

ABSTRACT:

The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 16. Document ID: US 20030027248 A1

L21: Entry 16 of 23 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027248
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027248 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/6, 530/350, 536/23.2

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 17. Document ID: US 20030027161 A1

L21: Entry 17 of 23 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027161
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027161 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2, 800/8

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 18. Document ID: US 20030022210 A1

L21: Entry 18 of 23 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022210
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022210 A1

TITLE: T cell induced tissue repair and regeneration

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonyhadi, Mark	Issaquah	WA	US	
Berenson, Ron	Mercer Island	WA	US	

US-CL-CURRENT: 435/6; 424/93.7, 435/368

ABSTRACT:

The present invention relates to methods for the use of T cells or supernatants therefrom, and more particularly, activated T cells, in facilitating and/or regulating the differentiation, de-differentiation, maturation, organization, repair, and regeneration of various cells/tissues. Methods for inducing tissue repair and regeneration in vitro and in vivo are disclosed. The present invention also relates to compositions of cells, including activated T cells and/or cells resulting from the co-culture with activated T cells, and their use in inducing tissue repair and regeneration in vivo.

☐ 19. Document ID: US 20020165191 A1

L21: Entry 19 of 23 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165191
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165191 A1

TITLE: Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moonen, Chrit	Bordeaux		FR	

US-CL-CURRENT: 514/44; 607/108

ABSTRACT:

The invention provides methods for using local heat to control gene expression. The heat shock protein (hsp) gene promoter is recombined with a selected therapeutic gene and expressed in selected cells. Local controlled heating is used to activate the hsp promoter, for example by using focused ultrasound controlled by MRI.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 20. Document ID: US 20020156001 A1

L21: Entry 20 of 23 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020156001
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020156001 A1

TITLE: Novel fibroblast growth factor (FGF23) and methods for use

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Econs, Michael	Indianapolis	IN	US	
White, Ken	Carmel	IN	US	
Strom, Tim Matthias	Munchen		DE	
Meitinger, Thomas	Munchen		DE	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/6, 435/69.1, 530/399, 536/23.5

ABSTRACT:

The invention relates to novel nucleic acids encoding a fibroblast growth factor-23 (FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 21. Document ID: US 20020102604 A1

L21: Entry 21 of 23 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102604
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102604 A1

TITLE: Full-length human cDNAs encoding potentially secreted proteins

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Milne Edwards, Jean-Baptiste Dumas	Paris	FR
Bougueleret, Lydie	Petit Lancy	CH
Jobert, Severin	Paris	FR

US-CL-CURRENT: 435/7.1; 530/350, 536/23.1

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 22. Document ID: US 6794363 B2

L21: Entry 22 of 23 File: USPT Sep 21, 2004

US-PAT-NO: 6794363
DOCUMENT-IDENTIFIER: US 6794363 B2

TITLE: Isolated amyloid inhibitor protein (APIP) and compositions thereof

DATE-ISSUED: September 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bejanin; Stephane	Paris			FR
Tanaka; Hiroaki	Antony			FR

US-CL-CURRENT: 514/12; 435/23, 530/350, 536/23.5

ABSTRACT:

The invention provides polynucleotides and polypeptides encoding an isolated amyloid inhibitor protein (APIP) and compositions thereof. The polypeptides of the subject invention can be used to inhibit the catabolism or sequential cleavage of arnyloid beta precursor protein (APP) by Sequential cleavage of APP by beta secretase and gamma secretase.

10 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 23. Document ID: US 6239172 B1

L21: Entry 23 of 23 File: USPT May 29, 2001

US-PAT-NO: 6239172
DOCUMENT-IDENTIFIER: US 6239172 B1
**** See image for Certificate of Correction ****

TITLE: Formulations for treating disease and methods of using same

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kaesemeyer; Wayne H.	Augusta	GA		

US-CL-CURRENT: 514/460

ABSTRACT:

A therapeutic mixture comprised of L-arginine and angiogenic growth factors is disclosed for the treatment of diseases related to endothelial dysfunction.

14 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 20040185507 A1

Using default format because multiple data bases are involved.

L22: Entry 1 of 7 File: PGPB Sep 23, 2004

PGPUB-DOCUMENT-NUMBER: 20040185507
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040185507 A1

TITLE: Anti-integrin antibodies, compositions, methods and uses

PUBLICATION-DATE: September 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Giles-Komar, Jill	Downingtown	PA	US	
Snyder, Linda	Pottstown	PA	US	
Trikha, Mohit	Paoli	PA	US	
Nakada, Marian T.	Malvern	PA	US	

US-CL-CURRENT: 435/7.2; 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20040120952 A1

L22: Entry 2 of 7 File: PGPB Jun 24, 2004

PGPUB-DOCUMENT-NUMBER: 20040120952
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040120952 A1

TITLE: Anti-TNF antibodies and peptides of human tumor necrosis factor

PUBLICATION-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knight, David M.	Berwin	PA	US	
Shealy, David J.	Downingtown	PA	US	

US-CL-CURRENT: 424/145.1

ABSTRACT:

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

☐ 3. Document ID: US 20040077648 A1

L22: Entry 3 of 7 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077648
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077648 A1

TITLE: Methods and compositions of novel triazine compounds

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Timmer, Richard T.	Decatur	GA	US	
Alexander, Christopher W.	Norcross	GA	US	
Pillarisetti, Sivaram	Norcross	GA	US	
Saxena, Uday	Atlanta	GA	US	
Campbell, Karen A.	Durham	NC	US	

US-CL-CURRENT: 514/241; 544/212, 544/223

ABSTRACT:

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

☐ 4. Document ID: US 20030096754 A1

L22: Entry 4 of 7 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096754
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096754 A1

TITLE: Vascular endothelial growth factor variants

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pollitt, N. Stephen	Los Altos	CA	US	
Abraham, Judith A.	San Jose	CA	US	

US-CL-CURRENT: 514/12

ABSTRACT:

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20030040044 A1

L22: Entry 5 of 7 File: PGPB Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040044
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040044 A1

TITLE: Anti-dual integrin antibodies, compositions, methods and uses

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Heavner, George	Malvern	PA	US	
Giles-Komar, Jill	Downingtown	PA	US	
Snyder, Linda	Pottstown	PA	US	
Trikha, Mohit	Paoli	PA	US	

US-CL-CURRENT: 435/69.1; 424/146.1, 435/320.1, 435/326, 530/387.2, 530/388.26, 536/23.53

ABSTRACT:

The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 6. Document ID: US 20020019350 A1

L22: Entry 6 of 7 File: PGPB Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019350
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019350 A1

TITLE: Targeted angiogenesis

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levine, Arnold J.	New York	NY	US	
Mitterer, Artur	Orth, Donau		AT	
Falkner, Falko-Guenter	Orth, Donau		AT	
Scheiflinger, Friedrich	Vienna		AT	
Dorner, Friedrich	Vienna		AT	

US-CL-CURRENT: 514/12; 530/399

ABSTRACT:

The invention relates to compositions, methods, and gene therapy reagents to promote or to inhibit angiogenesis in the treatment of peripheral vascular or cardiovascular diseases, utilizing a chimeric molecule comprising an angiogenic factor linked to a targeting molecule that specifically binds to a vascular endothelium.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 6475796 B1

L22: Entry 7 of 7 File: USPT Nov 5, 2002

US-PAT-NO: 6475796
DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothelial growth factor variants

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollitt; N. Stephen	Los Altos	CA		
Abraham; Judith A.	San Jose	CA		

US-CL-CURRENT: 435/455; 424/198.1, 514/2, 530/350

ABSTRACT:

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

17 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17

Terms	Documents
(L19 AND inhale)	7

Items 1 - 307 of 307 One

1: Celec P, Yonemitsu Y. Related Articles

Vascular endothelial growth factor - basic science and its clinical implicatio
Pathophysiology. 2004 Oct;11(2):69-75.
PMID: 15364116 [PubMed - as supplied by publisher]

2: Tio RA, Tan ES, Jessurun GA, Veeger N, Jager PL, Slart RH, de Jong RM, Pruim J, Hospers GA, Willemsen AT, de Jongste MJ, van Boven AJ, van Veldhuisen DJ, Zijlstra F. Related Articles

PET for evaluation of differential myocardial perfusion dynamics after VEG gene therapy and laser therapy in end-stage coronary artery disease.
J Nucl Med. 2004 Sep;45(9):1437-43.
PMID: 15347709 [PubMed - in process]

3: Zbinden R, Vogel R, Meier B, Seiler C. Related Articles

Coronary collateral flow and peripheral blood monocyte concentration in pa treated with granulocyte-macrophage colony stimulating factor.
Heart. 2004 Aug;90(8):945-6. No abstract available.
PMID: 15253981 [PubMed - indexed for MEDLINE]

4: Kolsut P, Malecki M, Firek B, Teresinska A, Janik P, Religa Z. Related Articles

[Gene therapy with phVEGF165 plasmid--preliminary report]
Kardiol Pol. 2004 Feb;60 Suppl 1:I-82-9. Polish. No abstract available.
PMID: 15247953 [PubMed - indexed for MEDLINE]

5: Mills R, Bhatt DL. Related Articles

The Yin and Yang of arterial inflammation.
J Am Coll Cardiol. 2004 Jul 7;44(1):50-2. No abstract available.
PMID: 15234405 [PubMed - indexed for MEDLINE]

6: Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM. Related Articles

Interleukin-10 serum levels and systemic endothelial vasoreactivity in patier with coronary artery disease.
J Am Coll Cardiol. 2004 Jul 7;44(1):44-9.
PMID: 15234404 [PubMed - indexed for MEDLINE]

7: Grunenfelder J, Umbehr M, Plass A, Bestmann L, Maly FE, Zund G, Turina M. Related Articles

Genetic polymorphisms of apolipoprotein E4 and tumor necrosis factor beta predisposing factors for increased inflammatory cytokines after cardiopulmc bypass.
J Thorac Cardiovasc Surg. 2004 Jul;128(1):92-7.
PMID: 15224026 [PubMed - indexed for MEDLINE]

8: Asakage M, Tsuno NH, Kitayama J, Kawai K, Okaji Y, Yazawa K, Kaisaki S, Takahashi K, Nagawa H. Related Articles

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest.
Anticancer Drugs. 2004 Jul;15(6):625-32.
PMID: 15205608 [PubMed - indexed for MEDLINE]

9: Penny WF, Hammond HK. Related Articles

Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease.
Curr Gene Ther. 2004 Jun;4(2):225-30.
PMID: 15180588 [PubMed - in process]

10: Choy E. Related Articles

Clinical experience with inhibition of interleukin-6.
Rheum Dis Clin North Am. 2004 May;30(2):405-15, viii. Review.
PMID: 15172049 [PubMed - indexed for MEDLINE]

11: Antoniades C, Tousoulis D, Tountas C, Tentolouris C, Toutouza M, Vasiliadou C, Tsioufis C, Toutouzas P, Stefanadis C. Related Articles

Vascular endothelium and inflammatory process, in patients with combinec Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitami
Diabet Med. 2004 Jun;21(6):552-8.
PMID: 15154938 [PubMed - indexed for MEDLINE]

12: Rosinberg A, Khan TA, Sellke FW, Laham RJ. Related Articles

Therapeutic angiogenesis for myocardial ischemia.
Expert Rev Cardiovasc Ther. 2004 Mar;2(2):271-83. Review.
PMID: 15151475 [PubMed - indexed for MEDLINE]

13: Christiansen JF, Hartwig D, Bechtel JF, Kluter H, Sievers H, Schonbeck U, Bartels C. Related Articles

Diseased vein grafts express elevated inflammatory cytokine levels compar with atherosclerotic coronary arteries.
Ann Thorac Surg. 2004 May;77(5):1575-9.
PMID: 15111145 [PubMed - indexed for MEDLINE]

14: Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL. Related Articles

Reduced pericardial levels of endostatin correlate with collateral developm patients with ischemic heart disease.
J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.
PMID: 15093871 [PubMed - indexed for MEDLINE]

15: Dimkovic N. Related Articles

[Erythropoietin administration in the predialysis period]
Med Pregl. 2003 Nov-Dec;56(11-12):529-35. Review. Serbian.
PMID: 15080045 [PubMed - indexed for MEDLINE]

16: Gouni-Berthold I, Sachinidis A. Related Articles

Molecular mechanisms explaining the preventive effects of catechins on th development of proliferative diseases.
Curr Pharm Des. 2004;10(11):1261-71. Review.
PMID: 15078140 [PubMed - indexed for MEDLINE]

17: Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Froland SS, Semb AG, Aukrust P, Damas JK. Related Articles

Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Circulation. 2004 Apr 27;109(16):1966-72. Epub 2004 Mar 29.
PMID: 15051633 [PubMed - indexed for MEDLINE]

18: Ikonomidis I, Andreotti F, Nihoyannopoulos P. Related Articles

Reduction of daily life ischaemia by aspirin in patients with angina: underl link between thromboxane A2 and macrophage colony stimulating factor.
Heart. 2004 Apr;90(4):389-93.
PMID: 15020512 [PubMed - indexed for MEDLINE]

19: Yohannes P, Rao M, Burjonrappa S, Sudan R. Related Articles

Laparoscopic nephron-sparing surgery in a Jehovah's Witness patient.
J Endourol. 2004 Feb;18(1):59-62.
PMID: 15006056 [PubMed - indexed for MEDLINE]

20: Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D. Related Articles

Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).
Gene Ther. 2004 Mar;11(6):512-21.
PMID: 14999223 [PubMed - indexed for MEDLINE]

21: Syed IS, Sanborn TA, Rosengart TK. Related Articles

Therapeutic angiogenesis: a biologic bypass.
Cardiology. 2004;101(1-3):131-43. Review.
PMID: 14988635 [PubMed - indexed for MEDLINE]

22: Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Related Articles

Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]

23: Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Related Articles

Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndrome (MIDAS) pilot trial.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):733-8. Epub 2004 Feb 12.
PMID: 14962945 [PubMed - indexed for MEDLINE]

24: Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK. Related Articles

Adenoviral-mediated transfer of vascular endothelial growth factor 121 cD enhances myocardial perfusion and exercise performance in the nonischem state.
J Thorac Cardiovasc Surg. 2004 Feb;127(2):535-40.
PMID: 14762365 [PubMed - indexed for MEDLINE]

25: Lesperance F, Frasure-Smith N, Theroux P, Irwin M. Related Articles

The association between major depression and levels of soluble intercellula adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes.
Am J Psychiatry. 2004 Feb;161(2):271-7.

PMID: 14754776 [PubMed - indexed for MEDLINE]

26: Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP. Related Articles

Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.
J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.
PMID: 14752410 [PubMed - indexed for MEDLINE]

27: Symes JF. Related Articles

Gene therapy for ischemic heart disease: therapeutic potential.
Am J Cardiovasc Drugs. 2001;1(3):159-66. Review.
PMID: 14728030 [PubMed - indexed for MEDLINE]

28: Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Related Articles

Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit cor plaques.
Am J Cardiol. 2004 Jan 1;93(1):6-9.
PMID: 14697457 [PubMed - indexed for MEDLINE]

29: Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G. Related Articles

Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.
Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.
PMID: 14691039 [PubMed - indexed for MEDLINE]

30: Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A. Related Articles

Age-dependent depression in circulating endothelial progenitor cells in pati undergoing coronary artery bypass grafting.
J Am Coll Cardiol. 2003 Dec 17;42(12):2073-80.
PMID: 14680729 [PubMed - indexed for MEDLINE]

31: Bruemmer D, Law RE. Related Articles

Thiazolidinedione regulation of smooth muscle cell proliferation.
Am J Med. 2003 Dec 8;115 Suppl 8A:87S-92S. Review.
PMID: 14678872 [PubMed - indexed for MEDLINE]

32: Kolsut P, Malecki M, Zelazny P, Teresinska A, Firek B, Janik P, Religa Z. Related Articles

Gene therapy of coronary artery disease with phvegf165--early outcome.
Kardiol Pol. 2003 Nov;59(11):373-84. English, Polish.
PMID: 14668888 [PubMed - indexed for MEDLINE]

33: Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Related Articles

Meal modulation of circulating interleukin 18 and adiponectin concentratio healthy subjects and in patients with type 2 diabetes mellitus.
Am J Clin Nutr. 2003 Dec;78(6):1135-40.
PMID: 14668275 [PubMed - indexed for MEDLINE]

34: Baklanov D, Simons M. Related Articles

Arteriogenesis: lessons learned from clinical trials.
Endothelium. 2003;10(4-5):217-23. Review.

PMID: 14660081 [PubMed - indexed for MEDLINE]

35: Zee RY, Fernandez-Ortiz A, Macaya C, Pintor E, Fernandez-Cruz A, Lindpaintner K. Related Articles

IL-1 cluster genes and occurrence of post-percutaneous transluminal coron angioplasty restenosis: a prospective, angiography-based evaluation.
Atherosclerosis. 2003 Dec;171(2):259-64.
PMID: 14644395 [PubMed - indexed for MEDLINE]

36: Roguin A, Resar JR. Related Articles

Genetics and susceptibility of coronary collateral formation.
Circulation. 2003 Nov 25;108(21):e149; author reply e149. No abstract available.
PMID: 14638531 [PubMed - indexed for MEDLINE]

37: DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B. Related Articles

Interleukin-6 -174G-->C polymorphism is associated with improved outco high-risk breast cancer.
Cancer Res. 2003 Nov 15;63(22):8051-6.
PMID: 14633738 [PubMed - indexed for MEDLINE]

38: Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A. Related Articles

Long-term treatment with a specific Rho-kinase inhibitor suppresses cardia allograft vasculopathy in mice.
Circ Res. 2004 Jan 9;94(1):46-52. Epub 2003 Nov 13.
PMID: 14615290 [PubMed - indexed for MEDLINE]

39: Grines C, Rubanyi GM, Kleiman NS, Marrott P, Watkins MW. Related Articles

Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease.
Am J Cardiol. 2003 Nov 7;92(9B):24N-31N. Review.
PMID: 14615023 [PubMed - indexed for MEDLINE]

40: Moien-Afshari F, McManus BM, Laher I. Related Articles

Immunosuppression and transplant vascular disease: benefits and adverse effects.
Pharmacol Ther. 2003 Nov;100(2):141-56. Review.
PMID: 14609717 [PubMed - indexed for MEDLINE]

41: Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Related Articles

Human epicardial adipose tissue is a source of inflammatory mediators.
Circulation. 2003 Nov 18;108(20):2460-6. Epub 2003 Oct 27.
PMID: 14581396 [PubMed - indexed for MEDLINE]

42: Koch W, Tiroch K, von Beckerath N, Schomig A, Kastrati A. Related Articles

Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting.
Cytokine. 2003 Nov 21;24(4):161-71.
PMID: 14572794 [PubMed - indexed for MEDLINE]

43: Blake GJ. Related Articles

Inflammatory biomarkers of the patient with myocardial insufficiency.
Curr Opin Crit Care. 2003 Oct;9(5):369-74. Review.

PMID: 14508149 [PubMed - indexed for MEDLINE]

44: Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunich L, Criscuolo M, Capogrossi MC, Laguens R. Related Articles

Arteriogenesis induced by intramyocardial vascular endothelial growth fact 165 gene transfer in chronically ischemic pigs.
Hum Gene Ther. 2003 Sep 20;14(14):1307-18.
PMID: 14503966 [PubMed - indexed for MEDLINE]

45: Girndt M, Kohler H. Related Articles

Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk.
Nephrol Dial Transplant. 2003 Oct;18(10):1976-9. Review. No abstract available.
PMID: 13679468 [PubMed - indexed for MEDLINE]

46: Ruel M, Sellke FW. Related Articles

Angiogenic protein therapy.
Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
PMID: 12973700 [PubMed - indexed for MEDLINE]

47: Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW. Related Articles

Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.
Circulation. 2003 Sep 9;108 Suppl 1:II335-40.
PMID: 12970256 [PubMed - indexed for MEDLINE]

48: Wei M, Kuukasjarvi P, Laurikka J, Kaukinen S, Honkonen EL, Metsanoja R, Tarkka M. Related Articles

Relation of cytokines to vasodilation after coronary artery bypass grafting.
World J Surg. 2003 Oct;27(10):1093-8. Epub 2003 Aug 21.
PMID: 12925902 [PubMed - indexed for MEDLINE]

49: Watkins MW, Rubanyi GM. Related Articles

Gene therapy for coronary artery disease: preclinical and initial clinical resu with intracoronary administration of Ad5FGF-4.
Ernst Schering Res Found Workshop. 2003(43):61-78. Review. No abstract available.
PMID: 12894451 [PubMed - indexed for MEDLINE]

50: Geraldes P, Sirois MG, Tanguay JF. Related Articles

Specific contribution of estrogen receptors on mitogen-activated protein kin pathways and vascular cell activation.
Circ Res. 2003 Sep 5;93(5):399-405. Epub 2003 Jul 31.
PMID: 12893737 [PubMed - indexed for MEDLINE]

51: Murata S, Miniati DN, Kown MH, Koransky ML, Balsam LB, Lijkwan MA, Martens JM, Robbins RC. Related Articles

Elevated cyclic adenosine monophosphate ameliorates ischemia-reperfusio injury in rat cardiac allografts.
J Heart Lung Transplant. 2003 Jul;22(7):802-9.
PMID: 12873549 [PubMed - indexed for MEDLINE]

52: Aldhahi W, Hamdy O. Related Articles

Adipokines, inflammation, and the endothelium in diabetes.
Curr Diab Rep. 2003 Aug;3(4):293-8. Review.

PMID: 12866991 [PubMed - indexed for MEDLINE]

☐ **53:** Azar RR, Klayme S, Germanos M, Kassab R, Tawm S, Aboujaoude S, Naman R. Related Articles

Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protei cytokines, and adhesion molecules in healthy volunteers.
Am J Cardiol. 2003 Jul 15;92(2):236-9. No abstract available.
PMID: 12860235 [PubMed - indexed for MEDLINE]

☐ **54:** Berg HF, Maraha B, Scheffer GJ, Peeters MF, Kluytmans JA. Related Articles

Effect of clarithromycin on inflammatory markers in patients with atherosclerosis.
Clin Diagn Lab Immunol. 2003 Jul;10(4):525-8.
PMID: 12853380 [PubMed - indexed for MEDLINE]

☐ **55:** Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M. Related Articles

Toward surgical angiogenesis using slow-released basic fibroblast growth factor.
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.
PMID: 12853053 [PubMed - indexed for MEDLINE]

☐ **56:** Hedman M, Yla-Herttuala S. Related Articles

Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.
Drugs Today (Barc). 2000 Sep;36(9):609-17.
PMID: 12847566 [PubMed]

☐ **57:** Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, Cleutjens KB, Daemen MJ. Related Articles

The dynamic extracellular matrix: intervention strategies during heart failu and atherosclerosis.
J Pathol. 2003 Jul;200(4):516-25. Review.
PMID: 12845619 [PubMed - indexed for MEDLINE]

☐ **58:** Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Related Articles

Myocardial and lung injury after cardiopulmonary bypass: role of interleuk (IL)-10.
Ann Thorac Surg. 2003 Jul;76(1):117-23.
PMID: 12842524 [PubMed - indexed for MEDLINE]

☐ **59:** Buschmann IR, Busch HJ, Mies G, Hossmann KA. Related Articles

Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor.
Circulation. 2003 Aug 5;108(5):610-5. Epub 2003 Jun 30.
PMID: 12835229 [PubMed - indexed for MEDLINE]

☐ **60:** Suarez EC. Related Articles

Plasma interleukin-6 is associated with psychological coronary risk factors: moderation by use of multivitamin supplements.
Brain Behav Immun. 2003 Aug;17(4):296-303.
PMID: 12831832 [PubMed - indexed for MEDLINE]

☐ **61:** Kastrup J. Related Articles

Therapeutic angiogenesis in ischemic heart disease: gene or recombinant

vascular growth factor protein therapy?
Curr Gene Ther. 2003 Jun;3(3):197-206. Review.
PMID: 12762479 [PubMed - indexed for MEDLINE]

62: Yoshioka S, Tsukamoto T, Chihara K. Related Articles

[Vascular smooth muscle cells in coronary heart disease]
Nippon Rinsho. 2003 Apr;61 Suppl 4:80-5. Review. Japanese. No abstract available.
PMID: 12734957 [PubMed - indexed for MEDLINE]

63: Amann FW. Related Articles

[Coronary stents]
Ther Umsch. 2003 Apr;60(4):179-82. German.
PMID: 12731426 [PubMed - indexed for MEDLINE]

64: Rasmussen HS, Rasmussen CS, Macko J. Related Articles

VEGF gene therapy for coronary artery disease and peripheral vascular dis
Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.
PMID: 12699842 [PubMed - indexed for MEDLINE]

65: Despres JP, Lemieux I, Pascot A, Almeras N, Dumont M, Nadeau A, Bergeron J, Prud'homme D. Related Articles

Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese with the atherogenic dyslipidemia of the metabolic syndrome.
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):702-3. No abstract available.
PMID: 12692010 [PubMed - indexed for MEDLINE]

66: Khurana R, Simons M. Related Articles

Insights from angiogenesis trials using fibroblast growth factor for advance arteriosclerotic disease.
Trends Cardiovasc Med. 2003 Apr;13(3):116-22. Review.
PMID: 12691676 [PubMed - indexed for MEDLINE]

67: Abo-Auda W, Benza RL. Related Articles

Therapeutic angiogenesis: review of current concepts and future directions.
J Heart Lung Transplant. 2003 Apr;22(4):370-82. Review. No abstract available.
PMID: 12681415 [PubMed - indexed for MEDLINE]

68: Hughes GC, Post MJ, Simons M, Annex BH. Related Articles

Translational physiology: porcine models of human coronary artery disease implications for preclinical trials of therapeutic angiogenesis.
J Appl Physiol. 2003 May;94(5):1689-701. Review.
PMID: 12679343 [PubMed - indexed for MEDLINE]

69: Kwak HJ, Pae HO, Oh GS, Choi BM, Jang SI, Jung S, Chung HT. Related Articles

Molsidomine ameliorates experimental allergic encephalomyelitis in Lewis
Immunopharmacol Immunotoxicol. 2003 Feb;25(1):41-52.
PMID: 12675198 [PubMed - indexed for MEDLINE]

70: Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators. Related Articles

Serum level of the antiinflammatory cytokine interleukin-10 is an importan prognostic determinant in patients with acute coronary syndromes.
Circulation. 2003 Apr 29;107(16):2109-14. Epub 2003 Mar 31.
PMID: 12668510 [PubMed - indexed for MEDLINE]

71: Blake GJ, Ridker PM. Related Articles

C-reactive protein and other inflammatory risk markers in acute coronary syndromes.
J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):37S-42S. Review.
PMID: 12644339 [PubMed - indexed for MEDLINE]

72: Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Related Articles

Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis.
Circulation. 2003 Mar 11;107(9):1308-14.
PMID: 12628953 [PubMed - indexed for MEDLINE]

73: Cotton JM, Hong Y, Hawe E, Mathur A, Humphries SE, Brown AS, Martin JF, Erusalimsky JD. Related Articles

Rise of circulating thrombopoietin following cardiothoracic surgery is potentiated in patients with coronary atherosclerosis: correlation with a preceding increase in levels of interleukin-6.
Thromb Haemost. 2003 Mar;89(3):538-43.
PMID: 12624639 [PubMed - indexed for MEDLINE]

74: Braun-Dullaeus RC, Ziegler A, Bohle RM, Bauer E, Hein S, Tillmanns H, Haberbosch W. Related Articles

Quantification of the cell-cycle inhibitors p27(Kip1) and p21(Cip1) in hum atherectomy specimens: primary stenosis versus restenosis.
J Lab Clin Med. 2003 Mar;141(3):179-89.
PMID: 12624599 [PubMed - indexed for MEDLINE]

75: Kusumanto YH, Hospers GA, Mulder NH, Tio RA. Related Articles

Therapeutic angiogenesis with vascular endothelial growth factor in periph and coronary artery disease: a review.
Int J Cardiovasc Intervent. 2003;5(1):27-34. Review.
PMID: 12623562 [PubMed - indexed for MEDLINE]

76: Sellke FW, Ruel M. Related Articles

Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]

77: Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O, Koskinen PK, Lemstrom KB. Related Articles

Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits.
Transplantation. 2003 Feb 15;75(3):334-9.
PMID: 12589154 [PubMed - indexed for MEDLINE]

78: Khan TA, Sellke FW, Laham RJ. Related Articles

Therapeutic angiogenesis: protein-based therapy for coronary artery disease
Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review.
PMID: 12562312 [PubMed - indexed for MEDLINE]

79: Sim EK, Zhang L, Shim WS, Lim YL, Ge R. Related Articles

Therapeutic angiogenesis for coronary artery disease.
J Card Surg. 2002 Jul-Aug;17(4):350-4. Review.
PMID: 12546086 [PubMed - indexed for MEDLINE]

☐ **80:** Kutryk MJ, Stewart DJ. Related Articles

Angiogenesis of the heart.
Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review.
PMID: 12539168 [PubMed - indexed for MEDLINE]

☐ **81:** SoRelle R. Related Articles

Erythropoietin--not at the Olympics but maybe for anemic heart failure pat
Circulation. 2003 Jan 21;107(2):e9004. No abstract available.
PMID: 12538444 [PubMed - indexed for MEDLINE]

☐ **82:** Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Related Articles

Insulin resistance and adiposity correlate with acute-phase reaction and sol
cell adhesion molecules in type 2 diabetes.
Atherosclerosis. 2003 Feb;166(2):387-94.
PMID: 12535753 [PubMed - indexed for MEDLINE]

☐ **83:** Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L. Related Articles

Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth mu
cell proliferation.
Circ Res. 2003 Jan 10;92(1):96-103.
PMID: 12522126 [PubMed - indexed for MEDLINE]

☐ **84:** Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E. Related Articles

An association between coronary artery calcification score, lipid profile, an
selected markers of chronic inflammation in ESRD patients treated with
peritoneal dialysis.
Am J Kidney Dis. 2003 Jan;41(1):203-11.
PMID: 12500238 [PubMed - indexed for MEDLINE]

☐ **85:** van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group. Related Articles

Strong decrease of high sensitivity C-reactive protein with high-dose
atorvastatin in patients with type 2 diabetes mellitus.
Atherosclerosis. 2003 Jan;166(1):129-35.
PMID: 12482559 [PubMed - indexed for MEDLINE]

☐ **86:** Tamirisa KP, Mukherjee D. Related Articles

Gene therapy in cardiovascular diseases.
Curr Gene Ther. 2002 Dec;2(4):427-35. Review.
PMID: 12477254 [PubMed - indexed for MEDLINE]

☐ **87:** Lee CH, Smits PC. Related Articles

Vascular growth factors for coronary angiogenesis.
J Interv Cardiol. 2002 Dec;15(6):511-8. Review.
PMID: 12476656 [PubMed - indexed for MEDLINE]

☐ **88:** Conraads VM, Beckers P, Bosmans J, De Clerck LS, Stevens WJ, Vrints CJ, Brutsaert DL. Related Articles

Combined endurance/resistance training reduces plasma TNF-alpha recept
levels in patients with chronic heart failure and coronary artery disease.
Eur Heart J. 2002 Dec;23(23):1854-60.
PMID: 12445534 [PubMed - indexed for MEDLINE]

89: Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G. Related Articles

Angiogenic gene therapy strategies for the treatment of cardiovascular dise
Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.
PMID: 12435049 [PubMed - indexed for MEDLINE]

90: Sun D, Xu C, Li J, Jiao X, Chen Y. Related Articles

[Changes of inflammatory factors in patients with coronary artery disease during perioperation]
Zhonghua Wai Ke Za Zhi. 2002 Aug;40(8):571-3. Chinese.
PMID: 12417066 [PubMed - indexed for MEDLINE]

91: Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A. Related Articles

Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Hypertension. 2002 Nov;40(5):687-93.
PMID: 12411463 [PubMed - indexed for MEDLINE]

92: Grube E, Gerckens U, Buellesfeld L. Related Articles

Drug-eluting stents: clinical experiences and perspectives.
Minerva Cardioangiol. 2002 Oct;50(5):469-73. Review.
PMID: 12384629 [PubMed - indexed for MEDLINE]

93: Sheiban I, Carrieri L, Catuzzo B, Destefanis P, Oliaro E, Moretti C, Trevi GP. Related Articles

Drug-eluting stent: the emerging technique for the prevention of restenosis.
Minerva Cardioangiol. 2002 Oct;50(5):443-53. Review.
PMID: 12384626 [PubMed - indexed for MEDLINE]

94: Os I, Os A, Sandset PM, Bolling S, Seljeflot I, Djurovic S, Westheim A. Related Articles

Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pat inhibitor antigen, a circulating anticoagulant, is related to plasma homocyst
Cardiology. 2002;98(1-2):6-12.
PMID: 12373040 [PubMed - indexed for MEDLINE]

95: Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG. Related Articles

Systemic interleukin-6 responses following administration of adenovirus g transfer vectors to humans by different routes.
Mol Ther. 2002 Aug;6(2):287-97.
PMID: 12349828 [PubMed - indexed for MEDLINE]

96: Vallely MP, Bannon PG, Hughes CF, Kritharides L. Related Articles

Endothelial expression of intercellular adhesion molecule 1 and vascular ce adhesion molecule 1 is suppressed by postbypass plasma containing increa soluble intercellular adhesion molecule 1 and vascular cell adhesion molec
J Thorac Cardiovasc Surg. 2002 Oct;124(4):758-67.
PMID: 12324734 [PubMed - indexed for MEDLINE]

97: Zhang C, Yang J, Feng J, Jennings LK. Related Articles

Short-term administration of basic fibroblast growth factor enhances coron collateral development without exacerbating atherosclerosis and balloon in induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.
J Lab Clin Med. 2002 Aug;140(2):119-25.

PMID: 12228768 [PubMed - indexed for MEDLINE]

98: Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM. Related Articles

Plasma vascular endothelial growth factor (VEGF) levels after intramuscul and intramyocardial gene transfer of VEGF-1 plasmid DNA.
Hum Gene Ther. 2002 Sep 1;13(13):1595-603.
PMID: 12228014 [PubMed - indexed for MEDLINE]

99: Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Related Articles

Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?
Stroke. 2002 Sep;33(9):2187-91.
PMID: 12215585 [PubMed - indexed for MEDLINE]

100: Billia F, Carter K, Rao V, Gorczynski R, Feindel C, Ross HJ. Related Articles

Transforming growth factor-beta expression is significantly lower in heart preserved with blood/insulin versus crystalloid cardioplegia.
J Heart Lung Transplant. 2002 Aug;21(8):918-22.
PMID: 12163095 [PubMed - indexed for MEDLINE]

101: Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P. Related Articles

Basic fibroblast growth factor changes in response to coronary angioplast patients with stable angina.
Int J Cardiol. 2002 Aug;84(2-3):195-9.
PMID: 12127372 [PubMed - indexed for MEDLINE]

102: Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. Related Articles

Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.
J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5.
PMID: 12084593 [PubMed - indexed for MEDLINE]

103: Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD. Related Articles

Acute rise of circulating vascular endothelial growth factor-A in patients v coronary artery disease following cardiothoracic surgery.
Eur Heart J. 2002 Jun;23(12):953-9.
PMID: 12069450 [PubMed - indexed for MEDLINE]

104: Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M. Related Articles

The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.
Clin Cardiol. 2002 Jun;25(6):271-8.
PMID: 12058790 [PubMed - indexed for MEDLINE]

105: Vale PR, Isner JM, Rosenfield K. Related Articles

Therapeutic angiogenesis in critical limb and myocardial ischemia.
J Interv Cardiol. 2001 Oct;14(5):511-28. Review.
PMID: 12053643 [PubMed - indexed for MEDLINE]

106: Rauchhaus M, Gross M, Schulz S, Francis DP, Greiser P, Norwig A, Weidhase L, Coats AJ, Dietz R, Anker SD, Glaser C. Related Articles

The E-selectin SER128ARG gene polymorphism and restenosis after

successful coronary angioplasty.
Int J Cardiol. 2002 Jun;83(3):249-57.
PMID: 12036529 [PubMed - indexed for MEDLINE]

107: Werner GS. Related Articles

Promotion of collateral growth by granulocyte-macrophage colony-stimul factor in patients with coronary artery disease.
Circulation. 2002 May 14;105(19):e175; author reply e175. No abstract available.
PMID: 12010922 [PubMed - indexed for MEDLINE]

108: Sindermann JR, Skaletz-Rorowski A, Bartels A, Hohage H, Plenz G, Schmidt A, Breithardt G. Related Articles

Paclitaxel and cyclosporine A show supra-additive antiproliferative effect smooth muscle cells by activation of protein kinase C.
Basic Res Cardiol. 2002 Mar;97(2):125-31.
PMID: 12002259 [PubMed - indexed for MEDLINE]

109: Dudek D, Heba G, Rzeszutko Å□, Dubiel JS. Related Articles

[Therapeutic angiogenesis for coronary artery disease. Contemporary resu and perspectives]
Przegl Lek. 2001;58(11):1000-3. Review. Polish.
PMID: 11987827 [PubMed - indexed for MEDLINE]

110: Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A. Related Articles

Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia.
J Am Coll Cardiol. 2002 May 1;39(9):1555-61.
PMID: 11985922 [PubMed - indexed for MEDLINE]

111: Lowe HC, Oesterle SN, Burkhoff D. Related Articles

Alternatives to traditional coronary bypass surgery.
Semin Thorac Cardiovasc Surg. 2002 Jan;14(1):110-8. Review.
PMID: 11977024 [PubMed - indexed for MEDLINE]

112: Auer J, Berent R, Labetanig E, Eber B. Related Articles

Serum neopterin and activity of coronary artery disease.
Heart Dis. 2001 Sep-Oct;3(5):297-301.
PMID: 11975809 [PubMed - indexed for MEDLINE]

113: Rosen LS. Related Articles

Clinical experience with angiogenesis signaling inhibitors: focus on vascu endothelial growth factor (VEGF) blockers.
Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review.
PMID: 11965229 [PubMed - indexed for MEDLINE]

114: Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P. Related Articles

Serum basic fibroblast growth factor levels in exercise-induced myocardi ischemia more likely a marker of endothelial dysfunction than a marker o ischemia?
Eur J Med Res. 2002 Mar 28;7(3):93-7.
PMID: 11953278 [PubMed - indexed for MEDLINE]

115: Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH. Related Articles

Clinical applications of cardiovascular angiogenesis.
J Card Surg. 2001 Nov-Dec;16(6):490-7. Review.
PMID: 11925031 [PubMed - indexed for MEDLINE]

116: Link A, Bohm M, Nickenig G. Related Articles

[Acute coronary syndrome--better risk stratification by determination of inflammatory parameters?]
Med Klin (Munich). 2002 Feb 15;97(2):63-9. Review. German.
PMID: 11910871 [PubMed - indexed for MEDLINE]

117: [No authors listed] Related Articles

FGF-4 gene therapy GENERX--Collateral Therapeutics.
BioDrugs. 2002;16(1):75-6. Review.
PMID: 11909005 [PubMed - indexed for MEDLINE]

118: Hojo Y, Ikeda U, Takahashi M, Shimada K. Related Articles

Increased levels of monocyte-related cytokines in patients with unstable angina.
Atherosclerosis. 2002 Apr;161(2):403-8.
PMID: 11888524 [PubMed - indexed for MEDLINE]

119: Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C. Related Articles

Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.
J Intern Med. 2001 Nov;250(5):373-81.
PMID: 11887971 [PubMed - indexed for MEDLINE]

120: Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Related Articles

Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical t
Circulation. 2002 Feb 19;105(7):788-93.
PMID: 11854116 [PubMed - indexed for MEDLINE]

121: Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A. Related Articles

Inflammatory response after open heart surgery: release of heat-shock pro 70 and signaling through toll-like receptor-4.
Circulation. 2002 Feb 12;105(6):685-90.
PMID: 11839622 [PubMed - indexed for MEDLINE]

122: von Schacky C, Baumann K, Angerer P. Related Articles

The effect of n-3 fatty acids on coronary atherosclerosis: results from SCI an angiographic study, background and implications.
Lipids. 2001;36 Suppl:S99-102.
PMID: 11838000 [PubMed - indexed for MEDLINE]

123: Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Related Articles

Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.
Clin Sci (Lond). 2002 Feb;102(2):187-94.

PMID: 11834138 [PubMed - indexed for MEDLINE]

☐ **124:** Spieker LE, Luscher TF, Noll G. Related Articles

Current strategies and perspectives for correcting endothelial dysfunction atherosclerosis.
J Cardiovasc Pharmacol. 2001 Nov;38 Suppl 2:S35-41. Review.
PMID: 11811375 [PubMed - indexed for MEDLINE]

☐ **125:** Khan TA, Sellke FW, Laham RJ. Related Articles

Therapeutic Angiogenesis for Coronary Artery Disease.
Curr Treat Options Cardiovasc Med. 2002 Feb;4(1):65-74.
PMID: 11792229 [PubMed - as supplied by publisher]

☐ **126:** Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Coli L, De Pascalis A, Iannelli S. Related Articles

Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease i ESRD patients.
Kidney Int. 2002 Jan;61(1):324-35.
PMID: 11786115 [PubMed - indexed for MEDLINE]

☐ **127:** Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Related Articles

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comort conditions.
Hum Gene Ther. 2002 Jan 1;13(1):65-100.
PMID: 11779413 [PubMed - indexed for MEDLINE]

☐ **128:** Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Related Articles

Safety of local delivery of low- and intermediate-dose adenovirus gene tra vectors to individuals with a spectrum of morbid conditions.
Hum Gene Ther. 2002 Jan 1;13(1):15-63.
PMID: 11779412 [PubMed - indexed for MEDLINE]

☐ **129:** Freedman SB, Isner JM. Related Articles

Therapeutic angiogenesis for coronary artery disease.
Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.
PMID: 11777364 [PubMed - indexed for MEDLINE]

☐ **130:** Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Related Articles

Tranilast inhibits transplant-associated coronary arteriosclerosis in a murii model of cardiac transplantation.
Eur J Pharmacol. 2001 Dec 21;433(2-3):163-8.
PMID: 11755148 [PubMed - indexed for MEDLINE]

☐ **131:** Mueller XM, Tevaearai HT, Genton CY, Chaubert P, von Segesser LK. Related Articles

Is an endocardial connection necessary for growth factor induced angioge in transmyocardial laser revascularization?
ASAIO J. 2001 Nov-Dec;47(6):662-6.
PMID: 11730207 [PubMed - indexed for MEDLINE]

☐ **132:** Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H. Related Articles

Simultaneous surgical revascularization and angiogenic gene therapy in d coronary artery disease.
Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34.
PMID: 11717016 [PubMed - indexed for MEDLINE]

☐ **133:** Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Related Articles

Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strateg
JAMA. 2001 Nov 7;286(17):2107-13.
PMID: 11694151 [PubMed - indexed for MEDLINE]

☐ **134:** Ikeda U, Ito T, Shimada K. Related Articles

Interleukin-6 and acute coronary syndrome.
Clin Cardiol. 2001 Nov;24(11):701-4.
PMID: 11714126 [PubMed - indexed for MEDLINE]

☐ **135:** Hong HJ, Hsiao G, Cheng TH, Yen MH. Related Articles

Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats.
Hypertension. 2001 Nov;38(5):1044-8.
PMID: 11711495 [PubMed - indexed for MEDLINE]

☐ **136:** Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F. Related Articles

Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization.
Am J Cardiol. 2001 Nov 15;88(10):1125-8.
PMID: 11703956 [PubMed - indexed for MEDLINE]

☐ **137:** Plutzky J. Related Articles

Inflammatory pathways in atherosclerosis and acute coronary syndromes.
Am J Cardiol. 2001 Oct 18;88(8A):10K-15K. Review.
PMID: 11694213 [PubMed - indexed for MEDLINE]

☐ **138:** Davda J, Labhasetwar V. Related Articles

An update on angiogenesis therapy.
Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review.
PMID: 11693956 [PubMed - indexed for MEDLINE]

☐ **139:** Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER. Related Articles

Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.
Am Heart J. 2001 Nov;142(5):872-80.
PMID: 11685177 [PubMed - indexed for MEDLINE]

☐ **140:** Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker S, Eberli FR, Meier B. Related Articles

Promotion of collateral growth by granulocyte-macrophage colony-stimul factor in patients with coronary artery disease: a randomized, double-blinc placebo-controlled study.
Circulation. 2001 Oct 23;104(17):2012-7.

PMID: 11673338 [PubMed - indexed for MEDLINE]

☐ **141:** Kastrup J, Jorgensen E. Related Articles

[Gene therapy of ischemic heart disease. Growth factors and angiogenesis/arteriogenesis]
Ugeskr Laeger. 2001 Jan 1;163(1):13-5. Danish. No abstract available.
PMID: 11586665 [PubMed - indexed for MEDLINE]

☐ **142:** Choukroun G. Related Articles

[Prevention and treatment of type 1 diabetes]
Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French.
PMID: 11577580 [PubMed - indexed for MEDLINE]

☐ **143:** Basara N. Related Articles

AdGVVEGF121.10 (GenVec).
Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review.
PMID: 11572658 [PubMed - indexed for MEDLINE]

☐ **144:** Sadamatsu K, Shimokawa H, Tashiro H, Yamamoto K. Related Articles

Long term treatment with enalapril reduces plasma concentrations of macrophage colony stimulating factor in patients with coronary artery dis
Heart. 2001 Oct;86(4):457-8. No abstract available.
PMID: 11559692 [PubMed - indexed for MEDLINE]

☐ **145:** Holm T, Berge RK, Andreassen AK, Ueland T, Kjekshus J, Simonsen S, Froland S, Gullestad L, Aukrust P. Related Articles

Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients.
Transplantation. 2001 Aug 27;72(4):706-11.
PMID: 11544435 [PubMed - indexed for MEDLINE]

☐ **146:** Pieniazek P, Karczewska E, Stepien E, Tracz W, Konturek SJ. Related Articles

Incidence of Chlamydia pneumoniae infection in patients with coronary a disease subjected to angioplasty or bypass surgery.
Med Sci Monit. 2001 Sep-Oct;7(5):995-1001.
PMID: 11535948 [PubMed - indexed for MEDLINE]

☐ **147:** Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Related Articles

Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease.
J Am Coll Cardiol. 2001 Aug;38(2):493-8.
PMID: 11499743 [PubMed - indexed for MEDLINE]

☐ **148:** Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. Related Articles

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor c via the PI 3-kinase/Akt pathway.
J Clin Invest. 2001 Aug;108(3):391-7.
PMID: 11489932 [PubMed - indexed for MEDLINE]

☐ **149:** Wilke NM, Zenovich AG, Jerosch-Herold M, Henry TD. Related Articles

Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis.
Curr Interv Cardiol Rep. 2001 Aug;3(3):205-212.
PMID: 11485690 [PubMed - as supplied by publisher]

☐ **150:** Simons M, Post MJ. Related Articles

Coronary Artery Disease: Vascular Endothelial Growth Factor and Fibrob Growth Factor.
Curr Interv Cardiol Rep. 2001 Aug;3(3):185-191.
PMID: 11485687 [PubMed - as supplied by publisher]

☐ **151:** Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J. Related Articles

Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1196-202.
PMID: 11451751 [PubMed - indexed for MEDLINE]

☐ **152:** Izawa A, Suzuki Ji, Takahashi W, Amano J, Isobe M. Related Articles

Tranilast inhibits cardiac allograft vasculopathy in association with p21 (Waf1/Cip1) expression on neointimal cells in murine cardiac transplantat model.
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1172-8.
PMID: 11451747 [PubMed - indexed for MEDLINE]

☐ **153:** Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Related Articles

Clinical outcome of a cohort of patients eligible for therapeutic angiogene transmyocardial revascularization.
Am Heart J. 2001 Jul;142(1):72-4.
PMID: 11431659 [PubMed - indexed for MEDLINE]

☐ **154:** Aziz T, Saad RA, Burgess M, Yonan N, Hasleton P, Hutchinson IV. Related Articles

Transforming growth factor beta and myocardial dysfunction following he transplantation.
Eur J Cardiothorac Surg. 2001 Jul;20(1):177-86.
PMID: 11423293 [PubMed - indexed for MEDLINE]

☐ **155:** Graff J, Andries D, Elsner M, Westrup D, Bassus S, Franz N, Klinkhardt U, Harder S. Related Articles

Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
Br J Clin Pharmacol. 2001 Jun;51(6):577-82.
PMID: 11422017 [PubMed - indexed for MEDLINE]

☐ **156:** Wei M, Kuukasjarvi P, Laurikka J, Pehkonen E, Kaukinen S, Laine S, Tarkka M. Related Articles

Cytokine responses in patients undergoing coronary artery bypass surgery ischemic preconditioning.
Scand Cardiovasc J. 2001 Mar;35(2):142-6.
PMID: 11405491 [PubMed - indexed for MEDLINE]

☐ **157:** Oesterle SN, Reifart N, Hauptmann E, Hayase M, Yeung AC. Related Articles

Percutaneous in situ coronary venous arterialization: report of the first hur catheter-based coronary artery bypass.
Circulation. 2001 May 29;103(21):2539-43.
PMID: 11382720 [PubMed - indexed for MEDLINE]

☐ **158:** Hillebrands JL, Raue HP, Klatter FA, Hylkema MN, Platteel I, Hardonk-Wubbena A, Nieuwenhuis P, Rozing J. Related Articles

Intrathymic immune modulation prevents acute rejection but not the

development of graft arteriosclerosis (chronic rejection).
Transplantation. 2001 Apr 15;71(7):914-24.
PMID: 11349727 [PubMed - indexed for MEDLINE]

159: Xue M, Ren S, Welch S, Shen GX. Related Articles

Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency.
J Vasc Res. 2001 Mar-Apr;38(2):144-52.
PMID: 11316950 [PubMed - indexed for MEDLINE]

160: Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA. Related Articles

Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a pha trial in coronary artery disease.
J Clin Pharmacol. 2001 Apr;41(4):378-85.
PMID: 11304894 [PubMed - indexed for MEDLINE]

161: Ray S, Panja M. Related Articles

Current understanding of pathogenesis of coronary artery disease and its f implications.
J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.
PMID: 11265801 [PubMed - indexed for MEDLINE]

162: Brizzi MF, Formato L, Bonamini R. Related Articles

The molecular mechanisms of angiogenesis: a new approach to cardiovas diseases.
Ital Heart J. 2001 Feb;2(2):81-92. Review.
PMID: 11256548 [PubMed - indexed for MEDLINE]

163: Morse MA. Related Articles

Technology evaluation: VEGF165 gene therapy, Valentis Inc.
Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review.
PMID: 11249737 [PubMed - indexed for MEDLINE]

164: Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC. Related Articles

Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy.
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3276-81.
PMID: 11248069 [PubMed - indexed for MEDLINE]

165: Rosengart TK, Hillebrand K. Related Articles

Gene therapy for coronary artery disease.
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]

166: Elghannam H, Tavackoli S, Ferlic L, Gotto AM Jr, Ballantyne CM, Marian AJ. Related Articles

A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy.
J Mol Med. 2000;78(10):562-8.
PMID: 11199329 [PubMed - indexed for MEDLINE]

167: Freedman SB, Isner JM. Related Articles

Therapeutic angiogenesis for ischemic cardiovascular disease.
J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review.
PMID: 11181008 [PubMed - indexed for MEDLINE]

168: Durairaj A, Mehra A, Singh RP, Faxon DP. Related Articles

Therapeutic angiogenesis.
Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review.
PMID: 11174906 [PubMed - indexed for MEDLINE]

169: Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S. Related Articles

Clinical applications of vascular gene therapy.
Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.
PMID: 11139796 [PubMed - indexed for MEDLINE]

170: Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Related Articles

Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acut inflammation.
Circulation. 2001 Jan 2;103(1):108-12.
PMID: 11136694 [PubMed - indexed for MEDLINE]

171: Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM. Related Articles

Gene therapy with vascular endothelial growth factor for inoperable coror artery disease: anesthetic management and results.
Anesth Analg. 2001 Jan;92(1):19-25.
PMID: 11133594 [PubMed - indexed for MEDLINE]

172: Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, O'Brien E. Related Articles

Endoglin is overexpressed after arterial injury and is required for transfor growth factor-beta-induced inhibition of smooth muscle cell migration.
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2546-52.
PMID: 11116051 [PubMed - indexed for MEDLINE]

173: Wildhirt SM, Weis M, Schulze C, Conrad N, Rieder G, Enders G, Hoepp C, von Scheidt W, Reichart B. Related Articles

An association between microvascular endothelial dysfunction, transcardi nitric oxide production and pro-inflammatory cytokines after heart transplantation in humans.
Transpl Int. 2000;13 Suppl 1:S228-34.
PMID: 11112001 [PubMed - indexed for MEDLINE]

174: Schumacher B, Hannekum A, Pecher P. Related Articles

[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]
Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]

175: Gopalan R, Goldberg S. Related Articles

Tranilast in the Therapy of Coronary Artery Disease.
Curr Interv Cardiol Rep. 2000 May;2(2):149-156.
PMID: 11096662 [PubMed - as supplied by publisher]

176: Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, Wahl LM, Related Articles

Cannon RO 3rd.

Divergent effects of hormone therapy on serum markers of inflammation i postmenopausal women with coronary artery disease on appropriate medi management.
J Am Coll Cardiol. 2000 Nov 15;36(6):1797-802.
PMID: 11092646 [PubMed - indexed for MEDLINE]

177: Miniati DN, Hoyt EG, Feeley BT, Poston RS, Robbins RC. Related Articles

Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen an Cdc2 kinase inhibit graft coronary artery disease.
Circulation. 2000 Nov 7;102(19 Suppl 3):III237-42.
PMID: 11082394 [PubMed - indexed for MEDLINE]

178: Gruberg L, Waksman R, Satler LF, Pichard AD, Kent KM. Related Articles

Novel approaches for the prevention of restenosis.
Expert Opin Investig Drugs. 2000 Nov;9(11):2555-78. Review.
PMID: 11060820 [PubMed - indexed for MEDLINE]

179: Kaski JC. Related Articles

[Inflammation, infection and coronary artery disease: myths and realities. Special XXXV Conference of the National Congress of the Spanish Socie Cardiology]
Rev Esp Cardiol. 2000 Oct;53(10):1311-7. Review. Spanish.
PMID: 11060248 [PubMed - indexed for MEDLINE]

180: Appels A, Bar FW, Bar J, Bruggeman C, de Baets M. Related Articles

Inflammation, depressive symptomtology, and coronary artery disease.
Psychosom Med. 2000 Sep-Oct;62(5):601-5.
PMID: 11020087 [PubMed - indexed for MEDLINE]

181: Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Related Articles

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients wi severe symptomatic chronic coronary artery disease.
Circulation. 2000 Oct 3;102(14):1605-10.
PMID: 11015335 [PubMed - indexed for MEDLINE]

182: Rosen CJ, Glowacki J, Craig W. Related Articles

Sex steroids, the insulin-like growth factor regulatory system, and aging: implications for the management of older postmenopausal women.
J Nutr Health Aging. 1998;2(1):39-44. Review.
PMID: 10995078 [PubMed - indexed for MEDLINE]

183: Woods A, Brull DJ, Humphries SE, Montgomery HE. Related Articles

Genetics of inflammation and risk of coronary artery disease: the central r of interleukin-6.
Eur Heart J. 2000 Oct;21(19):1574-83. Review. No abstract available.
PMID: 10988009 [PubMed - indexed for MEDLINE]

184: August P, Leventhal B, Suthanthiran M. Related Articles

Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence.
Curr Hypertens Rep. 2000 Apr;2(2):184-91. Review.

PMID: 10981147 [PubMed - indexed for MEDLINE]

☐ **185:** Kanda T, Inoue M, Kotajima N, Fujimaki S, Hoshino Y, Kurabayashi M, Kobayashi I, Tamura J. Related Articles

Circulating interleukin-6 and interleukin-6 receptors in patients with acute recent myocardial infarction.
Cardiology. 2000;93(3):191-6.
PMID: 10965091 [PubMed - indexed for MEDLINE]

☐ **186:** Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM. Related Articles

Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.
Circulation. 2000 Aug 29;102(9):965-74.
PMID: 10961959 [PubMed - indexed for MEDLINE]

☐ **187:** Mukherjee D, Ellis SG. Related Articles

New options for untreatable coronary artery disease: angiogenesis and las revascularization.
Cleve Clin J Med. 2000 Aug;67(8):577-83.
PMID: 10946453 [PubMed - indexed for MEDLINE]

☐ **188:** Hamano K, Bashuda H, Ito H, Shirasawa B, Okumura K, Esato K. Related Articles

Graft vasculopathy and tolerance: does the balance of Th cells contribute graft vasculopathy?
J Surg Res. 2000 Sep;93(1):28-34.
PMID: 10945940 [PubMed - indexed for MEDLINE]

☐ **189:** O'Brien T, Simari RD. Related Articles

Gene therapy for atherosclerotic cardiovascular disease: a time for optimi and caution.
Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.
PMID: 10943238 [PubMed - indexed for MEDLINE]

☐ **190:** Isobe M, Suzuki J, Morishita R, Kaneda Y, Amano J. Related Articles

Gene therapy for heart transplantation-associated coronary arteriosclerosi
Ann N Y Acad Sci. 2000 May;902:77-83.
PMID: 10865827 [PubMed - indexed for MEDLINE]

☐ **191:** Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA. Related Articles

Effects of a single intracoronary injection of basic fibroblast growth facto stable angina pectoris.
Am J Cardiol. 2000 Jun 15;85(12):1414-9.
PMID: 10856385 [PubMed - indexed for MEDLINE]

☐ **192:** Anderson JL, Muhlestein JB. Related Articles

The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia).
J Infect Dis. 2000 Jun;181 Suppl 3:S569-71.
PMID: 10839761 [PubMed - indexed for MEDLINE]

☐ **193:** Griffioen AW, Molema G. Related Articles

Angiogenesis: potentials for pharmacologic intervention in the treatment

cancer, cardiovascular diseases, and chronic inflammation.
Pharmacol Rev. 2000 Jun;52(2):237-68. Review.
PMID: 10835101 [PubMed - indexed for MEDLINE]

☐ **194:** Lucassen AM, de Waal RM, Verheugt FW. Related Articles

[Therapeutic angiogenesis as a new experimental treatment for vascular disease]
Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch.
PMID: 10774292 [PubMed - indexed for MEDLINE]

☐ **195:** Osterziel KJ, Blum WF, Strohm O, Dietz R. Related Articles

The severity of chronic heart failure due to coronary artery disease predict endocrine effects of short-term growth hormone administration.
J Clin Endocrinol Metab. 2000 Apr;85(4):1533-9.
PMID: 10770193 [PubMed - indexed for MEDLINE]

☐ **196:** Yutani C, Ishibashi-Ueda H, Suzuki T, Kojima A. Related Articles

Histologic evidence of foreign body granulation tissue and de novo lesion patients with coronary stent restenosis.
Cardiology. 1999;92(3):171-7.
PMID: 10754347 [PubMed - indexed for MEDLINE]

☐ **197:** Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD, Burdick MD, Strieter RM. Related Articles

IL-8 is an angiogenic factor in human coronary atherectomy tissue.
Circulation. 2000 Apr 4;101(13):1519-26.
PMID: 10747344 [PubMed - indexed for MEDLINE]

☐ **198:** Mehrabi MR, Sinzinger H, Ekmekcioglu C, Tamaddon F, Plesch K, Glogar HD, Maurer G, Stefenelli T, Lang IM. Related Articles

Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis.
Cardiovasc Res. 2000 Mar;45(4):874-82.
PMID: 10728413 [PubMed - indexed for MEDLINE]

☐ **199:** Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Related Articles

Expression and function of PPARgamma in rat and human vascular smoo muscle cells.
Circulation. 2000 Mar 21;101(11):1311-8.
PMID: 10725292 [PubMed - indexed for MEDLINE]

☐ **200:** Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Related Articles

Hormone replacement therapy and interrelation between serum interleukin and body mass index in postmenopausal women: a population-based study
J Clin Endocrinol Metab. 2000 Mar;85(3):1340-4.
PMID: 10720088 [PubMed - indexed for MEDLINE]

☐ **201:** Saitoh T, Kishida H, Tsukada Y, Fukuma Y, Sano J, Yasutake M, Fukuma N, Kusama Y, Hayakawa H. Related Articles

Clinical significance of increased plasma concentration of macrophage co stimulating factor in patients with angina pectoris.
J Am Coll Cardiol. 2000 Mar 1;35(3):655-65.
PMID: 10716468 [PubMed - indexed for MEDLINE]

Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire

☐ **202:** U, Nilsson J, Hamsten A. Related Articles

Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardia infarction: beneficial effects of bezafibrate treatment.
J Am Coll Cardiol. 2000 Mar 1;35(3):647-54.
PMID: 10716467 [PubMed - indexed for MEDLINE]

☐ **203:** Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF. Related Articles

Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.
Cardiovasc Res. 1999 Nov;44(2):294-302.
PMID: 10690306 [PubMed - indexed for MEDLINE]

☐ **204:** Chawla PS, Keelan MH, Kipshidze N. Related Articles

Angiogenesis for the treatment of vascular diseases.
Int Angiol. 1999 Sep;18(3):185-92. Review.
PMID: 10688416 [PubMed - indexed for MEDLINE]

☐ **205:** Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Meier B, Luscher TF. Related Articles

Tetrahydrobiopterin improves endothelial function in patients with corona artery disease.
J Cardiovasc Pharmacol. 2000 Feb;35(2):173-8.
PMID: 10672847 [PubMed - indexed for MEDLINE]

☐ **206:** Harig F, Cesnjevar R, Mahmoud FO, von der Emde J. Related Articles

Perioperative factors influencing interleukin-10 release under cardiopulm bypass.
Thorac Cardiovasc Surg. 1999 Dec;47(6):361-8.
PMID: 10670793 [PubMed - indexed for MEDLINE]

☐ **207:** Taher A, Ammash Z, Dabajah B, Nasrallah A, Mourad FH. Related Articles

Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: cas report and literature review.
Am J Hematol. 2000 Feb;63(2):90-3. Review.
PMID: 10629575 [PubMed - indexed for MEDLINE]

☐ **208:** Furukawa Y, Matsumori A, Hwang MW, Hirozane T, Ono K, Shioi T, Sasayama S. Related Articles

Cytokine gene expression during the development of graft coronary artery disease in mice.
Jpn Circ J. 1999 Oct;63(10):775-82.
PMID: 10553920 [PubMed - indexed for MEDLINE]

☐ **209:** Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell RN. Related Articles

Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical eff of IL-10 in vivo.
Am J Pathol. 1999 Dec;155(6):1929-39.
PMID: 10595923 [PubMed - indexed for MEDLINE]

☐ **210:** Yamada N. Related Articles

[Physiopathology and therapy of acute coronary syndrome--molecular mechanism of formation and disruption of coronary atheroma]

Nippon Naika Gakkai Zasshi. 1999 Sep 10;88(9):1731-5. Review. Japanese. No abstract available.
PMID: 10581755 [PubMed - indexed for MEDLINE]

☐ 211: Hachida M, Lu H, Zhang X, Saito S, Furutani Y, Matsuoka R, Hoshi H, Koyanagi H. Related Articles

Inhibitory effect of triptolide on platelet derived growth factor-A and coro arteriosclerosis after heart transplantation.
Transplant Proc. 1999 Nov;31(7):2719-23. No abstract available.
PMID: 10578264 [PubMed - indexed for MEDLINE]

☐ 212: Moussa I, Moses JW. Related Articles

Angiogenesis for treatment of ischemic heart disease: should we worry ab progression of atherosclerosis?
Circulation. 1999 Nov 30;100(22):e109. No abstract available.
PMID: 10578010 [PubMed - indexed for MEDLINE]

☐ 213: Rus H, Niculescu F. Related Articles

Inflammatory response in unstable angina.
Circulation. 1999 Nov 9;100(19):e98. No abstract available.
PMID: 10556236 [PubMed - indexed for MEDLINE]

☐ 214: Meeking DR, Cummings MH, Thorne S, Donald A, Clarkson P, Crook JR, Watts GF, Shaw KM. Related Articles

Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria.
Diabet Med. 1999 Oct;16(10):841-7.
PMID: 10547211 [PubMed - indexed for MEDLINE]

☐ 215: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC. Related Articles

Adenovirus-mediated acidic fibroblast growth factor gene transfer induce angiogenesis in the nonischemic rabbit heart.
Microvasc Res. 1999 Nov;58(3):238-49.
PMID: 10527767 [PubMed - indexed for MEDLINE]

☐ 216: Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG. Related Articles

Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.
PMID: 10522716 [PubMed - indexed for MEDLINE]

☐ 217: Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM. Related Articles

Gene therapy with vascular endothelial growth factor for inoperable coror artery disease.
Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.
PMID: 10509970 [PubMed - indexed for MEDLINE]

☐ 218: Kato K, Matsubara T, Iida K, Suzuki O, Sato Y. Related Articles

Elevated levels of pro-inflammatory cytokines in coronary artery thrombi.
Int J Cardiol. 1999 Aug 31;70(3):267-73.
PMID: 10501341 [PubMed - indexed for MEDLINE]

Sellke FW, Simons M. Related Articles

☐ **219:**

Angiogenesis in cardiovascular disease: current status and therapeutic potential.
Drugs. 1999 Sep;58(3):391-6. Review.
PMID: 10493268 [PubMed - indexed for MEDLINE]

☐ **220:** Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Sasayama S. Related Articles

FTY720, a new immunosuppressant, promotes long-term graft survival ar inhibits the progression of graft coronary artery disease in a murine model cardiac transplantation.
Circulation. 1999 Sep 21;100(12):1322-9.
PMID: 10491378 [PubMed - indexed for MEDLINE]

☐ **221:** Sato T, Yoshinouchi T, Sugimoto T, Sakamoto T, Fujieda H, Murao S, Sato H, Ohe T. Related Articles

Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes.
Jpn Circ J. 1999 Aug;63(8):583-8.
PMID: 10478806 [PubMed - indexed for MEDLINE]

☐ **222:** Hachida M, Zhang X, Lu H, Hoshi H, Koyanagi H. Related Articles

Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts.
Jpn Circ J. 1999 Apr;63(4):303-8.
PMID: 10475779 [PubMed - indexed for MEDLINE]

☐ **223:** Ishibashi T, Kijima M, Yokoyama K, Shindo J, Nagata K, Hirosaka A, Techigawara M, Abe Y, Sato E, Yamaguchi N, Watanabe N, Saito T, Maehara K, Ohmoto Y, Maruyama Y. Related Articles

Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease.
Jpn Circ J. 1999 Apr;63(4):249-54.
PMID: 10475771 [PubMed - indexed for MEDLINE]

☐ **224:** Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, Barreca A, Masperone MA, Brunelli C. Related Articles

Evaluation of growth hormone administration in patients with chronic hea failure secondary to coronary artery disease.
Am J Cardiol. 1999 Aug 15;84(4):430-3.
PMID: 10468082 [PubMed - indexed for MEDLINE]

☐ **225:** Hussain MM, Strickland DK, Bakillah A. Related Articles

The mammalian low-density lipoprotein receptor family.
Annu Rev Nutr. 1999;19:141-72. Review.
PMID: 10448520 [PubMed - indexed for MEDLINE]

☐ **226:** Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Related Articles

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Circulation. 1999 Aug 3;100(5):468-74.
PMID: 10430759 [PubMed - indexed for MEDLINE]

☐ **227:** Losordo DW, Vale PR, Isner JM. Related Articles

Gene therapy for myocardial angiogenesis.
Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.
PMID: 10426872 [PubMed - indexed for MEDLINE]

☐ **228:** Casterella PJ, Teirstein PS. Related Articles

Prevention of coronary restenosis.
Cardiol Rev. 1999 Jul-Aug;7(4):219-31. Review.
PMID: 10423674 [PubMed - indexed for MEDLINE]

☐ **229:** Nogueira JB. Related Articles

[Hypertensive cardiopathy. From arterial hypertension to congestive heart failure]
Rev Port Cardiol. 1999 Jun;18(6):635-46. Review. Portuguese.
PMID: 10422461 [PubMed - indexed for MEDLINE]

☐ **230:** Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M. Related Articles

Development of enzyme-linked immunosorbent assay for acidic fibroblas growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

☐ **231:** Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M. Related Articles

Exercise provides direct biphasic cardioprotection via manganese superox dismutase activation.
J Exp Med. 1999 Jun 7;189(11):1699-706.
PMID: 10359573 [PubMed - indexed for MEDLINE]

☐ **232:** Patterson C, Runge MS. Related Articles

Therapeutic angiogenesis: the new electrophysiology?
Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.
PMID: 10338451 [PubMed - indexed for MEDLINE]

☐ **233:** Zhang X, Hachida M, Lu H, Hoshi H, Koyanagi H. Related Articles

Effect of 15-deoxyspergualine on coronary arteriosclerosis and platelet-de growth factor-A mRNA expression in the transplanted heart.
Transplant Proc. 1999 May;31(3):1706-9. No abstract available.
PMID: 10331045 [PubMed - indexed for MEDLINE]

☐ **234:** Hachida M, Zhang X, Lu H, Hoshi H, Koyanagi H. Related Articles

Multiglycosidorum tripterygii, a new immunosuppressant, supresses coro arteriosclerosis after heart transplantation.
J Heart Lung Transplant. 1999 Mar;18(3):248-54.
PMID: 10328151 [PubMed - indexed for MEDLINE]

☐ **235:** Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Related Articles

Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumon infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
Circulation. 1999 Mar 30;99(12):1540-7.
PMID: 10096928 [PubMed - indexed for MEDLINE]

☐ **236:** Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS. Related Articles

Association of plasma fibrinogen concentration with vascular access failu hemodialysis patients.
Nephrol Dial Transplant. 1999 Jan;14(1):137-41.
PMID: 10052493 [PubMed - indexed for MEDLINE]

☐ **237:** Dickson TJ, Gurudutt V, Nguyen AQ, Kumfer K, Maxted W, Brown J, Mahomed Y, Sharp T, Aufiero TX, Fineberg N, March KL. Related Articles

Establishment of a clinically correlated human pericardial fluid bank: evaluation of intrapericardial diagnostic potential.
Clin Cardiol. 1999 Jan;22(1 Suppl 1):I40-2.
PMID: 9929767 [PubMed - indexed for MEDLINE]

☐ **238:** Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Related Articles

Gene therapy for myocardial angiogenesis: initial clinical results with dire myocardial injection of phVEGF165 as sole therapy for myocardial ischei
Circulation. 1998 Dec 22-29;98(25):2800-4.
PMID: 9860779 [PubMed - indexed for MEDLINE]

☐ **239:** Ito H, Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. Related Articles

Coronary arteriosclerosis did not occur in the transplanted hearts of tolera induced rats: analysis from platelet-derived growth factor expression.
Transplant Proc. 1998 Nov;30(7):3871-2. No abstract available.
PMID: 9838694 [PubMed - indexed for MEDLINE]

☐ **240:** Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW. Related Articles

Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.
J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.
PMID: 9832695 [PubMed - indexed for MEDLINE]

☐ **241:** Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K. Related Articles

Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF progression of atherosclerosis.
Circulation. 1998 Nov 17;98(20):2108-16.
PMID: 9815864 [PubMed - indexed for MEDLINE]

☐ **242:** Iwakura A, Komeda M, Fujita M. Related Articles

[Coronary stenosis and mechanisms of collateral vessel growth]
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
PMID: 9796310 [PubMed - indexed for MEDLINE]

☐ **243:** Vogel RA, Corretti MC, Gellman J. Related Articles

Cholesterol, cholesterol lowering, and endothelial function.
Prog Cardiovasc Dis. 1998 Sep-Oct;41(2):117-36. Review.
PMID: 9790413 [PubMed - indexed for MEDLINE]

☐ **244:** Metais C, Li J, Li J, Simons M, Sellke FW. Related Articles

Effects of coronary artery disease on expression and microvascular respor

VEGF.
Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.
PMID: 9746492 [PubMed - indexed for MEDLINE]

☐ **245:** Yazdani S, Simon AD, Vidhun R, Gulotta C, Schwartz A, Rabbani LE. Related Articles

Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions.
Am Heart J. 1998 Aug;136(2):357-61.
PMID: 9704702 [PubMed - indexed for MEDLINE]

☐ **246:** Kagan SA, Myers SI. Related Articles

Mediators of restenosis.
Surg Clin North Am. 1998 Jun;78(3):481-500. Review.
PMID: 9673658 [PubMed - indexed for MEDLINE]

☐ **247:** Remme WJ. Related Articles

The sympathetic nervous system and ischaemic heart disease.
Eur Heart J. 1998 Jun;19 Suppl F:F62-71. Review.
PMID: 9651738 [PubMed - indexed for MEDLINE]

☐ **248:** Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Related Articles

Therapeutic angiogenesis with basic fibroblast growth factor: technique a early results.
Ann Thorac Surg. 1998 Jun;65(6):1540-4.
PMID: 9647055 [PubMed - indexed for MEDLINE]

☐ **249:** Hachida M, Zhang XL, Lu H, Hoshi H, Koyanagi H. Related Articles

Inhibitory effect of Multiglycosidorum tripterygii on coronary arteriosclei after heart transplantation.
Transplantation. 1998 Jun 15;65(11):1446-50.
PMID: 9645800 [PubMed - indexed for MEDLINE]

☐ **250:** Foegh ML, Ramwell PW. Related Articles

Pharmacologic control of smooth muscle cells in allografts.
Transpl Immunol. 1997 Dec;5(4):267-75. Review. No abstract available.
PMID: 9504146 [PubMed - indexed for MEDLINE]

☐ **251:** Schwartz SM. Related Articles

Smooth muscle migration in vascular development and pathogenesis.
Transpl Immunol. 1997 Dec;5(4):255-60. Review. No abstract available.
PMID: 9504144 [PubMed - indexed for MEDLINE]

☐ **252:** Eickelberg O, Roth M, Block LH. Related Articles

Effects of amlodipine on gene expression and extracellular matrix formati human vascular smooth muscle cells and fibroblasts: implications for vasc protection.
Int J Cardiol. 1997 Dec 31;62 Suppl 2:S31-7. Review.
PMID: 9488193 [PubMed - indexed for MEDLINE]

☐ **253:** Brilla CG, Rybinski L, Gehrke D, Rupp H. Related Articles

[Transmyocardial laser revascularization--an innovative pathophysiologic concept]
Herz. 1997 Aug;22(4):183-9. Review. German.
PMID: 9378452 [PubMed - indexed for MEDLINE]

☐ **254:** Shanahan CM, Cary NR, Osbourn JK, Weissberg PL. Related Articles

Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2437-47.
PMID: 9409213 [PubMed - indexed for MEDLINE]

☐ **255:** Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Yonemitsu Y, Kuga T, Egashira K, Sueishi K, Takeshita A. Related Articles

Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1beta in pi vivo.
Circulation. 1997 Nov 4;96(9):3104-11.
PMID: 9386181 [PubMed - indexed for MEDLINE]

☐ **256:** Bombardini T, Picano E. Related Articles

The coronary angiogenetic effect of heparin: experimental basis and clinic evidence.
Angiology. 1997 Nov;48(11):969-76. Review.
PMID: 9373049 [PubMed - indexed for MEDLINE]

☐ **257:** Suzuki J, Isobe M, Yamazaki S, Horie S, Okubo Y, Sekiguchi M. Related Articles

Inhibition of accelerated coronary atherosclerosis with short-term blockad intercellular adhesion molecule-1 and lymphocyte function-associated ant 1 in a heterotopic murine model of heart transplantation.
J Heart Lung Transplant. 1997 Nov;16(11):1141-8.
PMID: 9402514 [PubMed - indexed for MEDLINE]

☐ **258:** Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W. Related Articles

Increased neopterin in patients with chronic and acute coronary syndrome
J Am Coll Cardiol. 1997 Sep;30(3):703-7.
PMID: 9283529 [PubMed - indexed for MEDLINE]

☐ **259:** Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K. Related Articles

Appropriate hematocrit levels of erythropoietin supplementary therapy in stage renal failure complicated by coronary artery disease.
Can J Cardiol. 1997 Aug;13(8):747-53. Review.
PMID: 9284841 [PubMed - indexed for MEDLINE]

☐ **260:** Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S, Fujiwara H. Related Articles

Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
J Am Coll Cardiol. 1997 May;29(6):1214-20.
PMID: 9137215 [PubMed - indexed for MEDLINE]

☐ **261:** Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Related Articles

Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)
Eur J Endocrinol. 1997 Apr;136(4):377-81.
PMID: 9150696 [PubMed - indexed for MEDLINE]

☐ **262:** Grant MB, Wargovich TJ, Ellis EA, Tarnuzzer R, Caballero S, Estes K, Related Articles

Rossing M, Spoerri PE, Pepine C.

Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 -5 in human atherectomy specimens.
Regul Pept. 1996 Dec 17;67(3):137-44.
PMID: 8988513 [PubMed - indexed for MEDLINE]

263: Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML. Related Articles

L-arginine prevents heart transplant arteriosclerosis by modulating the vas cell proliferative response to insulin-like growth factor-I and interleukin-6
J Heart Lung Transplant. 1996 Dec;15(12):1248-57.
PMID: 8981210 [PubMed - indexed for MEDLINE]

264: Hasper D, Hummel M, Docke WD, Kleber FX, Felix SB, Hetzer R, Volk HD. Related Articles

[Inflammatory mediators in patients with biventricular assist device syste
Z Kardiol. 1996 Nov;85(11):820-7. German.
PMID: 9064944 [PubMed - indexed for MEDLINE]

265: Newby AC, George SJ. Related Articles

Proliferation, migration, matrix turnover, and death of smooth muscle cell native coronary and vein graft atherosclerosis.
Curr Opin Cardiol. 1996 Nov;11(6):574-82. Review.
PMID: 8968671 [PubMed - indexed for MEDLINE]

266: Imagawa DK, Dawson S 3rd, Holt CD, Kirk PS, Kaldas FM, Shackleton CR, Seu P, Rudich SM, Kinkhabwala MM, Martin P, Goldstein LI, Murray NG, Terasaki PI, Busuttil RW. Related Articles

Hyperlipidemia after liver transplantation: natural history and treatment w the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.
Transplantation. 1996 Oct 15;62(7):934-42.
PMID: 8878387 [PubMed - indexed for MEDLINE]

267: Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DE. Related Articles

Growth hormone treatment increases circulating lipoprotein(a) in children chronic renal failure.
J Pediatr Endocrinol Metab. 1996 Sep-Oct;9(5):533-7.
PMID: 8961129 [PubMed - indexed for MEDLINE]

268: Lombardi G, Colao A, Ferone D, Marzullo P, Landi ML, Longobardi S, Iervolino E, Cuocolo A, Fazio S, Merola B, Sacca L. Related Articles

Cardiovascular aspects in acromegaly: effects of treatment.
Metabolism. 1996 Aug;45(8 Suppl 1):57-60.
PMID: 8769383 [PubMed - indexed for MEDLINE]

269: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M. Related Articles

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.
Surgery. 1996 Aug;120(2):182-8.
PMID: 8751581 [PubMed - indexed for MEDLINE]

270: Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Eldar M, Barak V. Related Articles

Increased serum concentrations of interleukin-1 beta in patients with coro artery disease.
Heart. 1996 Jul;76(1):24-8.

PMID: 8774323 [PubMed - indexed for MEDLINE]

☐ 271: Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, Nakaike R, Takayanagi T, Egashira K, Takeshita A. Related Articles

Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes anc vasospastic responses induced by chronic treatment with interleukin-1 bet pigs in vivo.
J Clin Invest. 1995 Sep;96(3):1288-94.
PMID: 7657803 [PubMed - indexed for MEDLINE]

☐ 272: Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R. Related Articles

Proliferative activity in coronary atherectomy tissue. Clinical, histopathol and immunohistochemical correlates.
Chest. 1995 Sep;108(3):815-20.
PMID: 7656639 [PubMed - indexed for MEDLINE]

☐ 273: Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. Related Articles

The three processes leading to post PTCA restenosis: dependence on the l substrate.
Thromb Haemost. 1995 Jul;74(1):552-9. Review. No abstract available.
PMID: 8578523 [PubMed - indexed for MEDLINE]

☐ 274: Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, Adelman AG, Rabinovitch M. Related Articles

Expression of tumour necrosis factor alpha and accumulation of fibronect coronary artery restenotic lesions retrieved by atherectomy.
Br Heart J. 1995 Jun;73(6):534-9.
PMID: 7626352 [PubMed - indexed for MEDLINE]

☐ 275: Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kierulf P. Related Articles

Effect of long-term, moderate-dose supplementation with omega-3 fatty a on monocyte procoagulant activity and release of interleukin-6 in patients coronary artery disease.
Thromb Res. 1995 Feb 15;77(4):337-46.
PMID: 7740525 [PubMed - indexed for MEDLINE]

☐ 276: Hombach V, Waltenberger J, Voisard R, Hoher M. Related Articles

[Recurrent stenosis following coronary angioplasty. Clinical, cell biologic and molecular aspects]
Z Kardiol. 1995 Jan;84(1):5-21. Review. German.
PMID: 7863714 [PubMed - indexed for MEDLINE]

☐ 277: Mann JF. Related Articles

Hypertension and cardiovascular effects--long-term safety and potential lc term benefits of r-HuEPO.
Nephrol Dial Transplant. 1995;10 Suppl 2:80-4.
PMID: 7644111 [PubMed - indexed for MEDLINE]

☐ 278: Schulte HM, Bamberger CM, Elsen H, Herrmann G, Bamberger AM, Barth J. Related Articles

Systemic interleukin-1 alpha and interleukin-2 secretion in response to acı stress and to corticotropin-releasing hormone in humans.
Eur J Clin Invest. 1994 Nov;24(11):773-7.
PMID: 7890016 [PubMed - indexed for MEDLINE]

☐ **279:** Dzau VJ. Related Articles

Cell biology and genetics of angiotensin in cardiovascular disease.
J Hypertens Suppl. 1994 Jul;12(4):S3-10. Review.
PMID: 7965271 [PubMed - indexed for MEDLINE]

☐ **280:** Hofling B, Gonschior P, Nikol S, Bauriedel G, Welsch U, Nerlich A. Related Articles

[Pathophysiology and pathobiochemistry of restenosis]
Z Kardiol. 1994 May;83(5):313-8. Review. German.
PMID: 8053238 [PubMed - indexed for MEDLINE]

☐ **281:** Pfeifer PB, Collins EG. Related Articles

Cardiac allograft vasculopathy.
J Cardiovasc Nurs. 1994 Apr;8(3):68-86. Review.
PMID: 8207461 [PubMed - indexed for MEDLINE]

☐ **282:** Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Related Articles

Localization of insulin-like growth factor I and inhibition of coronary smc muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?
Circulation. 1994 Apr;89(4):1511-7.
PMID: 7908609 [PubMed - indexed for MEDLINE]

☐ **283:** Bauriedel G, Kandolf R, Welsch U, Hofling B. Related Articles

[Mechanisms of re-stenosis after angioplasty]
Z Kardiol. 1994;83 Suppl 4:31-41. Review. German.
PMID: 7856278 [PubMed - indexed for MEDLINE]

☐ **284:** Wilcox JN. Related Articles

Molecular biology: insight into the causes and prevention of restenosis aft arterial intervention.
Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review.
PMID: 8213576 [PubMed - indexed for MEDLINE]

☐ **285:** Anderson HV, Vignale SJ, Benedict CR, Willerson JT. Related Articles

Restenosis after coronary angioplasty.
J Interv Cardiol. 1993 Sep;6(3):187-202. Review.
PMID: 10151016 [PubMed - indexed for MEDLINE]

☐ **286:** Johansson SR, Nilsson J, Hamsten A, Emanuelsson H. Related Articles

Mitogenic activity in connection with coronary angioplasty.
Eur Heart J. 1993 Jul;14(7):904-9.
PMID: 8375413 [PubMed - indexed for MEDLINE]

☐ **287:** Clausell N, Molossi S, Rabinovitch M. Related Articles

Increased interleukin-1 beta and fibronectin expression are early features development of the postcardiac transplant coronary arteriopathy in piglets
Am J Pathol. 1993 Jun;142(6):1772-86.
PMID: 8506947 [PubMed - indexed for MEDLINE]

☐ **288:** Badimon JJ, Fuster V, Chesebro JH, Badimon L. Related Articles

Coronary atherosclerosis. A multifactorial disease.
Circulation. 1993 Mar;87(3 Suppl):II3-16. Review.
PMID: 8443920 [PubMed - indexed for MEDLINE]

289: Hase H, Imamura Y, Nakamura R, Inishi Y, Machii K, Yamaguchi T. Related Articles

Effects of rHuEPO therapy on exercise capacity in hemodialysis patients coronary artery disease.
Jpn Circ J. 1993 Feb;57(2):131-7.
PMID: 8450597 [PubMed - indexed for MEDLINE]

290: Luscher TF, Tanner FC, Tschudi MR, Noll G. Related Articles

Endothelial dysfunction in coronary artery disease.
Annu Rev Med. 1993;44:395-418. Review.
PMID: 8476260 [PubMed - indexed for MEDLINE]

291: Lindemann A, Rumberger B. Related Articles

Vascular complications in patients treated with granulocyte colony-stimul factor (G-CSF)
Eur J Cancer. 1993;29A(16):2338-9. No abstract available.
PMID: 8110510 [PubMed - indexed for MEDLINE]

292: Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. Related Articles

A cascade model for restenosis. A special case of atherosclerosis progress
Circulation. 1992 Dec;86(6 Suppl):III47-52. Review.
PMID: 1424051 [PubMed - indexed for MEDLINE]

293: Fuster V, Badimon JJ, Badimon L. Related Articles

Clinical-pathological correlations of coronary disease progression and regression.
Circulation. 1992 Dec;86(6 Suppl):III1-11. Review.
PMID: 1424042 [PubMed - indexed for MEDLINE]

294: Sasayama S, Fujita M. Related Articles

Recent insights into coronary collateral circulation.
Circulation. 1992 Mar;85(3):1197-204. Review.
PMID: 1371432 [PubMed - indexed for MEDLINE]

295: Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Konishi H, Shibata Y. Related Articles

[Autologous blood transfusion with erythropoietin in heart surgery in an anemic patient]
Nippon Kyobu Geka Gakkai Zasshi. 1992 Feb;40(2):282-5. Japanese.
PMID: 1593170 [PubMed - indexed for MEDLINE]

296: Juliard JM, Himbert D, Steg PG. Related Articles

[Can coronary "restenosis" after percutaneous angioplasty be prevented?]
Presse Med. 1992 Feb 1;21(4):149-52. Review. French. No abstract available.
PMID: 1532070 [PubMed - indexed for MEDLINE]

297: Wizemann V, Kaufmann J, Kramer W. Related Articles

Effect of erythropoietin on ischemia tolerance in anemic hemodialysis pat with confirmed coronary artery disease.
Nephron. 1992;62(2):161-5.
PMID: 1436308 [PubMed - indexed for MEDLINE]

298: Rosendorff C. Related Articles

Reversal of structural changes in hypertensive arteries--a major prospect f the future.

S Afr Med J. 1991 Sep 21;Suppl:4-6. Review.
PMID: 1925814 [PubMed - indexed for MEDLINE]

☐ **299:** Hermans WR, Rensing BJ, Strauss BH, Serruys PW. Related Articles

Prevention of restenosis after percutaneous transluminal coronary angiopl the search for a "magic bullet".
Am Heart J. 1991 Jul;122(1 Pt 1):171-87. Review. No abstract available.
PMID: 2063736 [PubMed - indexed for MEDLINE]

☐ **300:** Wilcox JN. Related Articles

Thrombin and other potential mechanisms underlying restenosis.
Circulation. 1991 Jul;84(1):432-5. No abstract available.
PMID: 2060116 [PubMed - indexed for MEDLINE]

☐ **301:** DeFeudis FV. Related Articles

Coronary atherosclerosis: current therapeutic approaches and future trend:
Life Sci. 1991;49(10):689-705. Review.
PMID: 1875779 [PubMed - indexed for MEDLINE]

☐ **302:** Kragel AH, Travis WD, Feinberg L, Pittaluga S, Striker LM, Roberts WC, Lotze MT, Yang JJ, Rosenberg SA. Related Articles

Pathologic findings associated with interleukin-2-based immunotherapy f cancer: a postmortem study of 19 patients.
Hum Pathol. 1990 May;21(5):493-502.
PMID: 2338330 [PubMed - indexed for MEDLINE]

☐ **303:** Popma JJ, Topol EJ. Related Articles

Factors influencing restenosis after coronary angioplasty.
Am J Med. 1990 Jan;88(1N):16N-24N. Review.
PMID: 2195881 [PubMed - indexed for MEDLINE]

☐ **304:** Ouchi Y, Orimo H. Related Articles

The role of calcium antagonists in the treatment of atherosclerosis and hypertension.
J Cardiovasc Pharmacol. 1990;16 Suppl 2:S1-4. Review.
PMID: 1369701 [PubMed - indexed for MEDLINE]

☐ **305:** Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ. Related Articles

Myocardial toxic effects during recombinant interleukin-2 therapy.
J Natl Cancer Inst. 1989 Jan 4;81(1):59-63.
PMID: 2783257 [PubMed - indexed for MEDLINE]

☐ **306:** Friedman EA. Related Articles

Renal failure in diabetes: a substantive problem in provision of health car
Verh K Acad Geneeskd Belg. 1989;51(2):81-149; discussion 149-51. Review.
PMID: 2678807 [PubMed - indexed for MEDLINE]

☐ **307:** Fuster V, Griggs TR. Related Articles

Porcine von Willebrand disease: implications for the pathophysiology of atherosclerosis and thrombosis.
Prog Hemost Thromb. 1986;8:159-83. Review.
PMID: 3550894 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

1: J Natl Cancer Inst. 1989 Jan 4;81(1):59-63. Related Article

Myocardial toxic effects during recombinant interleukin-2 thera

Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ.

Department of Medicine, University of Maryland Cancer Center, Baltimore 2

Arterial and pulmonary artery catheters were used to monitor the cardiopulm effects of recombinant interleukin-2 (rIL-2) given iv at a dose of 100,000 U/k every 8 hours on days 1-5 to 10 patients with metastatic solid tumors. As anticipated, a severe capillary leak syndrome developed in all patients. Myoc infarction (MI) occurred unexpectedly in three patients, as evidenced by a fo injury pattern on ECG and elevations of creatinine phosphokinase myocardia band fractions. All patients receiving rIL-2 exhibited major reductions in thei ventricular stroke work index (47 +/- 11 g.m/m2 to 29 +/- g.m/m2), an index cardiac contractility. It remains uncertain whether the MIs were a byproduct capillary leak syndrome in patients with underlying coronary artery disease c whether rIL-2 directly or indirectly damages cardiac muscle.

PMID: 2783257 [PubMed - indexed for MEDLINE]

1: Ann Thorac Surg. 1998 Jun;65(6):1540-4.

Related Article

ELSEVIER SCIENCE
FULL-TEXT ARTICLE

Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.

Angiogenesis Research Center, Department of Surgery at Beth Israel Deacon Medical Center, Boston, Massachusetts 02215, USA. fsellke@bidmc.harvarc

BACKGROUND: Patients not amenable to complete myocardial revascularis by conventional methods present a difficult clinical problem. Here we presen early results and technical considerations of the administration of basic fibrol growth factor for the induction of collateral growth using heparin-alginate sl release devices in patients undergoing coronary artery bypass grafting. METHODS: Eight patients were enrolled. Patients were candidates if they h least one graftable obstructed coronary artery and at least one major arterial distribution not amenable to revascularization, a serum creatinine level less t mg/dL, ejection fraction greater than 0.20, and estimated operative mortality less than 25%. During conventional coronary artery bypass grafting, 10 hepa alginate devices, each containing either 1 microg or 10 microg of basic fibrol growth factor, were implanted in the epicardial fat in multiple regions of the unrevascularizable territory and also in the distal distribution of a grafted or artery. RESULTS: There was no mortality and no evidence of renal, hematol or hepatic toxicity during follow-up. Three months after the operation, all pa remain free of angina. Seven patients were examined with stress perfusion sc Three patients had clear enhancement of perfusion to the unrevascularized myocardium, 1 patient had a new fixed defect, and 3 had minimal overall ch but had evidence of new small, fixed perfusion defects. Seven patients had improved or similar myocardial contractile function (ejection fraction at 3-m follow-up = 0.53 +/- 0.22 versus 0.47 +/- 0.14 preoperatively). One patient suffered a perioperative myocardial infarction in the area of basic fibroblast growth factor administration. CONCLUSIONS: This preliminary study demonstrates the safety and technical feasibility of therapeutic angiogenesis basic fibroblast growth factor delivered by heparin-alginate slow-release dev Further studies examining the safety, clinical efficacy, and long-term results ongoing.

Publication Types:

- Clinical Trial



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for growth factor AND coronary artery disease AND Go Clear

Limits Preview/Index History Clipboard Details

No items found.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Oct 13 2004 06:44:09



No items found.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Oct 13 2004 06:44:09

1: Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Related Articles

Safety of local delivery of low- and intermediate-dose adenovirus gene trans vectors to individuals with a spectrum of morbid conditions.
Hum Gene Ther. 2002 Jan 1;13(1):15-63.
PMID: 11779412 [PubMed - indexed for MEDLINE]



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for growth factor AND coronary artery disease AND Go Clear

Limits Preview/Index History Clipboard Details

No items found.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Oct 13 2004 06:44:09

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for FGF AND inhalation Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 31 of 31

One

1: Thienthong S, Krisanaprakornkit W, Sinkuakool C, Taesiri W, Jitraniyom P. Related Articles

Concentrations and costs of a thirty second priming technique with sevoflura using the circle circuit.
J Med Assoc Thai. 2003 Jul;86(7):617-21.
PMID: 12948255 [PubMed - indexed for MEDLINE]

2: Tempia A, Olivei MC, Calza E, Lambert H, Scotti L, Orlando E, Livigni S, Guglielmotti E. Related Articles

The anesthetic conserving device compared with conventional circle system under different flow conditions for inhaled anesthesia.
Anesth Analg. 2003 Apr;96(4):1056-61, table of contents.
PMID: 12651660 [PubMed - indexed for MEDLINE]

3: Feldman JM. Related Articles

A simple strategy for faster induction and more cost-effective use of anesthe vapor.
J Clin Monit Comput. 1999 Jan;15(1):17-21.
PMID: 12578057 [PubMed - indexed for MEDLINE]

4: Euliano TY, van Oostrom JH, van der Aa J. Related Articles

Waste gas monitor reduces wasted volatile anesthetic.
J Clin Monit Comput. 1999 Jul;15(5):287-93.
PMID: 12568134 [PubMed - indexed for MEDLINE]

5: Petroz GC, Lerman J. Related Articles

Preparation of the Siemens KION anesthetic machine for patients susceptibl malignant hyperthermia.
Anesthesiology. 2002 Apr;96(4):941-6.
PMID: 11964603 [PubMed - indexed for MEDLINE]

6: Lerou JG, Verheijen R, Booij LH. Related Articles

Model-based administration of inhalation anaesthesia. 4. Applying the syste model.
Br J Anaesth. 2002 Feb;88(2):175-83.
PMID: 11883384 [PubMed - indexed for MEDLINE]

7: Lerou JG, Booij LH. Related Articles

Model-based administration of inhalation anaesthesia. 3. Validating the syst model.
Br J Anaesth. 2002 Jan;88(1):24-37.
PMID: 11883376 [PubMed - indexed for MEDLINE]

8: Gotohda T, Tokunaga I, Kubo S, Morita K, Kitamura O, Eguchi A. Related Articles

Effect of toluene inhalation on astrocytes and neurotrophic factor in rat brair
Forensic Sci Int. 2000 Sep 11;113(1-3):233-8.
PMID: 10978631 [PubMed - indexed for MEDLINE]

☐ 9: Hendrickx JF, Vandeput DM, De Geyndt AM, De Ridder KP, Haenen JS, Deloof T, De Wolf AM. Related Articles

Maintaining sevoflurane anesthesia during low-flow anesthesia using a singl vaporizer setting change after overpressure induction.
J Clin Anesth. 2000 Jun;12(4):303-7.
PMID: 10960203 [PubMed - indexed for MEDLINE]

☐ 10: Hendrickx JF, Vandeput DM, De Geyndt AM, DeLoof T, De Wolf AM. Related Articles

Coasting after overpressure induction with sevoflurane.
J Clin Anesth. 2000 Mar;12(2):100-3.
PMID: 10818322 [PubMed - indexed for MEDLINE]

☐ 11: Ceccarelli P, Bigatello LM, Hess D, Kwo J, Melendez L, Hurford WE. Related Articles

Inhaled nitric oxide delivery by anesthesia machines.
Anesth Analg. 2000 Feb;90(2):482-8.Erratum in: Anesth Analg 2000 Mar;90(3):516.
PMID: 10648344 [PubMed - indexed for MEDLINE]

☐ 12: Bonome C, Belda J, Alvarez-Refojo F, Soro M, Fernandez-Goti C, Cortes A. Related Articles

Low-flow anesthesia and reduced animal size increase carboxyhemoglobin levels in swine during desflurane and isoflurane breakdown in dried soda li
Anesth Analg. 1999 Oct;89(4):909-16.
PMID: 10607409 [PubMed - indexed for MEDLINE]

☐ 13: Okada K, Nakayama H, Aizawa J, Okada H, Nunokawa N, Wakusawa R. Related Articles

[Low flow anesthesia at a fresh gas flow of 10 ml.kg-1.min-1 for hours usii time-cycled ventilator]
Masui. 1999 May;48(5):500-5. Japanese.
PMID: 10380504 [PubMed - indexed for MEDLINE]

☐ 14: Igarashi M, Watanabe H, Iwasaki H, Namiki A. Related Articles

Clinical evaluation of low-flow sevoflurane anaesthesia for paediatric patie
Acta Anaesthesiol Scand. 1999 Jan;43(1):19-23.
PMID: 9926182 [PubMed - indexed for MEDLINE]

☐ 15: Avramov MN, Griffin JD, White PF. Related Articles

The effect of fresh gas flow and anesthetic technique on the ability to contr acute hemodynamic responses during surgery.
Anesth Analg. 1998 Sep;87(3):666-70.
PMID: 9728850 [PubMed - indexed for MEDLINE]

☐ 16: Okada K, Asano N, Kimura O, Okada H, Nishio S, Wakusawa R. Related Articles

[Low flow anesthesia using a fresh gas flow of 600 ml.min-1 for 5 hours]
Masui. 1997 Oct;46(10):1321-8. Japanese.
PMID: 9369046 [PubMed - indexed for MEDLINE]

☐ 17: Biro P. Related Articles

[Anesthetic gas consumption and costs in a closed system with the PhysioF anesthesia equipment]
Anaesthesist. 1993 Sep;42(9):638-43. German.

PMID: 8214536 [PubMed - indexed for MEDLINE]

☐ **18:** Tweed WA, Amatya R, Spoerel WE. Related Articles

Re-evaluation of the Farman entrainer in a low-pressure system for field anaesthesia.
Can J Anaesth. 1990 Nov;37(8):924-7.
PMID: 2253301 [PubMed - indexed for MEDLINE]

☐ **19:** Tweed WA, Amatya R, Spoerel WE. Related Articles

A low-pressure portable anaesthesia system for field use: clinical trials.
Can J Anaesth. 1990 Nov;37(8):928-31.
PMID: 2147595 [PubMed - indexed for MEDLINE]

☐ **20:** Conterato JP, Lindahl SG, Meyer DM, Bires JA. Related Articles

Assessment of spontaneous ventilation in anesthetized children with use of pediatric circle or a Jackson-Rees system.
Anesth Analg. 1989 Oct;69(4):484-90.
PMID: 2782648 [PubMed - indexed for MEDLINE]

☐ **21:** Mertzlufft F, Brandt L, Nick D, Jantzen JP, Dick W. Related Articles

[The washout behavior of isoflurane following balanced anesthesia and its on postoperative oxygen supply]
Anaesthesist. 1989 Aug;38(8):401-7. German.
PMID: 2782597 [PubMed - indexed for MEDLINE]

☐ **22:** Shah NK, Loughlin CJ, Bedford RF. Related Articles

Comparison of the Bain and the ADE systems during controlled ventilation adults.
Br J Anaesth. 1989 Feb;62(2):150-2.
PMID: 2493798 [PubMed - indexed for MEDLINE]

☐ **23:** Rampton AJ, Mallaiah S, Garrett CP. Related Articles

Increased ventilation requirements during obstetric general anaesthesia.
Br J Anaesth. 1988 Dec;61(6):730-7.
PMID: 3145001 [PubMed - indexed for MEDLINE]

☐ **24:** Hatch DJ, Yates AP, Lindahl SG. Related Articles

Flow requirements and rebreathing during mechanically controlled ventilat in a T-piece (Mapleson E) system.
Br J Anaesth. 1987 Dec;59(12):1533-40.
PMID: 3122808 [PubMed - indexed for MEDLINE]

☐ **25:** Duncan PW, Lawes EG, Bland B, Downing JW. Related Articles

Fresh gas flow requirements using the ADE anaesthetic system during late pregnancy.
Br J Anaesth. 1987 Mar;59(3):360-3.
PMID: 3103662 [PubMed - indexed for MEDLINE]

☐ **26:** Lindahl SG, Charlton AJ, Hatch DJ. Related Articles

Ventilatory responses to rebreathing and carbon dioxide inhalation during anaesthesia in children.
Br J Anaesth. 1985 Dec;57(12):1188-96.
PMID: 3936525 [PubMed - indexed for MEDLINE]

☐ **27:** Lindahl SG, Charlton AJ, Hatch DJ. Related Articles

Accuracy of prediction of fresh gas flow requirements during spontaneous breathing with the T-piece.
Eur J Anaesthesiol. 1984 Sep;1(3):269-74.
PMID: 6443091 [PubMed - indexed for MEDLINE]

☐ **28:** Kay B, Beatty PC, Healy TE, Accoush ME, Calpin M. Related Articles

Change in the work of breathing imposed by five anaesthetic breathing syst
Br J Anaesth. 1983 Dec;55(12):1239-47.
PMID: 6580908 [PubMed - indexed for MEDLINE]

☐ **29:** Aldrete JA, Cubillos P, Sherrill D. Related Articles

Humidity and temperature changes during low flow and closed system anaesthesia.
Acta Anaesthesiol Scand. 1981 Aug;25(4):312-4.
PMID: 7315178 [PubMed - indexed for MEDLINE]

☐ **30:** Byrick RJ. Related Articles

Respiratory compensation during spontaneous ventilation with the Bain cir
Can Anaesth Soc J. 1980 Mar;27(2):96-105.
PMID: 6767540 [PubMed - indexed for MEDLINE]

☐ **31:** Velazquez JL, Feingold A, Walther P. Related Articles

Response time of the Narkotest anesthetic gas monitor.
Anesth Analg. 1977 May-Jun;56(3):395-7.
PMID: 559440 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Oct 13 2004 06:44:09

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 304 of 304 One p

1: Sousa JM, Hermann JL, Guimaraes JB, Menezes PP, Carvalho AC. Related Articles, L

Evaluation of systolic, diastolic, and pulse pressure as risk factors for severe coronary arteriosclerotic disease in women with unstable angina non-ST-elevation acute myocardial infarction.
Arq Bras Cardiol. 2004 May;82(5):430-3, 426-9. Epub 2004 Jun 08. English, Portuguese.
PMID: 15340673 [PubMed - in process]

2: Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Related Articles, L

Platelet function predicts myocardial damage in patients with acute myocardia infarction.
Circulation. 2004 Sep 14;110(11):1392-7. Epub 2004 Aug 16.
PMID: 15313953 [PubMed - in process]

3: Gaspardone A, De Fabritiis P, Scaffa R, Nardi P, Palombi F, Versaci F, Chiariello L. Related Articles, L

[Stem cell mobilization after coronary artery bypass grafting]
Ital Heart J. 2004 Jan;5(1 Suppl):23-8. Italian.
PMID: 15253141 [PubMed - in process]

4: Wang YN, Che SM, Ma AQ. Related Articles, L

Clinical significance of serum cytokines IL-1beta, sIL-2R, IL-6, TNF-alpha, a IFN-v in acute coronary syndrome.
Chin Med Sci J. 2004 Jun;19(2):120-4.
PMID: 15250248 [PubMed - indexed for MEDLINE]

5: Canos DA, Mintz GS, Berzingi CO, Apple S, Kotani J, Pichard AD, Satler LF, Suddath WO, Waksman R, Lindsay J Jr, Weissman NJ. Related Articles, L

Clinical, angiographic, and intravascular ultrasound characteristics of early saphenous vein graft failure.
J Am Coll Cardiol. 2004 Jul 7;44(1):53-6.
PMID: 15234406 [PubMed - indexed for MEDLINE]

6: Uva MS, Rodrigues V, Monteiro N, Pereira F, Bervens D, Caria R, Mesquita A, Pedro A, Bau J, Matias F, Magalhaes MP. Related Articles, L

Coronary surgery: which method to use?
Rev Port Cardiol. 2004 Apr;23(4):517-30. English, Portuguese.
PMID: 15224641 [PubMed - in process]

7: Arslanagic A, Gerc V. Related Articles, L

[New approach in the diagnosis of acute coronary syndrome]
Med Arh. 2004;58(2 Suppl 1):43-5. Review. Bosnian.
PMID: 15202307 [PubMed - indexed for MEDLINE]

8: Sardella G, De Luca L, Adorisio R, Di Russo C, Fedele F. Related Articles, L

Effects of rotational atherectomy with a reduced burr-to-artery ratio on corona no-reflow.
Minerva Cardioangiol. 2004 Jun;52(3):209-17. English, Italian.

PMID: 15194982 [PubMed - in process]

☐ **9:** Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U; PENTUA Investigators. Related Articles, L

A dose-finding study of fondaparinux in patients with non-ST-segment elevati acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA Study.
J Am Coll Cardiol. 2004 Jun 16;43(12):2183-90.
PMID: 15193678 [PubMed - indexed for MEDLINE]

☐ **10:** Forlani S, Tomai F, De Paulis R, Turani F, Colella DF, Nardi P, De Notaris S, Moscarelli M, Magliano G, Crea F, Chiariello L. Related Articles, L

Preoperative shift from glibenclamide to insulin is cardioprotective in diabeti patients undergoing coronary artery bypass surgery.
J Cardiovasc Surg (Torino). 2004 Apr;45(2):117-22.
PMID: 15179345 [PubMed - indexed for MEDLINE]

☐ **11:** Chang SM, Yazbek N, Lakkis NM. Related Articles, L

Use of statins prior to percutaneous coronary intervention reduces myonecro and improves clinical outcome.
Catheter Cardiovasc Interv. 2004 Jun;62(2):193-7.
PMID: 15170709 [PubMed - in process]

☐ **12:** Bazzino O, Fuselli JJ, Botto F, Perez De Arenaza D, Bahit C, Dadone J; PACS group of investigators. Related Articles, L

Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with r ST-elevation acute coronary syndromes.
Eur Heart J. 2004 May;25(10):859-66.
PMID: 15140534 [PubMed - indexed for MEDLINE]

☐ **13:** Lopez-Fernandez S, Cequier A, Iraculis E, Gomez-Hospital JA, Teruel L, Valero J, Beltran P, Garcia del Blanco B, Jara F, Esplugas E. Related Articles, L

[Elevated troponin I levels in patients with acute coronary syndrome without elevation are associated with increased complexity of the culprit lesion]
Rev Esp Cardiol. 2004 Apr;57(4):291-8. Spanish.
PMID: 15104982 [PubMed - in process]

☐ **14:** Psychari SN, Iliodromitis EK, Hamodraka E, Liakos G, Velissaridou A, Apostolou TS, Kremastinos DT. Related Articles, L

Preinfarction angina does not alter infarct size and in hospital outcome after acute myocardial infarction with ST elevation.
Int J Cardiol. 2004 Apr;94(2-3):187-91.
PMID: 15093979 [PubMed - indexed for MEDLINE]

☐ **15:** Nagai R. Related Articles, L

[Recent progress in diagnosis of and therapy for angina pectoris]
Nippon Naika Gakkai Zasshi. 2004 Mar 10;93(3):545-50. Review. Japanese. No abstract available.
PMID: 15052818 [PubMed - indexed for MEDLINE]

☐ **16:** Trevelyan J, Needham EW, Smith SC, Mattu RK. Related Articles, L

Impact of the recommendations for the redefinition of myocardial infarction diagnosis and prognosis in an unselected United Kingdom cohort with suspe cardiac chest pain.
Am J Cardiol. 2004 Apr 1;93(7):817-21.
PMID: 15050481 [PubMed - indexed for MEDLINE]

Kontos MC, Shah R, Fritz LM, Anderson FP, Tatum JL, Ornato JP, Jesse

☐ **17:** RL. Related Articles, L

Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients.
J Am Coll Cardiol. 2004 Mar 17;43(6):958-65.
PMID: 15028350 [PubMed - indexed for MEDLINE]

☐ **18:** Higham H, Sear JW, Sear YM, Kemp M, Hooper RJ, Foex P. Related Articles, L

Peri-operative troponin I concentration as a marker of long-term postoperativ adverse cardiac outcomes--a study in high-risk surgical patients.
Anaesthesia. 2004 Apr;59(4):318-23.
PMID: 15023100 [PubMed - indexed for MEDLINE]

☐ **19:** Seino Y, Takano T. Related Articles, L

[Multi-maker strategy for diagnosis of acute coronary syndrome]
Nippon Naika Gakkai Zasshi. 2004 Feb 10;93(2):241-8. Review. Japanese. No abstract available.
PMID: 15007930 [PubMed - indexed for MEDLINE]

☐ **20:** Tambara K, Fujita M, Miyamoto S, Doi K, Nishimura K, Komeda M. Related Articles, L

Pericardial fluid level of heart-type cytoplasmic fatty acid-binding protein (H FABP) is an indicator of severe myocardial ischemia.
Int J Cardiol. 2004 Feb;93(2-3):281-4.
PMID: 14975559 [PubMed - indexed for MEDLINE]

☐ **21:** Dudek D, Bartus S, Zmudka K, Legutko J, Turek P, Rzeszutko Å□, Chyrchel M, Dubiel JS. Related Articles, L

[Safety and efficacy of ANGIOGUARD protection device for the prevention distal embolization during PCI in patients with unstable angina]
Przegl Lek. 2003;60(8):499-503. Polish.
PMID: 14974339 [PubMed - indexed for MEDLINE]

☐ **22:** Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Related Articles, L

Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasiv or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substuc
Circulation. 2004 Feb 10;109(5):580-6.
PMID: 14769678 [PubMed - indexed for MEDLINE]

☐ **23:** Weisel RD, Lipton IH, Lyall RN, Baird RJ. Related Articles, L

Cardiac metabolism and performance following cold potassium cardioplegia
Circulation. 1978 Sep;58(3 Pt 2):I217-26.
PMID: 14740705 [PubMed - indexed for MEDLINE]

☐ **24:** Hamm CW; Deutsche Gesellschaft fur Kardiologie- Herz- und Kreislaufforschung. Related Articles, L

[Guidelines: acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations]
Z Kardiol. 2004 Jan;93(1):72-90. German. No abstract available.
PMID: 14740245 [PubMed - indexed for MEDLINE]

☐ **25:** Patti G, D'Ambrosio A, Mega S, Giorgi G, Zardi EM, Zardi DM, Dicuonzo G, Dobrina A, Di Sciascio G. Related Articles, L

Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction.
J Am Coll Cardiol. 2004 Jan 7;43(1):35-8.

PMID: 14715179 [PubMed - indexed for MEDLINE]

☐ **26:** Kini AS, Lee PC, Mitre CA, Kim MC, Kamran M, Duffy ME, Marmur JD, Sharma SK. Related Articles, L

Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome.
Am J Med. 2003 Dec 15;115(9):708-14.
PMID: 14693323 [PubMed - indexed for MEDLINE]

☐ **27:** Mark B, Schneider S, Schiele R, Taubert G, Kilkowski C, Seidl K, Nagel D, Seiler D, Senges J, Zahn R. Related Articles, L

Comparison of different cardiac markers in monitoring percutaneous coronar interventions with frequent use of stents and gpIIbIIIa-antagonists.
Z Kardiol. 2003 Dec;92(12):1018-24.
PMID: 14663612 [PubMed - indexed for MEDLINE]

☐ **28:** Nageh T, Sherwood RA, Harris BM, Byrne JA, Thomas MR. Related Articles, L

Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary interventi
Int J Cardiol. 2003 Dec;92(2-3):285-93.
PMID: 14659867 [PubMed - indexed for MEDLINE]

☐ **29:** Wang X, Wei M, Kuukasjarvi P, Laurikka J, Jarvinen O, Rinne T, Honkonen EL, Tarkka M. Related Articles, L

Novel pharmacological preconditioning with diazoxide attenuates myocardia stunning in coronary artery bypass grafting.
Eur J Cardiothorac Surg. 2003 Dec;24(6):967-73.
PMID: 14643816 [PubMed - indexed for MEDLINE]

☐ **30:** Jozan-Jilling M, Horvath I, Kis E, Bodnar I, Baross M, Zsigmond A, Kovacs E, Papp L. Related Articles, L

[Facilitated revascularisation in myocardial infarction with ST-segment elevation]
Orv Hetil. 2003 Aug 10;144(32):1583-6. Hungarian.
PMID: 12974183 [PubMed - indexed for MEDLINE]

☐ **31:** Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-Maj E, Kobielusz-Gembala I. Related Articles, L

Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activati in stable angina and acute coronary syndromes.
Coron Artery Dis. 2003 Sep;14(6):431-8.
PMID: 12966263 [PubMed - indexed for MEDLINE]

☐ **32:** Iliou MC, Fumeron C, Benoit MO, Tuppin P, Calonge VM, Moatti N, Buisson C, Jacquot C. Related Articles, L

Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and Ne Cardiac Markers Evaluation (CHANCE) study.
Am J Kidney Dis. 2003 Sep;42(3):513-23.
PMID: 12955679 [PubMed - indexed for MEDLINE]

☐ **33:** Okmen E, Cakmak M, Tartan Z, Cam N. Related Articles, L

Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters patients with unstable angina and non-Q-wave myocardial infarction.
Heart Vessels. 2003 Jul;18(3):117-22.
PMID: 12955426 [PubMed - indexed for MEDLINE]

☐ **34:** Leborgne L, Cheneau E, Pichard A, Ajani A, Pakala R, Yazdi H, Satler L, Kent K, Suddath WO, Pinnow E, Canos D, Waksman R. Related Articles, L

Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft.

Am Heart J. 2003 Sep;146(3):501-6.
PMID: 12947370 [PubMed - indexed for MEDLINE]

☐ **35:** Christenson RH, Leino EV, Giugliano RP, Bahr RD. Related Articles, L

Usefulness of prodromal unstable angina pectoris in predicting better survive and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy).
Am J Cardiol. 2003 Sep 1;92(5):598-600.
PMID: 12943885 [PubMed - indexed for MEDLINE]

☐ **36:** Ferreira R. Related Articles, L

New diagnostic criteria of acute myocardial infarction.
Rev Port Cardiol. 2003 May;22(5):735-40. No abstract available.
PMID: 12940186 [PubMed - indexed for MEDLINE]

☐ **37:** Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P; GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators. Related Articles, L

Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CAI surgery cohort of the GUARDIAN study.
J Thorac Cardiovasc Surg. 2003 Aug;126(2):420-7.
PMID: 12928639 [PubMed - indexed for MEDLINE]

☐ **38:** Matsumoto Y, Endo M, Kasashima F, Abe Y, Kosugi I, Sasaki H. Related Articles, L

[Off-pump coronary artery bypass grafting for octogenarians with acute coronary syndrome]
Kyobu Geka. 2003 Jul;56(8 Suppl):682-7. Japanese.
PMID: 12910951 [PubMed - indexed for MEDLINE]

☐ **39:** Yin R, Feng J, Chen D, Wu H. Related Articles, L

Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction.
Chin Med Sci J. 2000 Dec;15(4):205-9.
PMID: 12906138 [PubMed - indexed for MEDLINE]

☐ **40:** Kizer JR, Muttrej MR, Matthai WH, McConnell J, Nardone H, Sonel AF, Keane MG, Wilensky RL. Related Articles, L

Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention.
Eur Heart J. 2003 Jul;24(14):1314-22.
PMID: 12871688 [PubMed - indexed for MEDLINE]

☐ **41:** Hasdai D, Behar S, Boyko V, Danchin N, Bassand JP, Battler A. Related Articles, L

Cardiac biomarkers and acute coronary syndromes--the Euro Heart Survey o Acute Coronary Syndromes Experience.
Eur Heart J. 2003 Jul;24(13):1189-94.
PMID: 12831812 [PubMed - indexed for MEDLINE]

☐ **42:** Mahmud E, Shaw KD, Penny WF. Related Articles, L

Patients at low risk for periprocedural myocardial infarction can be identifiec assessment immediately following percutaneous coronary intervention.
J Invasive Cardiol. 2003 Jun;15(6):343-7.
PMID: 12777674 [PubMed - indexed for MEDLINE]

☐ **43:** Capellan O, Hollander JE, Pollack C Jr, Hoekstra JW, Wilke E, Tiffany B, Sites FD, Shofer FS, Gibler WB. Related Articles, L

Prospective evaluation of emergency department patients with potential

coronary syndromes using initial absolute CK-MB vs. CK-MB relative index
J Emerg Med. 2003 May;24(4):361-7.
PMID: 12745035 [PubMed - indexed for MEDLINE]

☐ **44:** Veselka J. Related Articles, L

[Risk stratification in unstable angina pectoris and non-Q myocardial infarct: anamnesis, physical examination, electrocardiography, specific cardiac mark
Vnitr Lek. 2002 Dec;48 Suppl 1:51-5. Review. Czech.
PMID: 12744018 [PubMed - indexed for MEDLINE]

☐ **45:** Prati F, Pawlowski T, Gil R, Labellarte A, Gziut A, Caradonna E, Manzoli A, Pappalardo A, Burzotta F, Boccanelli A. Related Articles, L

Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study.
Circulation. 2003 May 13;107(18):2320-5. Epub 2003 Apr 21.
PMID: 12707236 [PubMed - indexed for MEDLINE]

☐ **46:** Svensson L, Isaksson L, Axelsson C, Nordlander R, Herlitz J. Related Articles, L

Predictors of myocardial damage prior to hospital admission among patients with acute chest pain or other symptoms raising a suspicion of acute coronar syndrome.
Coron Artery Dis. 2003 May;14(3):225-31.
PMID: 12702926 [PubMed - indexed for MEDLINE]

☐ **47:** Boufous S, Kelleher PW, Pain CH, Dann LM, Ieraci S, Jalaludin BB, Gray AL, Harris SE, Juergens CP. Related Articles, L

Impact of a chest-pain guideline on clinical decision-making.
Med J Aust. 2003 Apr 21;178(8):375-80.
PMID: 12697008 [PubMed - indexed for MEDLINE]

☐ **48:** Lafuente Gormaz C, Terrancle de Juan I, Broseta Viana L. Related Articles, L

[Cardiac troponins and their current clinical application]
Med Clin (Barc). 2003 Mar 22;120(10):389-94. Review. Spanish. No abstract available.
PMID: 12681105 [PubMed - indexed for MEDLINE]

☐ **49:** Lim SH, Sayre MR, Gibler WB. Related Articles, L

2-D echocardiography prediction of adverse events in ED patients with chest pain.
Am J Emerg Med. 2003 Mar;21(2):106-10.
PMID: 12671809 [PubMed - indexed for MEDLINE]

☐ **50:** Kovacs F, Dobos A. Related Articles, L

[Macro-creatine kinase: an interesting occurrence that can cause diagnostic mistake]
Orv Hetil. 2003 Feb 9;144(6):275-8. Hungarian.
PMID: 12666634 [PubMed - indexed for MEDLINE]

☐ **51:** Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Related Articles, L

Troponin I elevation and cardiac events after percutaneous coronary intervention.
Am Heart J. 2003 Mar;145(3):522-8.
PMID: 12660677 [PubMed - indexed for MEDLINE]

☐ **52:** Nakai K, Nakai K, Suwabe A. Related Articles, L

[Biochemical marker for myocardial injury]
Rinsho Byori. 2002 Dec;50(12):1140-5. Review. Japanese.

PMID: 12652682 [PubMed - indexed for MEDLINE]

☐ **53:** Qin QP, Laitinen P, Majamaa-Voltti K, Eriksson S, Kumpula EK, Pettersson K. Related Articles, L

Release patterns of pregnancy associated plasma protein A (PAPP-A) in pati with acute coronary syndromes.
Scand Cardiovasc J. 2002 Dec;36(6):358-61.
PMID: 12626203 [PubMed - indexed for MEDLINE]

☐ **54:** Kutryk MJ, Wardeh AJ, Knook AH, Foley DP, Giessen WJ, Hamburger JN, Brand Mv M, Feyter PJ, Becker GJ, Serruys PW. Related Articles, L

First clinical experience with the R Stent: a new highly flexible stainless stee tube intracoronary stent.
Int J Cardiovasc Intervent. 1999;2(3):163-169.
PMID: 12623585 [PubMed - as supplied by publisher]

☐ **55:** Collinson PO, Stubbs PJ, Kessler AC; Multicentre Evaluation Of Routine Immunoassay Of Troponin T Study. Related Articles, L

Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-ME mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice.
Heart. 2003 Mar;89(3):280-6.
PMID: 12591831 [PubMed - indexed for MEDLINE]

☐ **56:** Auer J, Berent R, Lassnig E, Eber B. Related Articles, L

C-reactive protein and coronary artery disease.
Jpn Heart J. 2002 Nov;43(6):607-19.
PMID: 12558125 [PubMed - indexed for MEDLINE]

☐ **57:** Pascual Figal DA, Noguera Velasco JA, Rodenas Checa J, Murcia Aleman T, Martinez Cadenas J, Ferrandiz Gomis R, Martinez Hernandez P, Valdes Chavarri M. Related Articles, L

[Chest pain in clinical practice: impact of routine troponin determination on clinical manifestations and care]
Rev Esp Cardiol. 2003 Jan;56(1):43-8. Spanish.
PMID: 12549999 [PubMed - indexed for MEDLINE]

☐ **58:** Morinigo JL, Sanchez PL, Martin F, Pabon P, Arribas A, Nieto F, Rodriguez J, Ledesma C, Cascon M, Diego M, Martin Luengo C. Related Articles, L

[Long-term prognostic value of troponin I in patients admitted to a coronary for unstable angina]
Rev Esp Cardiol. 2003 Jan;56(1):29-34. Spanish.
PMID: 12549997 [PubMed - indexed for MEDLINE]

☐ **59:** Mateos-Careres PJ, Garcia-Mendez A, Farre J, Sanchez de Miguel L, Gomez J, de Andres R, Rico L, Romero J, Lopez-Farre A. Related Articles, L

Prior aspirin use in unstable angina patients with modified plasma inflammat markers and endothelial nitric oxide synthase in neutrophils.
Eur J Clin Invest. 2002 Dec;32(12):895-900.
PMID: 12534448 [PubMed - indexed for MEDLINE]

☐ **60:** Lim J, Hawkins RC, Ng K, Chan SP, Cheng A, Ng KS. Related Articles, L

A preliminary study of the utility of combined cardiac markers in the evaluat of patients presenting early with suspected acute coronary syndrome.
Ann Acad Med Singapore. 2002 Nov;31(6):772-6.
PMID: 12520833 [PubMed - indexed for MEDLINE]

☐ **61:** Wang L, Wu Y, Li L. Related Articles, L

[Evaluation on usage of serum troponin-I, CK-MBmass and myoglobin

measurements in diagnosing acute myocardial infarction]
Hua Xi Yi Ke Da Xue Xue Bao. 2000 Jun;31(2):239-41, 245. Chinese.
PMID: 12515148 [PubMed - indexed for MEDLINE]

☐ **62:** Khosravi J, Diamandi A, Krishna RG, Bodani U, Mistry J, Khaja N. Related Articles, L

Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease.
Clin Biochem. 2002 Oct;35(7):531-8.
PMID: 12493581 [PubMed - indexed for MEDLINE]

☐ **63:** Wong BY, Gnarpe J, Teo KK, Ohman EM, Prosser C, Gibler WB, Langer A, Chang WC, Armstrong PW. Related Articles, L

Does chronic Chlamydia pneumoniae infection increase the risk of myocardi injury? Insights from patients with non-ST-elevation acute coronary syndron
Am Heart J. 2002 Dec;144(6):987-94.
PMID: 12486422 [PubMed - indexed for MEDLINE]

☐ **64:** Kennon S, Price CP, Mills PG, MacCallum PK, Cooper J, Hooper J, Clarke H, Timmis AD. Related Articles, L

Cumulative risk assessment in unstable angina: clinical, electrocardiographic autonomic, and biochemical markers.
Heart. 2003 Jan;89(1):36-41.
PMID: 12482787 [PubMed - indexed for MEDLINE]

☐ **65:** Bosch X, Casanovas N, Miranda-Guardiola F, Diez-Aja S, Sitges M, Anguera I, Sanz G, Betriu A. Related Articles, L

[Long-term prognosis of women with non-ST-segment elevation acute coron syndromes. a case-control study]
Rev Esp Cardiol. 2002 Dec;55(12):1235-42. Spanish.
PMID: 12459072 [PubMed - indexed for MEDLINE]

☐ **66:** Ikeda J, Zenimoto M, Kita M, Mori M. Related Articles, L

[Usefulness of cardiac troponin I in patients with acute myocardial infarction
Rinsho Byori. 2002 Oct;50(10):982-6. Japanese.
PMID: 12451679 [PubMed - indexed for MEDLINE]

☐ **67:** Hirayama A, Kodama K. Related Articles, L

[Pathophysiology of unstable angina evaluated by biochemical markers]
Nippon Rinsho. 1994 Aug;52 Suppl(Pt 2):324-9. Review. Japanese. No abstract available.
PMID: 12439989 [PubMed - indexed for MEDLINE]

☐ **68:** Levinsky MJ, Ohman EM. Related Articles, L

Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients.
Am Heart J. 2002 Nov;144(5):750-2. No abstract available.
PMID: 12422141 [PubMed - indexed for MEDLINE]

☐ **69:** Zarich SW, Qamar AU, Werdmann MJ, Lizak LS, McPherson CA, Bernstein LH. Related Articles, L

Value of a single troponin T at the time of presentation as compared to serial CK-MB determinations in patients with suspected myocardial ischemia.
Clin Chim Acta. 2002 Dec;326(1-2):185-92.
PMID: 12417111 [PubMed - indexed for MEDLINE]

☐ **70:** Sejersten M, Young D, Clemmensen P, Lipton J, VerSteeg D, Wall T, Maynard C, Wagner G. Related Articles, L

Comparison of the ability of paramedics with that of cardiologists in diagnos ST-segment elevation acute myocardial infarction in patients with acute ches pain.

Am J Cardiol. 2002 Nov 1;90(9):995-8. No abstract available.
PMID: 12398970 [PubMed - indexed for MEDLINE]

☐ 71: Magadle R, Weiner P, Beckerman M, Berar-Yanay N. Related Articles, L

C-reactive protein as a marker for active coronary artery disease in patients v chest pain in the emergency room.
Clin Cardiol. 2002 Oct;25(10):456-60.
PMID: 12375803 [PubMed - indexed for MEDLINE]

☐ 72: Aviles RJ, Wright RS, Aviles JM, McDonald F, Ballman K, Harker-Murray A, Scott C, Lauer MS, Kopecky SL, Jaffe AS. Related Articles, L

Long-term prognosis of patients with clinical unstable angina pectoris witho elevation of creatine kinase but with elevation of cardiac troponin i levels.
Am J Cardiol. 2002 Oct 15;90(8):875-8. No abstract available.
PMID: 12372578 [PubMed - indexed for MEDLINE]

☐ 73: Demaria RG, Carrier M, Fortier S, Martineau R, Fortier A, Cartier R, Pellerin M, Hebert Y, Bouchard D, Page P, Perrault LP. Related Articles, L

Reduced mortality and strokes with off-pump coronary artery bypass graftin surgery in octogenarians.
Circulation. 2002 Sep 24;106(12 Suppl 1):I5-10.
PMID: 12354700 [PubMed - indexed for MEDLINE]

☐ 74: Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E; TACTICS-TIMI 18 Investigators. Related Articles, L

Prospective analysis of creatine kinase muscle-brain fraction and comparisor with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes.
J Am Coll Cardiol. 2002 Sep 18;40(6):1044-50.
PMID: 12354426 [PubMed - indexed for MEDLINE]

☐ 75: Sanchis J, Bodi V, Navarro A, Llacer A, Blasco M, Mainar L, Monmeneu JV, Insa L, Ferrero JA, Chorro FJ, Sanjuan R. Related Articles, L

[Prognostic factors in unstable angina with dynamic electrocardiographic changes. Value of fibrinogen]
Rev Esp Cardiol. 2002 Sep;55(9):921-7. Spanish.
PMID: 12236921 [PubMed - indexed for MEDLINE]

☐ 76: Malasky BR, Alpert JS. Related Articles, L

Diagnosis of myocardial injury by biochemical markers: problems and promises.
Cardiol Rev. 2002 Sep-Oct;10(5):306-17. Review.
PMID: 12215194 [PubMed - indexed for MEDLINE]

☐ 77: Fesmire FM. Related Articles, L

Improved identification of acute coronary syndromes with delta cardiac seru marker measurements during the emergency department evaluation of chest p patients.
Cardiovasc Toxicol. 2001;1(2):117-23. Review.
PMID: 12213983 [PubMed - indexed for MEDLINE]

☐ 78: Manini AF, Gisondi MA, van der Vlugt TM, Schreiber DH. Related Articles, L

Adverse cardiac events in emergency department patients with chest pain six months after a negative inpatient evaluation for acute coronary syndrome.
Acad Emerg Med. 2002 Sep;9(9):896-902.
PMID: 12208678 [PubMed - indexed for MEDLINE]

☐ 79: Bodi V, Facila L, Sanchis J, Llacer A, Nunez J, Mainar L, Gomez- Related Articles, L

Aldaravi R, Monmeneu JV, Blasco ML, Sanjuan R, Insa L, Chorro FJ.

[Short-term prognosis of patients admitted for probable acute coronary syndrome without ST-segment elevation. Role of new myocardial damage markers and acute-phase reactants]
Rev Esp Cardiol. 2002 Aug;55(8):823-30. Spanish.
PMID: 12199978 [PubMed - indexed for MEDLINE]

☐ **80:** Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Related Articles, L

Biochemical detection of minor myocardial injury after elective, uncomplica successful percutaneous coronary intervention in patients with stable angina: clinical outcome.
Ann Clin Biochem. 2002 Jul;39(Pt 4):392-7.
PMID: 12117443 [PubMed - indexed for MEDLINE]

☐ **81:** de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. Related Articles, L

The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTI TIMI 18 studies.
J Am Coll Cardiol. 2002 Jul 17;40(2):238-44.
PMID: 12106926 [PubMed - indexed for MEDLINE]

☐ **82:** Selim NA, Hmouda HT. Related Articles, L

A pilot study of cardiac troponin I in patients with acute myocardial infarctic and unstable angina.
Saudi Med J. 2002 May;23(5):526-8.
PMID: 12070573 [PubMed - indexed for MEDLINE]

☐ **83:** Matsumoto Y, Endoh M, Kasashima F, Abe Y, Kosugi I, Hirano Y, Ueyama T, Sasaki H. Related Articles, L

[Off-pump Cx grafting for unstable angina with left main trunk lesion]
Kyobu Geka. 2002 Jun;55(6):474-8. Japanese.
PMID: 12058459 [PubMed - indexed for MEDLINE]

☐ **84:** Wu ZK, Pehkonen E, Laurikka J, Kaukinen L, Honkonen EL, Kaukinen S, Tarkka MR. Related Articles, L

Ischemic preconditioning protects right ventricular function in coronary arter bypass grafting patients experiencing angina within 48-72 hours.
J Cardiovasc Surg (Torino). 2002 Jun;43(3):319-26.
PMID: 12055563 [PubMed - indexed for MEDLINE]

☐ **85:** Bossi I, Savonitto S, Cavallini C, Delgado A, Pirola R, Klugmann S. Related Articles, L

[Predictive elements and prevention of myocardial damage during angioplasty/stenting]
Ital Heart J Suppl. 2002 Mar;3(3):275-85. Review. Italian.
PMID: 12040843 [PubMed - indexed for MEDLINE]

☐ **86:** Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM; SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Related Articles, L

Prognostic significance of elevated troponin I after percutaneous coronary intervention.
J Am Coll Cardiol. 2002 Jun 5;39(11):1738-44.
PMID: 12039485 [PubMed - indexed for MEDLINE]

☐ **87:** Kovacevic B, Stajnic M, Cemerlic-Adic N, Dejanovic J. Related Articles, L

[Terminology and diagnostic criteria for non-Q wave myocardial infarct]

Med Pregl. 2002 Jan-Feb;55(1-2):28-33. Croatian.
PMID: 12037934 [PubMed - indexed for MEDLINE]

☐ **88:** Saitoh M, Kondoh T, Wakao K, Kitamura K, Nomoto S, Matsuo K, Yamada A, Yanagawa T. Related Articles, L

Prognostic significance of the number of leads with ST depression during an anginal attack in high risk patients with unstable angina.
Intern Med. 2002 Apr;41(4):270-6.
PMID: 11993786 [PubMed - indexed for MEDLINE]

☐ **89:** Auer J, Berent R, Labetanig E, Eber B. Related Articles, L

Serum neopterin and activity of coronary artery disease.
Heart Dis. 2001 Sep-Oct;3(5):297-301.
PMID: 11975809 [PubMed - indexed for MEDLINE]

☐ **90:** Cavusoglu E, Sharma SK, Frishman W. Related Articles, L

Unstable angina pectoris and non-Q-wave myocardial infarction.
Heart Dis. 2001 Mar-Apr;3(2):116-30. Review.
PMID: 11975780 [PubMed - indexed for MEDLINE]

☐ **91:** Lestin M, Hergert M, Lestin HG, Brinker C, Storm H, Kuhrt E, Kuhrt B, Lambrecht HG, Kuhnel W. Related Articles, L

Evaluation of the chemiluminescence immunoassays for the measurement of troponin I, myoglobin and CK-MB using the IMMULITE system in compari to other measuring systems.
Clin Lab. 2002;48(3-4):211-21.
PMID: 11934224 [PubMed - indexed for MEDLINE]

☐ **92:** Straumann E, Bertel O. Related Articles, L

[Acute coronary syndrome and myocardial infarct--new definitions]
Ther Umsch. 2002 Feb;59(2):66-71. German.
PMID: 11887551 [PubMed - indexed for MEDLINE]

☐ **93:** Sanchez de Miguel L, Arriero MM, Farre J, Jimenez P, Garcia-Mendez A, de Frutos T, Jimenez A, Garcia R, Cabestrero F, Gomez J, de Andres R, Monton M, Martin E, De la Calle-Lombana LM, Rico L, Romero J, Lopez-Farre A. Related Articles, L

Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: expression of the nitric oxide synthase isoforms.
J Am Coll Cardiol. 2002 Mar 6;39(5):818-25.
PMID: 11869847 [PubMed - indexed for MEDLINE]

☐ **94:** Gruberg L, Fuchs S, Waksman R, Pichard AD, Kent KM, Laird JR, Wu H, Elsayyad S, Allen CM, Satler LF. Related Articles, L

Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcom analysis.
Catheter Cardiovasc Interv. 2002 Feb;55(2):174-9.
PMID: 11835642 [PubMed - indexed for MEDLINE]

☐ **95:** Stork T, Gareis R, Muller R, Hammerle M, Muller-Bardorff M, Braun R, Frohlich E, Koenig W, Mockel M. Related Articles, L

[Suspected acute coronary syndrome in patients without ST-elevation. Exclusion of infarction, early clinical estimation and non-coronary diagnose
Dtsch Med Wochenschr. 2002 Feb 8;127(6):260-5. German.
PMID: 11832985 [PubMed - indexed for MEDLINE]

☐ **96:** Caragher TE, Fernandez BB, Jacobs FL, Barr LA. Related Articles, L

Evaluation of quantitative cardiac biomarker point-of-care testing in the

emergency department.
J Emerg Med. 2002 Jan;22(1):1-7.
PMID: 11809549 [PubMed - indexed for MEDLINE]

☐ **97:** Cantwell RV, Aviles RJ, Bjornsson J, Wright RS, Freeman WK, Oh JK, Hoyer JD, Markovic S, Jaffe AS. Related Articles, L

Cardiac amyloidosis presenting with elevations of cardiac troponin I and ang pectoris.
Clin Cardiol. 2002 Jan;25(1):33-7.
PMID: 11808838 [PubMed - indexed for MEDLINE]

☐ **98:** Takagi Y, Yasuhara T, Gomi K. Related Articles, L

[Creatine kinase and its isozymes]
Rinsho Byori. 2001 Nov;Suppl 116:52-61. Review. Japanese.
PMID: 11797380 [PubMed - indexed for MEDLINE]

☐ **99:** Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. Related Articles, L

An integrated clinical approach to predicting the benefit of tirofiban in non-S elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Eur Heart J. 2002 Feb;23(3):223-9.
PMID: 11792137 [PubMed - indexed for MEDLINE]

☐ **100:** Graven T, Kruger O, Bronstad G. Related Articles, L

Epidemiological consequences of introducing new biochemical markers for detection of acute myocardial infarction.
Scand Cardiovasc J. 2001 Sep;35(4):233-7.
PMID: 11759116 [PubMed - indexed for MEDLINE]

☐ **101:** Ellis SG, Brener SJ, Lincoff AM, Moliterno DJ, Whitlow PL, Schneider JP, Topol EJ. Related Articles, L

beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise.
Circulation. 2001 Nov 27;104(22):2685-8.
PMID: 11723019 [PubMed - indexed for MEDLINE]

☐ **102:** Yang Z, Jia Y, Zhang J, Cao K, Zhang F, Ma G, Ma W. Related Articles, L

Changes in serum cardiac troponin I levels after percutaneous transluminal coronary angioplasty.
Chin Med J (Engl). 1999 Nov;112(11):1049-51.
PMID: 11721471 [PubMed - indexed for MEDLINE]

☐ **103:** Timurkaynak T, Ozdemir M, Cengel A, Cemri M, Ciftci H, Yalcin R, Boyaci B, Dortlemez O, Dortlemez H. Related Articles, L

Direct stenting in angiographically apparent thrombus-containing lesions.
J Invasive Cardiol. 2001 Nov;13(11):742-7.
PMID: 11689718 [PubMed - indexed for MEDLINE]

☐ **104:** Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW. Related Articles, L

Coronary restenosis elimination with a sirolimus eluting stent: first Europea human experience with 6-month angiographic and intravascular ultrasonic follow-up.
Eur Heart J. 2001 Nov;22(22):2125-30.
PMID: 11686669 [PubMed - indexed for MEDLINE]

☐ **105:** Collinson PO, Wiggins N, Gaze DC. Related Articles, L

Clinical evaluation of the ACS:180 cardiac troponin I assay.

Ann Clin Biochem. 2001 Sep;38(Pt 5):509-19.
PMID: 11587129 [PubMed - indexed for MEDLINE]

☐ **106:** Sarullo FM, Pasquale PD, D'Alfonso G, Amerigo L, Cannizzaro S, Castello A. Related Articles, L

Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
Ital Heart J. 2001 Aug;2(8):605-11.
PMID: 11577835 [PubMed - indexed for MEDLINE]

☐ **107:** Hamm CW. Related Articles, L

Acute coronary syndromes. The diagnostic role of troponins.
Thromb Res. 2001 Sep 30;103 Suppl 1:S63-9. Review.
PMID: 11567671 [PubMed - indexed for MEDLINE]

☐ **108:** Ng SM, Krishnaswamy P, Morissey R, Clopton P, Fitzgerald R, Maisel AS. Related Articles, L

Ninety-minute accelerated critical pathway for chest pain evaluation.
Am J Cardiol. 2001 Sep 15;88(6):611-7.
PMID: 11564382 [PubMed - indexed for MEDLINE]

☐ **109:** Roth A, Malov N, Golovner M, Sander J, Shapira I, Kaplinsky E, Laniado S. Related Articles, L

The "SHAHAL" experience in Israel for improving diagnosis of acute coronary syndromes in the prehospital setting.
Am J Cardiol. 2001 Sep 15;88(6):608-10.
PMID: 11564381 [PubMed - indexed for MEDLINE]

☐ **110:** Plebani M. Related Articles, L

Biochemical markers of cardiac damage: from efficiency to effectiveness.
Clin Chim Acta. 2001 Sep 15;311(1):3-7. Review.
PMID: 11557246 [PubMed - indexed for MEDLINE]

☐ **111:** Lateef F, Storrow AB, Gibler BW, Liu T. Related Articles, L

Heart emergency room: effective for both geriatric and younger patients.
Singapore Med J. 2001 Jun;42(6):259-63.
PMID: 11547963 [PubMed - indexed for MEDLINE]

☐ **112:** Saadeddin SM, Habbab MA, Ferns GA. Related Articles, L

Cardiac markers for assessing the acute coronary syndromes. A focus on cardiac troponins.
Saudi Med J. 2000 Mar;21(3):228-37. Review.
PMID: 11533790 [PubMed - indexed for MEDLINE]

☐ **113:** Arom KV, Emery RW, Flavin TF, Kshettry VR, Petersen RJ. Related Articles, L

OPCAB surgery: a critical review of two different categories of pre-operati ejection fraction.
Eur J Cardiothorac Surg. 2001 Sep;20(3):533-7.
PMID: 11509275 [PubMed - indexed for MEDLINE]

☐ **114:** Murena E, Molero U, Moio N, Pisani A, Stingone MA, Guardascione A, Grassia V, Scilla C, Marino A, Sibilio G. Related Articles, L

[Identification of patients with acute myocardial infarction that may be discharged early: prospective evaluation with simple clinical and instrumen indicators]
Ital Heart J Suppl. 2001 Jul;2(7):775-82. Italian.
PMID: 11508296 [PubMed - indexed for MEDLINE]

☐ **115:** Wu ZK, Pehkonen E, Laurikka J, Kaukinen L, Honkonen EL, Kaukinen S, Tarkka MR. Related Articles, L

Myocardial lactate production is not involved in the ischemic preconditioni mechanism in coronary artery bypass graft surgery patients.
J Cardiothorac Vasc Anesth. 2001 Aug;15(4):412-7.
PMID: 11505341 [PubMed - indexed for MEDLINE]

☐ **116:** Lang K, Schindler S, Forberger C, Stein G, Figulla HR. Related Articles, L

Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure.
Clin Nephrol. 2001 Jul;56(1):44-51.
PMID: 11499658 [PubMed - indexed for MEDLINE]

☐ **117:** Walter S, Carlsson J, Cuneo A, Tebbe U. Related Articles, L

[Leading symptoms of chest pain in the emergency room. Using cardiac markers for risk stratification]
Dtsch Med Wochenschr. 2001 Jul 6;126(27):771-8. German.
PMID: 11486476 [PubMed - indexed for MEDLINE]

☐ **118:** Fromm R, Meyer D, Zimmerman J, Boudreaux A, Wun CC, Smalling R, Davis B, Habib G, Roberts R. Related Articles, L

A double-blind, multicentered study comparing the accuracy of diagnostic markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain.
Clin Cardiol. 2001 Jul;24(7):516-20.
PMID: 11444643 [PubMed - indexed for MEDLINE]

☐ **119:** Moukarbel GV, Arnaout MS, Alam SE. Related Articles, L

C-reactive protein is a marker for a complex culprit lesion anatomy in unsta angina.
Clin Cardiol. 2001 Jul;24(7):506-10.
PMID: 11444641 [PubMed - indexed for MEDLINE]

☐ **120:** Serebruany VL, Levine DJ, Nair GV, Meister AF, Gurbel PA. Related Articles, L

Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department.
J Thromb Thrombolysis. 2001 Apr;11(2):155-62.
PMID: 11406731 [PubMed - indexed for MEDLINE]

☐ **121:** Almeda FQ, Calvin JE, Parrillo JE, Sun FG, Barron JT. Related Articles, L

Prevalence of angiographically significant stenosis in patients with chest pa and an elevated troponin I level and normal creatine kinase and creatine kinase-MB levels.
Am J Cardiol. 2001 Jun 1;87(11):1286-9. No abstract available.
PMID: 11377357 [PubMed - indexed for MEDLINE]

☐ **122:** Lateef F, Storrow AB, Malone K, Liu T, Gibler BW. Related Articles, L

Comparison of a 6-hour and 9-hour protocol for evaluation of moderate-to-l risk chest pain patients in an emergency department diagnostic unit.
Singapore Med J. 2001 Feb;42(2):052-6.
PMID: 11358190 [PubMed - indexed for MEDLINE]

☐ **123:** Tjomsland O, Aaberge L, Almdahl SM, Moelstad P, Rootwelt K, Nordstrand K, Saatvedt K. Related Articles, L

Cardiac enzymes after transmyocardial laser treatment with CO2 laser.
Scand Cardiovasc J. 2001 Feb;35(1):19-24.
PMID: 11354566 [PubMed - indexed for MEDLINE]

☐ **124:** Goldmann BU, Hamm CW. Related Articles, L

[Risk stratification in acute coronary syndrome]
Herz. 2001 Apr;26 Suppl 1:24-9. German.
PMID: 11349623 [PubMed - indexed for MEDLINE]

☐ **125:** Kiraly C, Timar S. Related Articles, L

[Repeat thrombolysis in acute myocardial infarction]
Orv Hetil. 2001 Apr 1;142(13):665-9. Hungarian.
PMID: 11338569 [PubMed - indexed for MEDLINE]

☐ **126:** Andrews N, Jenkins J, Andrews G, Walker P. Related Articles, L

Using postoperative cardiac Troponin-I (cTi) levels to detect myocardial ischaemia in patients undergoing vascular surgery.
Cardiovasc Surg. 2001 Jun;9(3):254-65.
PMID: 11336849 [PubMed - indexed for MEDLINE]

☐ **127:** Balk EM, Ioannidis JP, Salem D, Chew PW, Lau J. Related Articles, L

Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergenc department: a meta-analysis.
Ann Emerg Med. 2001 May;37(5):478-94. Review.
PMID: 11326184 [PubMed - indexed for MEDLINE]

☐ **128:** Eto K, Ochiai M, Isshiki T, Takeshita S, Terakura M, Sato T, Ikeda Y, Handa S, Goto S. Related Articles, L

Platelet aggregability under shear is enhanced in patients with unstable angi pectoris who developed acute myocardial infarction.
Jpn Circ J. 2001 Apr;65(4):279-82.
PMID: 11316123 [PubMed - indexed for MEDLINE]

☐ **129:** Vasikaran SD, Hitchcock T, Burnett JR, Clugston RA. Related Articles, L

Measuring myocardial damage.
Med J Aust. 2001 Feb 19;174(4):163-4. No abstract available.
PMID: 11270754 [PubMed - indexed for MEDLINE]

☐ **130:** Rolstad OJ, Stromme JH, Mangschau A. Related Articles, L

[New cardiac markers--clinical benefits in early diagnosis of acute heart disease]
Tidsskr Nor Laegeforen. 2001 Feb 10;121(4):415-20. Norwegian.
PMID: 11255853 [PubMed - indexed for MEDLINE]

☐ **131:** Whitlow PL, Bass TA, Kipperman RM, Sharaf BL, Ho KK, Cutlip DE, Zhang Y, Kuntz RE, Williams DO, Lasorda DM, Moses JW, Cowley MJ, Eccleston DS, Horrigan MC, Bersin RM, Ramee SR, Feldman T. Related Articles, L

Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS).
Am J Cardiol. 2001 Mar 15;87(6):699-705.
PMID: 11249886 [PubMed - indexed for MEDLINE]

☐ **132:** Schuepp M, Ullmer E, Weinbacher M, Pfisterer M, Scholer A, Ritz R, Rickenbacher P. Related Articles, L

Chest pain early after percutaneous coronary intervention: incidence and relation to ECG changes, cardiac enzymes and follow-up events.
J Invasive Cardiol. 2001 Mar;13(3):211-6.
PMID: 11231646 [PubMed - indexed for MEDLINE]

☐ **133:** van Domburg RT, Cobbaert C, Muller-Bardorff M, Kampmann M, Kimman GP, Rauscher T, Schoolmann S, Zerback R, Katus HA, Simoons ML. Related Articles, L

Time-dependent diagnostic performance of a rapid troponin T version 2 bedside test in patients with acute coronary syndromes.
Scand J Clin Lab Invest. 2000 Dec;60(8):665-75.
PMID: 11218149 [PubMed - indexed for MEDLINE]

☐ **134:** O'Neil BJ, Ross MA. Related Articles, L

Cardiac markers protocols in a chest pain observation unit.
Emerg Med Clin North Am. 2001 Feb;19(1):67-86. Review.
PMID: 11214404 [PubMed - indexed for MEDLINE]

☐ **135:** Lukacs I, Sebo J, Fey E, Karpati P. Related Articles, L

[Experiences with determination of cardiac Troponin-I and CK-MB serum levels in acute coronary syndrome]
Orv Hetil. 2001 Jan 14;142(2):67-70. Hungarian.
PMID: 11209507 [PubMed - indexed for MEDLINE]

☐ **136:** Leowattana W, Mahanonda N, Bhuripanyo K, Pokum S, Kiartivich S. Related Articles, L

Serum cardiac troponin T in unstable angina pectoris patients.
J Med Assoc Thai. 2000 Nov;83 Suppl 2:S61-5.
PMID: 11194024 [PubMed - indexed for MEDLINE]

☐ **137:** Wu ZK, Pehkonen E, Laurikka J, Kaukinen L, Honkonen EL, Kaukinen S, Tarkka MR. Related Articles, L

Protective effect of unstable angina in coronary artery bypass surgery.
Scand Cardiovasc J. 2000 Oct;34(5):486-92.
PMID: 11191939 [PubMed - indexed for MEDLINE]

☐ **138:** Ashmaig ME, Starkey BJ, Ziada AM, Amro AA, Sobki SH, Ferns GA. Related Articles, L

Changes in serum concentrations of markers of myocardial injury following treadmill exercise testing in patients with suspected ischaemic heart disease
Med Sci Monit. 2001 Jan-Feb;7(1):54-7.
PMID: 11208493 [PubMed - indexed for MEDLINE]

☐ **139:** Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Related Articles, L

Detection of minor myocardial injury after successful percutaneous transluminal coronary angioplasty with or without stenting.
Med Sci Monit. 2000 Jul-Aug;6(4):708-12.
PMID: 11208396 [PubMed - indexed for MEDLINE]

☐ **140:** Sionis Green A, Bosch X, Miranda-Guardiola F, Anguera I, Sitges M, Diez-Aja S, Sanz G, Betriu A. Related Articles, L

[In-hospital evolution and current prognosis of unstable angina]
Rev Esp Cardiol. 2000 Dec;53(12):1573-82. Spanish.
PMID: 11171479 [PubMed - indexed for MEDLINE]

☐ **141:** Maisel AS, Templin K, Love M, Clopton P. Related Articles, L

A prospective study of an algorithm using cardiac troponin I and myoglobin adjuncts in the diagnosis of acute myocardial infarction and intermediate coronary syndromes in a veteran's hospital.
Clin Cardiol. 2000 Dec;23(12):915-20.
PMID: 11129678 [PubMed - indexed for MEDLINE]

☐ **142:** Stork TV, Wu AH, Muller-Bardorff M, Gareis R, Muller R, Hombach V, Katus H, Mockel M; North-Wurttemberg Infarction Study (NOWIS) Group. Related Articles, L

Diagnostic and prognostic role of myoglobin in patients with suspected acu coronary syndrome. North-Wurttemberg Infarction Study (NOWIS) Group.
Am J Cardiol. 2000 Dec 15;86(12):1371-4, A5.

PMID: 11113416 [PubMed - indexed for MEDLINE]

☐ **143:** Jernberg T, Lindahl B, James S, Ronquist G, Wallentin L. Related Articles, L

Comparison between strategies using creatine kinase-MB(mass), myoglobi and troponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a nondiagnostic electrocardiogram
Am J Cardiol. 2000 Dec 15;86(12):1367-71, A5.
PMID: 11113415 [PubMed - indexed for MEDLINE]

☐ **144:** McErlean E, Van Lente CF, Nissen SE. Related Articles, L

Using troponin T to diagnose acute coronary syndromes.
Cleve Clin J Med. 2000 Nov;67(11):843-9.
PMID: 11104335 [PubMed - indexed for MEDLINE]

☐ **145:** Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, Cannon CP, Braunwald E. Related Articles, L

Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy.
J Am Coll Cardiol. 2000 Nov 15;36(6):1812-7.
PMID: 11092649 [PubMed - indexed for MEDLINE]

☐ **146:** Harris BM, Nageh T, Marsden JT, Thomas MR, Sherwood RA. Related Articles, L

Comparison of cardiac troponin T and I and CK-MB for the detection of mi myocardial damage during interventional cardiac procedures.
Ann Clin Biochem. 2000 Nov;37 (Pt 6):764-9.
PMID: 11085620 [PubMed - indexed for MEDLINE]

☐ **147:** Ricchiuti V, Shear WS, Henry TD, Paulsen PR, Miller EA, Apple FS. Related Articles, L

Monitoring plasma cardiac troponin I for the detection of myocardial injury after percutaneous transluminal coronary angioplasty.
Clin Chim Acta. 2000 Dec;302(1-2):161-70.
PMID: 11074073 [PubMed - indexed for MEDLINE]

☐ **148:** Ellestad MH, Startt-Selvester R, Stanton E, VanNatta B, Ahmad J, Gawad Y, Swiger F. Related Articles, L

The utility of four biochemical markers in the triage of chest pain patients.
Cardiology. 2000;93(4):242-8.
PMID: 11025350 [PubMed - indexed for MEDLINE]

☐ **149:** van Domburg RT, Cobbaert C, Kimman GJ, Zerback R, Simoons ML. Related Articles, L

Long-term prognostic value of serial troponin T bedside tests in patients wi acute coronary syndromes.
Am J Cardiol. 2000 Sep 15;86(6):623-7.
PMID: 10980212 [PubMed - indexed for MEDLINE]

☐ **150:** Penttila I, Penttila K, Rantanen T. Related Articles, L

Laboratory diagnosis of patients with acute chest pain.
Clin Chem Lab Med. 2000 Mar;38(3):187-97. Review.
PMID: 10905753 [PubMed - indexed for MEDLINE]

☐ **151:** Dagnone E, Collier C, Pickett W, Ali N, Miller M, Tod D, Morton R. Related Articles, L

Chest pain with nondiagnostic electrocardiogram in the emergency department: a randomized controlled trial of two cardiac marker regimens.
CMAJ. 2000 May 30;162(11):1561-6.
PMID: 10862229 [PubMed - indexed for MEDLINE]

☐ **152:** deFilippi CR, Tocchi M, Parmar RJ, Rosanio S, Abreo G, Potter MA, Runge MS, Uretsky BF. Related Articles, L

Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinica outcomes.
J Am Coll Cardiol. 2000 Jun;35(7):1827-34.
PMID: 10841231 [PubMed - indexed for MEDLINE]

☐ **153:** Suzuki H, Murakami M, Kondo T, Shibata M, Ezumi H, Okabayashi H, Yorozuya M, Makishima N, Hamazaki Y, Nakatani M, Namiki A, Katagiri T. Related Articles, L

[Changes of serum hepatocyte growth factor in coronary artery disease]
J Cardiol. 2000 May;35(5):319-24. Japanese.
PMID: 10834175 [PubMed - indexed for MEDLINE]

☐ **154:** Sarullo FM, Schicchi R, Schiro M, Americo L, Bonni G, Faraone N, Di Pasquale P, Castello A, Mauri F. Related Articles, L

[The safety and efficacy of systemic salvage thrombolysis in acute myocarc infarct]
Ital Heart J Suppl. 2000 Jan;1(1):81-7. Italian.
PMID: 10832123 [PubMed - indexed for MEDLINE]

☐ **155:** Ottani F, Galvani M, Panteghini M, Dolci A, Plebani M, Tubaro M, Zaninotto M. Related Articles, L

[The role of biochemical markers of myocardial damage in clinical practice the diagnosis of infarct and risk stratification. The Intersociety Interdisciplinary Study Group of the ANMCO-SIBioC-SIMeL, Markers of Muocardial Lesions. L'Associazione Nazionale Medici Cardiologi Ospedali Societa Italiana di Biochimica Clinica-Societa Italiana di Medicina di Laboratorio]
Ital Heart J Suppl. 2000 Jan;1(1):54-64. Review. Italian.
PMID: 10832120 [PubMed - indexed for MEDLINE]

☐ **156:** Zhu X, Zhou A, Li J, Tan M. Related Articles, L

[Clinical evaluation of cardiac troponin I in ischemic heart diseases]
Hunan Yi Ke Da Xue Xue Bao. 1998;23(6):563-5. Chinese.
PMID: 10806770 [PubMed - indexed for MEDLINE]

☐ **157:** Clague JR, Vasudeva A, Ward DE, Pumphrey CW, Redwood DR. Related Articles, L

The AVE Micro Coronary Stent as a Bailout Device.
J Invasive Cardiol. 1997 Jun;9(5):339-343.
PMID: 10762922 [PubMed - as supplied by publisher]

☐ **158:** Sarullo FM, Americo L, Di Pasquale P, Castello A, Mauri F. Related Articles, L

Efficacy of rescue thrombolysis in patients with acute myocardial infarctior preliminary findings.
Cardiovasc Drugs Ther. 2000 Feb;14(1):83-9.
PMID: 10755205 [PubMed - indexed for MEDLINE]

☐ **159:** Cassin M, Badano LP, Solinas L, Macor F, Burelli C, Antonini-Canterin F, Cappelletti P, Rubin D, Tropeano P, Deganuto L, Nicolosi GL. Related Articles, L

[Is a more efficient operative strategy feasible for the emergency managem of the patient with acute chest pain?]
Ital Heart J Suppl. 2000 Feb;1(2):186-201. Review. Italian.
PMID: 10731376 [PubMed - indexed for MEDLINE]

☐ **160:** McErlean ES, Deluca SA, van Lente F, Peacock F 4th, Rao JS, Balog CA, Nissen SE. Related Articles, L

Comparison of troponin T versus creatine kinase-MB in suspected acute coronary syndromes.

Am J Cardiol. 2000 Feb 15;85(4):421-6.
PMID: 10728944 [PubMed - indexed for MEDLINE]

☐ **161:** Iglesias Garriz I, Sastre Ibarretxe M, Garrote Coloma C, Delgado Fernandez S, Corral Fernandez F, Obaya Rebollar JC, Fidalgo Andres ML. Related Articles, L

[The effect of pre-infarction unstable angina on the size of myocardial necrosis]
Rev Esp Cardiol. 2000 Jan;53(1):43-8. Spanish.
PMID: 10701322 [PubMed - indexed for MEDLINE]

☐ **162:** Poirey S, Polge A, Bertinchant JP, Bancel E, Boyer JC, Fabbro-Peray P, de Bornier BM, Ledermann B, Bonnier M, Bali JP. Related Articles, L

CK-MB mass test in ischemic myocardial injury. Comparison of two tests: BioMerieux Vidas and sanofi access immunoassays.
J Clin Lab Anal. 2000;14(2):43-7.
PMID: 10683612 [PubMed - indexed for MEDLINE]

☐ **163:** Lang K, Borner A, Figulla HR. Related Articles, L

Comparison of biochemical markers for the detection of minimal myocardi injury: superior sensitivity of cardiac troponin--T ELISA.
J Intern Med. 2000 Jan;247(1):119-23.
PMID: 10672139 [PubMed - indexed for MEDLINE]

☐ **164:** Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalan R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA. Related Articles, L

Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
JAMA. 2000 Jan 19;283(3):347-53.
PMID: 10647797 [PubMed - indexed for MEDLINE]

☐ **165:** Kurz DJ, Naegeli B, Bertel O. Related Articles, L

A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting.
Am Heart J. 2000 Jan;139(1 Pt 1):35-43.
PMID: 10618560 [PubMed - indexed for MEDLINE]

☐ **166:** Walter S, Carlsson J, Schroder R, Neuhaus KL, Sorges E, Tebbe U. Related Articles, L

[Enzymatic markers of reperfusion in acute myocardial infarct. With data fr the ISAM study]
Herz. 1999 Oct;24(6):430-9. Review. German.
PMID: 10546147 [PubMed - indexed for MEDLINE]

☐ **167:** Wu AH, Ghani F, Prigent F, Petry C, Armstrong G, Graff L. Related Articles, L

Reflex testing II: evaluation of an algorithm for use of cardiac markers in th assessment of emergency department patients with chest pain.
Clin Chim Acta. 1999 Oct;288(1-2):97-109.
PMID: 10529462 [PubMed - indexed for MEDLINE]

☐ **168:** Tomai F, De Paulis R, Penta de Peppo A, Colagrande L, Caprara E, Polisca P, De Matteis G, Ghini AS, Forlani S, Colella D, Chiariello L. Related Articles, L

Beneficial impact of isoflurane during coronary bypass surgery on troponin release.
G Ital Cardiol. 1999 Sep;29(9):1007-14.
PMID: 10514958 [PubMed - indexed for MEDLINE]

☐ **169:** Wu AH, Ford L. Related Articles, L

Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis?
Clin Chim Acta. 1999 Jun 30;284(2):161-74. Review.
PMID: 10451243 [PubMed - indexed for MEDLINE]

☐ **170:** Sribhen K, Bhuripanyo K, Raungratanaamporn O, Kiartivich S, Leowattana W, Chaithiraphan S. Related Articles, L

Improved detection of radiofrequency current-induced minor myocardial in by cardiac troponin T measurement.
J Med Assoc Thai. 1999 Mar;82(3):256-62.
PMID: 10410480 [PubMed - indexed for MEDLINE]

☐ **171:** Bertinchant JP, Polge A, Ledermann B, Genet L, Fabbro-Peray P, Raczka F, Brunet J, Poirey S, Wittenberg O, Pernel I, Nigond J. Related Articles, L

Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris.
Am J Cardiol. 1999 Jul 1;84(1):51-7.
PMID: 10404851 [PubMed - indexed for MEDLINE]

☐ **172:** Hollander JE, Muttreja MR, Dalesandro MR, Shofer FS. Related Articles, L

Risk stratification of emergency department patients with acute coronary syndromes using P-selectin.
J Am Coll Cardiol. 1999 Jul;34(1):95-105.
PMID: 10399997 [PubMed - indexed for MEDLINE]

☐ **173:** Christenson RH, Duh SH. Related Articles, L

Evidence based approach to practice guides and decision thresholds for car markers.
Scand J Clin Lab Invest Suppl. 1999;230:90-102. Review.
PMID: 10389207 [PubMed - indexed for MEDLINE]

☐ **174:** Wu AH. Related Articles, L

Biochemical markers of cardiac damage: from traditional enzymes to cardi specific proteins. IFCC Subcommittee on Standardization of Cardiac Mark (S-SCM).
Scand J Clin Lab Invest Suppl. 1999;230:74-82. Review.
PMID: 10389205 [PubMed - indexed for MEDLINE]

☐ **175:** Hamm CW. Related Articles, L

Risk stratifying acute coronary syndromes: gradient of risk and benefit.
Am Heart J. 1999 Jul;138(1 Pt 2):S6-11. Review.
PMID: 10385785 [PubMed - indexed for MEDLINE]

☐ **176:** Merchan Herrera A, Millan Nunez V, Lopez Minguez JR, Cimbora Ortega A, Garcia Guerrero JJ, Gonzalez Fernandez R, Geniz Gallardo I, Fernandez de la Concha J, Fernandez Mora G, Alonso Ruiz F. Related Articles, L

[The appearance of giant negative T waves in anterior acute myocardial inf with a Q wave is associated with minor myocardial damage and a minor extension of coronary disease]
Rev Esp Cardiol. 1999 May;52(5):294-300. Spanish.
PMID: 10368579 [PubMed - indexed for MEDLINE]

☐ **177:** Johnson PA, Goldman L, Sacks DB, Garcia T, Albano M, Bezai M, Pedan A, Cook EF, Lee TH. Related Articles, L

Cardiac troponin T as a marker for myocardial ischemia in patients seen at emergency department for acute chest pain.

Am Heart J. 1999 Jun;137(6):1137-44.
PMID: 10347343 [PubMed - indexed for MEDLINE]

☐ **178:** Sinkiewicz W, Romanski B, Bartuzi Z, Zbikowska M, Staszynska M. Related Articles, L

[Eosinophilic activation based on measurements of eosinophil cationic prot in patients with acute myocardial infarction and patients with angina pector
Przegl Lek. 1998;55(10):512-5. Polish.
PMID: 10224863 [PubMed - indexed for MEDLINE]

☐ **179:** Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Aubry P, Boudvillain Q, Sarfati L, Brochet E, Feldman LJ, Himbert D, Juliard JM, Assayag P. Related Articles, L

Elevated cardiac troponin I predicts a high-risk angiographic anatomy of th culprit lesion in unstable angina.
Am Heart J. 1999 May;137(5):815-20.
PMID: 10220629 [PubMed - indexed for MEDLINE]

☐ **180:** Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, Davis B, Habib G, Roberts R. Related Articles, L

Diagnostic marker cooperative study for the diagnosis of myocardial infarction.
Circulation. 1999 Apr 6;99(13):1671-7.
PMID: 10190875 [PubMed - indexed for MEDLINE]

☐ **181:** Chapelle JP. Related Articles, L

Cardiac troponin I and troponin T: recent players in the field of myocardial markers.
Clin Chem Lab Med. 1999 Jan;37(1):11-20. Review.
PMID: 10094373 [PubMed - indexed for MEDLINE]

☐ **182:** Meyer T, Binder L, Graeber T, Luthe H, Kreuzer H, Oellerich M, Buchwald AB. Related Articles, L

Superiority of combined CK-MB and troponin I measurements for the early risk stratification of unselected patients presenting with acute chest pain.
Cardiology. 1998;90(4):286-94.
PMID: 10085491 [PubMed - indexed for MEDLINE]

☐ **183:** Tun A, Khan IA, Win MT, Hussain A, Hla TA, Wattanasuwan N, Vasavada BC, Sacchi TJ. Related Articles, L

Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis c these cardiac markers.
Cardiology. 1998;90(4):280-5.
PMID: 10085490 [PubMed - indexed for MEDLINE]

☐ **184:** Zaninotto M, Altinier S, Lachin M, Celegon L, Plebani M. Related Articles, L

Strategies for the early diagnosis of acute myocardial infarction using biochemical markers.
Am J Clin Pathol. 1999 Mar;111(3):399-405.
PMID: 10078116 [PubMed - indexed for MEDLINE]

☐ **185:** Wu AH. Related Articles, L

Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laborat to bedside.
Ann Clin Lab Sci. 1999 Jan-Mar;29(1):18-23. Review.
PMID: 10074964 [PubMed - indexed for MEDLINE]

☐ **186:** Lindahl B, Venge P, Wallentin L. Related Articles, L

The FRISC experience with troponin T. Use as decision tool and comparisc

with other prognostic markers.
Eur Heart J. 1998 Nov;19 Suppl N:N51-8.
PMID: 9857941 [PubMed - indexed for MEDLINE]

☐ **187:** deFilippi CR, Parmar RJ, Potter MA, Tocchi M. Related Articles, L

Diagnostic accuracy, angiographic correlates and long-term risk stratificatic with the troponin T ultra sensitive Rapid Assay in chest pain patients at low risk for acute myocardial infarction.
Eur Heart J. 1998 Nov;19 Suppl N:N42-7.
PMID: 9857939 [PubMed - indexed for MEDLINE]

☐ **188:** Collinson PO. Related Articles, L

Troponin T or troponin I or CK-MB (or none?).
Eur Heart J. 1998 Nov;19 Suppl N:N16-24.
PMID: 9857934 [PubMed - indexed for MEDLINE]

☐ **189:** Chapelle JP. Related Articles, L

[Troponin, a new myocardial infarction marker]
Rev Med Liege. 1998 Oct;53(10):619-24. Review. French.
PMID: 9857757 [PubMed - indexed for MEDLINE]

☐ **190:** Sato T, Yoshinouchi T, Sakamoto T, Fujieda H, Murao S, Sato H, Kobayashi H, Ohe T. Related Articles, L

Hepatocyte growth factor(HGF): a new biochemical marker for acute myocardial infarction.
Heart Vessels. 1997;12(5):241-6.
PMID: 9846810 [PubMed - indexed for MEDLINE]

☐ **191:** Cartier R, Bouchard D, Martineau R. Related Articles, L

[Peri-operative benefits of beating-heart coronary revascularization in patie with triple vessel disease]
Ann Chir. 1998;52(8):801-6. French.
PMID: 9846432 [PubMed - indexed for MEDLINE]

☐ **192:** Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K. Related Articles, L

Troponin T and creatinine kinase isoenzyme MB mass in the diagnosis of myocardial infarction.
Ann Med. 1998 Oct;30(5):488-96.
PMID: 9814836 [PubMed - indexed for MEDLINE]

☐ **193:** Bouchard D, Cartier R. Related Articles, L

Off-pump revascularization of multivessel coronary artery disease has a decreased myocardial infarction rate.
Eur J Cardiothorac Surg. 1998 Oct;14 Suppl 1:S20-4.
PMID: 9814787 [PubMed - indexed for MEDLINE]

☐ **194:** Juarez U, Trejo W, Whente M, Contreras G, Cardenas M, Reyes PA. Related Articles, L

[The usefulness of determining myoglobin, creatine phosphokinase MB isoenzyme, lactate dehydrogenase and aspartate aminotransferase in the diagnosis of acute myocardial infarct]
Arch Inst Cardiol Mex. 1998 May-Jun;68(3):214-7. Spanish.
PMID: 9810342 [PubMed - indexed for MEDLINE]

☐ **195:** Holmvang L, Luscher MS, Clemmensen P, Thygesen K, Grande P. Related Articles, L

Very early risk stratification using combined ECG and biochemical assessn in patients with unstable coronary artery disease (A thrombin inhibition in

myocardial ischemia [TRIM] substudy). The TRIM Study Group.
Circulation. 1998 Nov 10;98(19):2004-9.
PMID: 9808597 [PubMed - indexed for MEDLINE]

☐ **196:** Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Boccara A, Aubry P, Nicaise P, Brochet E, Juliard JM, Himbert D, Assayag P. Related Articles, L

Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris.
Am J Cardiol. 1998 Oct 1;82(7):845-50.
PMID: 9781965 [PubMed - indexed for MEDLINE]

☐ **197:** Sato T, Yoshinouchi T, Sugimoto T, Sakamoto T, Fujieda H, Sato H, Murao S, Kobayashi H, Ohe T. Related Articles, L

[Significance of hepatocyte growth factor measurement in patients with acu myocardial infarction]
J Cardiol. 1998 Aug;32(2):77-82. Japanese.
PMID: 9752615 [PubMed - indexed for MEDLINE]

☐ **198:** Stokke M, Gronvold T, Siebke AM, Skjaeggestad O, Stromme JH. Related Articles, L

Serial measurements of cardiac markers to rule in or out acute myocardial damage less than 3 h after admission in acute chest pain patients without EC signs of acute myocardial infarction.
Scand J Clin Lab Invest. 1998 Jul;58(4):331-8.
PMID: 9741821 [PubMed - indexed for MEDLINE]

☐ **199:** Cartier R, Beaufigeau M, Hebert Y, Leclerc Y. Related Articles, L

[Revascularization of the circumflex artery with mechanical stabilization: initial experience]
Ann Chir. 1997;51(8):906-11. French.
PMID: 9734102 [PubMed - indexed for MEDLINE]

☐ **200:** Heeschen C, Goldmann BU, Moeller RH, Hamm CW. Related Articles, L

Analytical performance and clinical application of a new rapid bedside assa for the detection of serum cardiac troponin I.
Clin Chem. 1998 Sep;44(9):1925-30.
PMID: 9732978 [PubMed - indexed for MEDLINE]

☐ **201:** Christenson RH, Azzazy HM. Related Articles, L

Biochemical markers of the acute coronary syndromes.
Clin Chem. 1998 Aug;44(8 Pt 2):1855-64. Review.
PMID: 9702995 [PubMed - indexed for MEDLINE]

☐ **202:** Musumeci F, Feccia M, MacCarthy PA, Ellis GR, Mammana L, Brinn F, Penny WJ. Related Articles, L

Prospective randomized trial of single clamp technique versus intermittent ischaemic arrest: myocardial and neurological outcome.
Eur J Cardiothorac Surg. 1998 Jun;13(6):702-9.
PMID: 9686803 [PubMed - indexed for MEDLINE]

☐ **203:** Lindahl B, Gerhardt W. Related Articles, L

[Biochemical markers enable early diagnosis of myocardial damage]
Lakartidningen. 1998 Jun 24;95(26-27):3034-8. Review. Swedish.
PMID: 9679412 [PubMed - indexed for MEDLINE]

☐ **204:** Klein G, Kampmann M, Baum H, Rauscher T, Vukovic T, Hallermayer K, Rehner H, Muller-Bardorff M, Katus HA. Related Articles, L

Clinical performance of the new cardiac markers troponin T and CK-MB o the Elecsys 2010. A multicentre evaluation.
Wien Klin Wochenschr Suppl. 1998;3:40-51.

PMID: 9677671 [PubMed - indexed for MEDLINE]

☐ **205:** Polanczyk CA, Lee TH, Cook EF, Walls R, Wybenga D, Printy-Klein G, Ludwig L, Guldbrandsen G, Johnson PA. Related Articles, L

Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain.
J Am Coll Cardiol. 1998 Jul;32(1):8-14.
PMID: 9669242 [PubMed - indexed for MEDLINE]

☐ **206:** de Winter RJ, Koster RW, Sanders GT. Related Articles, L

[Early exclusion of ischemic myocardial damage made possible by new biochemical cardiac markers]
Ned Tijdschr Geneeskd. 1998 Apr 25;142(17):940-4. Review. Dutch.
PMID: 9623165 [PubMed - indexed for MEDLINE]

☐ **207:** Marchant E, Martinez A, Fajuri A, Guarda E, Valenzuela E, Cortes N, Arancibia C. Related Articles, L

[Rotational atherectomy (Rotablator) for percutaneous transluminal coronai angioplasty]
Rev Med Chil. 1997 Dec;125(12):1474-82. Spanish.
PMID: 9609023 [PubMed - indexed for MEDLINE]

☐ **208:** Willging S, Keller F, Steinbach G. Related Articles, L

Specificity of cardiac troponins I and T in renal disease.
Clin Chem Lab Med. 1998 Feb;36(2):87-92.
PMID: 9594044 [PubMed - indexed for MEDLINE]

☐ **209:** Bertinchant JP, Laperche T, Polge A, Raczka F, Beyne P, Ledermann B, Himbert D, Pernel I, Nigond J, Cohen-Solal A. Related Articles, L

[Prognostic significance of early raised cardiac troponine I in unstable angi Contribution to the identification of a high-risk sub-group]
Arch Mal Coeur Vaiss. 1997 Dec;90(12):1615-22. French.
PMID: 9587442 [PubMed - indexed for MEDLINE]

☐ **210:** Christenson RH, Newby LK, Ohman EM. Related Articles, L

Cardiac markers in the assessment of acute coronary syndromes.
Md Med J. 1997;Suppl:18-24. Review.
PMID: 9470339 [PubMed - indexed for MEDLINE]

☐ **211:** Anderson FP, Fritz ML, Kontos MC, McPherson RA, Jesse RL. Related Articles, L

Cost-effectiveness of cardiac troponin I in a systematic chest pain evaluatio protocol: use of cardiac troponin I lowers length of stay for low-risk cardiac patients.
Clin Lab Manage Rev. 1998 Mar-Apr;12(2):63-9.
PMID: 10178711 [PubMed - indexed for MEDLINE]

☐ **212:** Green GB, Beaudreau RW, Chan DW, DeLong D, Kelley CA, Kelen GD. Related Articles, L

Use of troponin T and creatine kinase-MB subunit levels for risk stratificati of emergency department patients with possible myocardial ischemia.
Ann Emerg Med. 1998 Jan;31(1):19-29.
PMID: 9437337 [PubMed - indexed for MEDLINE]

☐ **213:** Sax H, Contesse J, Dubach P, Reinhart WH. Related Articles, L

Creatine kinase MB during myocardial infarction: relationship to preexistin coronary heart disease and medication.
Acta Cardiol. 1997;52(5):423-30.
PMID: 9428940 [PubMed - indexed for MEDLINE]

☐ **214:** Solymoss BC, Bourassa MG, Wesolowska E, Dryda I, Theroux P, Mondor L, Perrault D, Gilfix BM. Related Articles, L

The role of cardiac troponin T and other new biochemical markers in evaluation and risk stratification of patients with acute chest pain syndrome
Clin Cardiol. 1997 Nov;20(11):934-42.
PMID: 9383587 [PubMed - indexed for MEDLINE]

☐ **215:** Gerhardt W, Ljungdahl L, Collinson PO, Lovis C, Mach F, Sylven C, Rasmanis G, Leinberger R, Zerback R, Muller-Bardorff M, Katus HA. Related Articles, L

An improved rapid troponin T test with a decreased detection limit: a multicentre study of the analytical and clinical performance in suspected myocardial damage.
Scand J Clin Lab Invest. 1997 Oct;57(6):549-57.
PMID: 9350075 [PubMed - indexed for MEDLINE]

☐ **216:** Pellegatta F, Pizzetti G, Lu Y, Radaelli A, Pomes D, Carlino M, Meloni C, Belotti G, Galli L, Vidal MJ, Chierchia SL. Related Articles, L

Soluble E-selectin and intercellular adhesion molecule-1 plasma levels increase during acute myocardial infarction.
J Cardiovasc Pharmacol. 1997 Oct;30(4):455-60.
PMID: 9335404 [PubMed - indexed for MEDLINE]

☐ **217:** Young GP, Gibler WB, Hedges JR, Hoekstra JW, Slovis C, Aghababian R, Smith M, Rubison M, Ellis J. Related Articles, L

Serial creatine kinase-MB results are a sensitive indicator of acute myocard infarction in chest pain patients with nondiagnostic electrocardiograms: the second Emergency Medicine Cardiac Research Group Study.
Acad Emerg Med. 1997 Sep;4(9):869-77.
PMID: 9305428 [PubMed - indexed for MEDLINE]

☐ **218:** Laurino JP, Pelletier TE, Eadry R, Kounavis A. Related Articles, L

Thrombus Precursor Protein and the measurement of thrombosis in patients with acute chest pain syndrome.
Ann Clin Lab Sci. 1997 Sep-Oct;27(5):338-45.
PMID: 9303172 [PubMed - indexed for MEDLINE]

☐ **219:** Grand A, Fournis Y, Siramy M, Ghadban W, Douieb A, Daboura A, Jaidane H, Fichter P, Huret JF, Hellio D. Related Articles, L

[Value of mass dosage of the MB isoenzyme of creatinine phosphokinase ir the diagnosis of recent myocardial infarction]
Arch Mal Coeur Vaiss. 1997 Jun;90(6):807-15. French.
PMID: 9295933 [PubMed - indexed for MEDLINE]

☐ **220:** Futterman LG, Lemberg L. Related Articles, L

SGOT, LDH, HBD, CPK, CK-MB, MB1MB2, cTnT, cTnC, cTnI.
Am J Crit Care. 1997 Jul;6(4):333-8. Review.
PMID: 9280555 [PubMed - indexed for MEDLINE]

☐ **221:** Wu AH. Related Articles, L

Use of cardiac markers as assessed by outcomes analysis.
Clin Biochem. 1997 Jun;30(4):339-50. Review.
PMID: 9209793 [PubMed - indexed for MEDLINE]

☐ **222:** Lopez-Jimenez F, Goldman L, Sacks DB, Thomas EJ, Johnson PA, Cook EF, Lee TH. Related Articles, L

Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data.
J Am Coll Cardiol. 1997 May;29(6):1241-5.
PMID: 9137219 [PubMed - indexed for MEDLINE]

☐ **223:** Galvani M, Ottani F, Ferrini D, Ladenson JH, Destro A, Baccos D, Rusticali F, Jaffe AS. Related Articles, L

Prognostic influence of elevated values of cardiac troponin I in patients witl unstable angina.
Circulation. 1997 Apr 15;95(8):2053-9.
PMID: 9133515 [PubMed - indexed for MEDLINE]

☐ **224:** Vikenes K, von der Lippe G, Farstad M, Nordrehaug JE. Related Articles, L

Clinical applicability of creatine kinase MB mass and the electrocardiogran versus conventional cardiac enzymes in the diagnosis of acute myocardial infarction.
Int J Cardiol. 1997 Mar;59(1):11-20.
PMID: 9080021 [PubMed - indexed for MEDLINE]

☐ **225:** Wu AH, Clive JM. Related Articles, L

Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain.
Clin Chem. 1997 Feb;43(2):326-32.
PMID: 9023135 [PubMed - indexed for MEDLINE]

☐ **226:** Aramendi JI, Pac J, Agredo J, Bello M, Otero A, Casanova J. Related Articles, L

[Minimally invasive coronary surgery. Thoracostomy-assisted thoracotomy Apropos a case]
Rev Esp Cardiol. 1996 Dec;49(12):925-7. Review. Spanish.
PMID: 9026845 [PubMed - indexed for MEDLINE]

☐ **227:** Bertinchant JP, Larue C, Pernel I, Ledermann B, Fabbro-Peray P, Beck L, Calzolari C, Trinquier S, Nigond J, Pau B. Related Articles, L

Release kinetics of serum cardiac troponin I in ischemic myocardial injury.
Clin Biochem. 1996 Dec;29(6):587-94.
PMID: 8939408 [PubMed - indexed for MEDLINE]

☐ **228:** Hamm CW. Related Articles, L

[Troponins--new markers for the detection of myocardial cell damage]
Fortschr Med. 1996 Nov 20;114(32):433-6. Review. German.
PMID: 9064267 [PubMed - indexed for MEDLINE]

☐ **229:** Swaanenburg JC, Pentinga M, DeJongste MJ, Kema IP, Weening MH. Related Articles, L

Implications of automated creatine kinase (CK)-MM1,2,3/CK-MB1,2 isofo analysis as an early marker for the detection of myocardial tissue damage.
Scand J Clin Lab Invest. 1996 Nov;56(7):627-33.
PMID: 8981658 [PubMed - indexed for MEDLINE]

☐ **230:** Andersen K, Eriksson P, Dellborg M. Related Articles, L

Ischaemia detected by continuous on-line vectorcardiographic monitoring predicts unfavourable outcome in patients admitted with probable unstable coronary disease.
Coron Artery Dis. 1996 Oct;7(10):753-60.
PMID: 8970766 [PubMed - indexed for MEDLINE]

☐ **231:** Varma MK, Puri GD, Chari P, Verma JS, Kohli KK. Related Articles, L

Perioperative myocardial infarction in coronary artery disease patients and ' risk' for coronary artery disease patients undergoing non-cardiac surgery.
Natl Med J India. 1996 Sep-Oct;9(5):214-7.
PMID: 8937059 [PubMed - indexed for MEDLINE]

☐ **232:** Zaninotto M, Altinier S, Lachin M, Carraro P, Plebani M. Related Articles, L

Fluoroenzymometric method to measure cardiac troponin I in sera of patien with myocardial infarction.
Clin Chem. 1996 Sep;42(9):1460-6.
PMID: 8787705 [PubMed - indexed for MEDLINE]

☐ **233:** Belli R, De Benedictis M, Varbella F, Castello V, Baduini G. Related Articles, L

[Coronary rotational atherectomy: initial experience at a hospital without a special department for heart surgery]
G Ital Cardiol. 1996 Jul;26(7):765-74. Italian.
PMID: 8964319 [PubMed - indexed for MEDLINE]

☐ **234:** Danbauchi SS. Related Articles, L

Ischaemic heart disease and myocardial infarction in ABU Teaching Hospit Zaria: a 10 year review (1985 to 1994); a short report.
Cent Afr J Med. 1996 Jul;42(7):209-11.
PMID: 8936788 [PubMed - indexed for MEDLINE]

☐ **235:** Spadafore JC, Lieber JG, Vasilenko P. Related Articles, L

Variance cardiography for emergency department evaluation of chest pain patients.
Acad Emerg Med. 1996 Apr;3(4):326-32.
PMID: 8881541 [PubMed - indexed for MEDLINE]

☐ **236:** Bernstein L, Spiekerman AM, Qamar A, Babb J. Related Articles, L

Effective resource management using a clinical and laboratory algorithm fo chest pain triage.
Clin Lab Manage Rev. 1996 Mar-Apr;10(2):143-52.
PMID: 10184517 [PubMed - indexed for MEDLINE]

☐ **237:** Quillard M, Koning R, Andres H, Cauliez B, Hue G, Letac B, Matray F, Lavoinne A. Related Articles, L

[Determination of cardiac troponin I on Stratus analyzer: prospective evaluation in unstable angina]
Ann Biol Clin (Paris). 1996;54(10-11):359-63. French.
PMID: 9092304 [PubMed - indexed for MEDLINE]

☐ **238:** Lindahl B. Related Articles, L

Biochemical markers of myocardial damage for early diagnosis and progno in patients with acute coronary syndromes. Minireview based on a doctorial thesis.
Ups J Med Sci. 1996;101(3):193-232. Review.
PMID: 9055387 [PubMed - indexed for MEDLINE]

☐ **239:** Hedges JR, Gibler WB, Young GP, Hoekstra JW, Slovis C, Aghababian R, Smith M, Rubison M. Related Articles, L

Multicenter study of creatine kinase-MB use: effect on chest pain clinical decision making.
Acad Emerg Med. 1996 Jan;3(1):7-15.
PMID: 8749961 [PubMed - indexed for MEDLINE]

☐ **240:** Elikowski W, Psuja P, Lewandowski K, Przybyl M, Wendland M, Wroblewski D, Jazienicki B, Przybyl L, Zawilska K. Related Articles, L

[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up]
Pol Arch Med Wewn. 1996 Jan;95(1):53-61. Polish.
PMID: 8677195 [PubMed - indexed for MEDLINE]

☐ **241:** Isabella G, Ramondo A, Cardaioli P, Reimers B, Pasquetto G, Carasi M, Razzolini R, Chioin R. Related Articles, L

[Rotational atherectomy and PTCA in complex coronary lesions (B2 and C the immediate and long-term results]
G Ital Cardiol. 1995 Sep;25(9):1127-38. Italian.
PMID: 8529849 [PubMed - indexed for MEDLINE]

☐ **242:** Dorogy ME, Hooks GS, Cameron RW, Davis RC. Related Articles, L

Clinical and angiographic correlates of normal creatine kinase with increase MB isoenzymes in possible acute myocardial infarction.
Am Heart J. 1995 Aug;130(2):211-7.
PMID: 7631598 [PubMed - indexed for MEDLINE]

☐ **243:** Wu AH, Lane PL. Related Articles, L

Metaanalysis in clinical chemistry: validation of cardiac troponin T as a ma for ischemic heart diseases.
Clin Chem. 1995 Aug;41(8 Pt 2):1228-33.
PMID: 7628112 [PubMed - indexed for MEDLINE]

☐ **244:** Yang Z, Zhang W, Liu Y. Related Articles, L

Prognostic efficacy of troponin T measurement in angina pectoris.
Chin Med J (Engl). 1995 Aug;108(8):626-30.
PMID: 7587497 [PubMed - indexed for MEDLINE]

☐ **245:** Verna E, Ceriani L, Casucci R, Repetto S, Roncari G, Binaghi G. Related Articles, L

Myocardial uptake of indium-111 antimyosin after coronary angioplasty. Relationship with the total burden of ischaemia.
Eur Heart J. 1995 Apr;16(4):478-84.
PMID: 7671892 [PubMed - indexed for MEDLINE]

☐ **246:** Ruan J, Zhao X, Li Q. Related Articles, L

[Dynamic observation of alpha-granule membrane protein 140 during the treatment of thrombolytic and anticoagulant therapy in patients with acute myocardial infarction]
Zhonghua Nei Ke Za Zhi. 1995 Apr;34(4):253-5. Chinese.
PMID: 7587606 [PubMed - indexed for MEDLINE]

☐ **247:** Ravkilde J, Nissen H, Horder M, Thygesen K. Related Articles, L

Independent prognostic value of serum creatine kinase isoenzyme MB mas cardiac troponin T and myosin light chain levels in suspected acute myocar infarction. Analysis of 28 months of follow-up in 196 patients.
J Am Coll Cardiol. 1995 Mar 1;25(3):574-81.
PMID: 7860899 [PubMed - indexed for MEDLINE]

☐ **248:** Tarr F, Somogyi A. Related Articles, L

Coronary artery bypass surgery on the beating heart.
Acta Chir Hung. 1995-96;35(1-2):35-47.
PMID: 8659237 [PubMed - indexed for MEDLINE]

☐ **249:** Ross RM, Baker T. Related Articles, L

Cardiac enzymes in patients undergoing caesarean section.
Can J Anaesth. 1995 Jan;42(1):46-50.
PMID: 7889584 [PubMed - indexed for MEDLINE]

☐ **250:** Gibler WB, Runyon JP, Levy RC, Sayre MR, Kacich R, Hattemer CR, Hamilton C, Gerlach JW, Walsh RA. Related Articles, L

A rapid diagnostic and treatment center for patients with chest pain in the

emergency department.
Ann Emerg Med. 1995 Jan;25(1):1-8.
PMID: 7802357 [PubMed - indexed for MEDLINE]

☐ **251:** Xu C, Chen Y, Lu M. Related Articles, L

[A clinical study on limitation of infarct size by ischemic preconditioning in 100 cases of acute myocardial infarction]
Zhonghua Nei Ke Za Zhi. 1995 Jan;34(1):16-8. Chinese.
PMID: 7600872 [PubMed - indexed for MEDLINE]

☐ **252:** Machler H, Metzler H, Sabin K, Anelli-Monti M, Rehak P, Rigler B, Gombotz H. Related Articles, L

Preoperative myocardial cell damage in patients with unstable angina undergoing coronary artery bypass graft surgery.
Anesthesiology. 1994 Dec;81(6):1324-31.
PMID: 7992899 [PubMed - indexed for MEDLINE]

☐ **253:** Schumacher B, Pecher P, Keilich M, Gunther HU, Stegmann T. Related Articles, L

[Emergency bypass operation after failed elective percutaneous transluminal coronary angioplasty]
Helv Chir Acta. 1994 Dec;60(6):1137-42. German.
PMID: 7875995 [PubMed - indexed for MEDLINE]

☐ **254:** Nukariya M, Hosoda Y, Kudou H, Minami S, Takazawa K, Gotou M, Satoh T, Kikuchi N, Watanabe M, Tahara M. Related Articles, L

[Effect of nicardipine cardioplegia on A-V conduction system in coronary bypass surgery]
Kyobu Geka. 1994 Nov;47(12):997-1000. Japanese.
PMID: 7990293 [PubMed - indexed for MEDLINE]

☐ **255:** Berlatzky Y, Landesberg G, Anner H, Luria MH, Eidelman LA, Mosseri M. Related Articles, L

Prolonged postoperative myocardial ischaemia and infarction in vascular surgery performed under regional anaesthesia.
Eur J Vasc Surg. 1994 Jul;8(4):413-8.
PMID: 8088391 [PubMed - indexed for MEDLINE]

☐ **256:** Hossein-Nia M, Kallis P, Brown PA, Chester MR, Kaski JC, Murday AJ, Treasure T, Holt DW. Related Articles, L

Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage.
Clin Chem. 1994 Jul;40(7 Pt 1):1265-71.
PMID: 8013097 [PubMed - indexed for MEDLINE]

☐ **257:** Ravkilde J, Nissen H, Mickley H, Andersen PE, Thayssen P, Horder M. Related Articles, L

Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris.
Am Heart J. 1994 Jan;127(1):13-20.
PMID: 8273732 [PubMed - indexed for MEDLINE]

☐ **258:** Bakker AJ, Koelemay MJ, Gorgels JP, van Vlies B, Smits R, Tijssen JG, Haagen FD. Related Articles, L

Troponin T and myoglobin at admission: value of early diagnosis of acute myocardial infarction.
Eur Heart J. 1994 Jan;15(1):45-53.
PMID: 8174583 [PubMed - indexed for MEDLINE]

☐ **259:** Uchino T, Belboul A, Liu B, el-Gatit A, Roberts D. Related Articles, L

Detection of perioperative myocardial structural damage by the estimation

cardiac myosin light chain I.
J Cardiovasc Surg (Torino). 1993 Dec;34(6):517-22.
PMID: 8300719 [PubMed - indexed for MEDLINE]

☐ **260:** Iskandrian AE, Kegel JG, Tecce MA, Wasserleben V, Cave V, Heo J. Related Articles, L

Simultaneous assessment of left ventricular perfusion and function with technetium-99m sestamibi after coronary artery bypass grafting.
Am Heart J. 1993 Nov;126(5):1199-203.
PMID: 8237766 [PubMed - indexed for MEDLINE]

☐ **261:** Tsuji R, Tanaka T, Sohmiya K, Hirota Y, Yoshimoto K, Kinoshita K, Kusaka Y, Kawamura K, Morita H, Abe S. Related Articles, L

Human heart-type cytoplasmic fatty acid-binding protein in serum and urin during hyperacute myocardial infarction.
Int J Cardiol. 1993 Oct 1;41(3):209-17.
PMID: 8288410 [PubMed - indexed for MEDLINE]

☐ **262:** Akyol O, Sencan O, Buyukberber S, Canbolat O, Durak I. Related Articles, L

Glutathione peroxidase activity in serum during acute myocardial infarctior and unstable angina pectoris.
Jpn Heart J. 1993 Sep;34(5):551-5.
PMID: 8301841 [PubMed - indexed for MEDLINE]

☐ **263:** Gerhardt W, Ljungdahl L, Herbert AK. Related Articles, L

Troponin-T and CK MB (mass) in early diagnosis of ischemic myocardial injury. The Helsingborg Study, 1992.
Clin Biochem. 1993 Aug;26(4):231-40.
PMID: 8242886 [PubMed - indexed for MEDLINE]

☐ **264:** Widimsky P, Gregor P, Dvorak J, Sladkova T, Herold M, Jirmar R, Hrdlicka S. Related Articles, L

[The optimal diagnostic approach in myocardial infarct]
Vnitr Lek. 1993 Feb;39(2):160-5. Czech.
PMID: 8506663 [PubMed - indexed for MEDLINE]

☐ **265:** Christakis GT, Rao V, Fremes SE, Chen E, Naylor CD, Goldman BS. Related Articles, L

Does coronary endarterectomy adversely affect the results of bypass surger
J Card Surg. 1993 Jan;8(1):72-8.
PMID: 8422492 [PubMed - indexed for MEDLINE]

☐ **266:** Stanislawska J, Opolski G, Slomka K, Niemczyk M, Gorecki A, Tadeusiak W, Kraska T. Related Articles, L

[Prognostic value of an early peak CK-MB in plasma of patients treated wit streptokinase for acute myocardial infarction]
Pol Arch Med Wewn. 1992 Nov;88(5):336-40. Polish.
PMID: 1300554 [PubMed - indexed for MEDLINE]

☐ **267:** Norregaard-Hansen K, Egstrup K, Nielsen JR, Jorgensen PJ, Petersen PH, Haghfelt T, Horder M. Related Articles, L

Lack of indication of myocardial cell damage after myocardial ischaemia in patients with severe stable angina.
Eur Heart J. 1992 Feb;13(2):188-93.
PMID: 1555615 [PubMed - indexed for MEDLINE]

☐ **268:** Ravkilde J, Hansen AB, Horder M, Jorgensen PJ, Thygesen K. Related Articles, L

Risk stratification in suspected acute myocardial infarction based on a sensi immunoassay for serum creatine kinase isoenzyme MB. A 2.5-year follow-u study in 156 consecutive patients.
Cardiology. 1992;80(2):143-51.

PMID: 1611633 [PubMed - indexed for MEDLINE]

☐ **269:** Mair J, Artner-Dworzak E, Dienstl A, Lechleitner P, Morass B, Smidt J, Wagner I, Wettach C, Puschendorf B. Related Articles, L

Early detection of acute myocardial infarction by measurement of mass concentration of creatine kinase-MB.
Am J Cardiol. 1991 Dec 15;68(17):1545-50.
PMID: 1746453 [PubMed - indexed for MEDLINE]

☐ **270:** Gonzalez-Juanatey JR, Garcia-Acuna JM, Amaro Cendon A, Jacquet Herter M, Pubul Nunez V, Pedreira Perez M, de la Pena MG. Related Articles, L

[Temporal electric stimulation and right ventricular extension in acute poste inferior myocardial infarction. Influence on clinical characteristics and prognosis]
Rev Port Cardiol. 1991 Dec;10(12):917-21. Spanish.
PMID: 1807297 [PubMed - indexed for MEDLINE]

☐ **271:** Seegobin RD, Goodland FC, Wilmshurst TH, Johnston J, Wainwright C, Norman J, Conway N. Related Articles, L

Postoperative myocardial damage in patients with coronary artery disease undergoing major non cardiac surgery.
Can J Anaesth. 1991 Nov;38(8):1005-11.
PMID: 1751996 [PubMed - indexed for MEDLINE]

☐ **272:** Hunt AC, Chow SL, Shiu MF, Chilton DC, Cummins B, Cummins P. Related Articles, L

Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty.
Eur Heart J. 1991 Jun;12(6):690-3.
PMID: 1860469 [PubMed - indexed for MEDLINE]

☐ **273:** Usui A, Kato K, Tsuboi H, Sone T, Sassa H, Abe T. Related Articles, L

Concentration of Mn-superoxide dismutase in serum in acute myocardial infarction.
Clin Chem. 1991 Mar;37(3):458-61.
PMID: 2004457 [PubMed - indexed for MEDLINE]

☐ **274:** Hirayama A, Arita M, Takagaki Y, Tsuji A, Kodama K, Inoue M. Related Articles, L

Clinical assessment of specific enzyme immunoassay for the human cardiac myosin light chain II (MLC II) with use of monoclonal antibodies.
Clin Biochem. 1990 Dec;23(6):515-22.
PMID: 2289310 [PubMed - indexed for MEDLINE]

☐ **275:** Meng Q, Yang X. Related Articles, L

[Serum isoforms of creatine kinase MM (MM3/MM1 ratio) in the diagnosis acute myocardial infarction]
Zhonghua Xin Xue Guan Bing Za Zhi. 1990 Dec;18(6):339-42, 382. Chinese.
PMID: 2093552 [PubMed - indexed for MEDLINE]

☐ **276:** Apple FS, Preese LM, Riley L, Gerken KL, Van Lente F. Related Articles, L

Financial impact of a rapid CK-MB-specific immunoassay on the diagnosis myocardial infarction.
Arch Pathol Lab Med. 1990 Oct;114(10):1017-20.
PMID: 2222141 [PubMed - indexed for MEDLINE]

☐ **277:** Araujo EC, Sousa AG, Nicolela Junior EL, Cano MN, Maldonado G, Feres F, Mattos LA, Pinto IM, Tanajura LF, Fontes VF. Related Articles, L

[Occlusion of secondary branches after angioplasty of the left descending coronary artery]

Arq Bras Cardiol. 1990 May;54(5):313-7. Portuguese.
PMID: 2288518 [PubMed - indexed for MEDLINE]

☐ **278:** Yang XS, Meng QY, Gong WR. Related Articles, L

[Diagnostic changes in serum creatine kinase MM isoenzyme sub-bands aft the onset of acute myocardial infarction]
Zhonghua Nei Ke Za Zhi. 1990 May;29(5):277-9, 316. Chinese.
PMID: 2242687 [PubMed - indexed for MEDLINE]

☐ **279:** Gonzalez-Hermosillo JA, Rubio E, Manzanares E, Fernandez G, Miguel Casanova J, Quijano F. Related Articles, L

[The diagnosis of perioperative myocardial infarction in heart surgery]
Arch Inst Cardiol Mex. 1990 May-Jun;60(3):267-76. Spanish.
PMID: 2241400 [PubMed - indexed for MEDLINE]

☐ **280:** Usui A, Kato K, Sasa H, Minaguchi K, Abe T, Murase M, Tanaka M, Takeuchi E. Related Articles, L

S-100ao protein in serum during acute myocardial infarction.
Clin Chem. 1990 Apr;36(4):639-41.
PMID: 2323043 [PubMed - indexed for MEDLINE]

☐ **281:** Mauri F, Mafrici A, Biraghi M, Cerri P, De Biase AM. Related Articles, L

Effectiveness of calcium antagonist drugs in patients with unstable angina a proven coronary artery disease.
Eur Heart J. 1988 Dec;9 Suppl N:158-63.
PMID: 3149935 [PubMed - indexed for MEDLINE]

☐ **282:** Boden WE, Kleiger RE, Schechtman KB, Capone RJ, Schwartz DJ, Gibson RS. Related Articles, L

Clinical significance and prognostic importance of left ventricular hypertro in non-Q-wave acute myocardial infarction.
Am J Cardiol. 1988 Nov 15;62(16):1000-4.
PMID: 2973215 [PubMed - indexed for MEDLINE]

☐ **283:** Tofler GH, Muller JE, Stone PH, Willich SN, Davis VG, Poole WK, Braunwald E. Related Articles, L

Factors leading to shorter survival after acute myocardial infarction in patie ages 65 to 75 years compared with younger patients.
Am J Cardiol. 1988 Nov 1;62(13):860-7.
PMID: 3177233 [PubMed - indexed for MEDLINE]

☐ **284:** Brush JE Jr, Brand DA, Acampora D, Goldman L, Cabin HS. Related Articles, L

Relation of peak creatine kinase levels during acute myocardial infarction t presence or absence of previous manifestations of myocardial ischemia (an pectoris or healed myocardial infarction).
Am J Cardiol. 1988 Sep 15;62(9):534-7.
PMID: 3414544 [PubMed - indexed for MEDLINE]

☐ **285:** Hedges JR, Rouan GW, Toltzis R, Goldstein-Wayne B, Stein EA. Related Articles, L

Use of cardiac enzymes identifies patients with acute myocardial infarction otherwise unrecognized in the emergency department.
Ann Emerg Med. 1987 Mar;16(3):248-52.
PMID: 3813158 [PubMed - indexed for MEDLINE]

☐ **286:** Medeiros LJ, Schotte D, Gerson B. Related Articles, L

Reliability and significance of increased creatine kinase MB isoenzyme in t serum of uremic patients.
Am J Clin Pathol. 1987 Jan;87(1):103-8.
PMID: 3799540 [PubMed - indexed for MEDLINE]

☐ **287:** Slack JD, Pinkerton CA. Related Articles, L

The electrocardiogram often fails to identify pericarditis after percutaneous transluminal coronary angioplasty.
J Electrocardiol. 1986 Oct;19(4):399-402.
PMID: 2947963 [PubMed - indexed for MEDLINE]

☐ **288:** Krawietz W, Fischer S, Neumeier D, Autenrieth G. Related Articles, L

[Increased CK-MB activity in a 54-year-old patient with unstable angina pectoris]
Internist (Berl). 1986 May;27(5):336-8. German. No abstract available.
PMID: 3525448 [PubMed - indexed for MEDLINE]

☐ **289:** Christakis GT, Fremes SE, Weisel RD, Madonik MM, McDonough JH, Tittley JG, Mickle DA, Ivanov J, Mickleborough LL, Goldman BS. Related Articles, L

Reducing the risk of urgent revascularization for unstable angina: a randomized clinical trial.
J Vasc Surg. 1986 May;3(5):764-72.
PMID: 3517388 [PubMed - indexed for MEDLINE]

☐ **290:** Karjalainen J, Heikkila J. Related Articles, L

"Acute pericarditis": myocardial enzyme release as evidence for myocarditi
Am Heart J. 1986 Mar;111(3):546-52.
PMID: 3953365 [PubMed - indexed for MEDLINE]

☐ **291:** Miyazawa K, Fukuyama H, Yamaguchi I, Kobayashi M, Washio M, Oda J. Related Articles, L

Serial determinations of serum enzymes following aorta-coronary bypass surgery and acute myocardial infarction.
Jpn Heart J. 1985 Jan;26(1):45-52.
PMID: 3874295 [PubMed - indexed for MEDLINE]

☐ **292:** Roberts AJ, Faro RS, Watson WD, Knauf DG, Hankins T, Alexander JA. Related Articles, L

Coronary artery bypass graft surgery: relative efficacy of initial proximal versus distal anastomoses.
Ann Thorac Surg. 1984 Jul;38(1):15-20.
PMID: 6375603 [PubMed - indexed for MEDLINE]

☐ **293:** Brummett C, Reves JG, Lell WA, Smith LR. Related Articles, L

Patient care problems in patients undergoing reoperation for coronary artery grafting surgery.
Can Anaesth Soc J. 1984 Mar;31(2):213-20.
PMID: 6423244 [PubMed - indexed for MEDLINE]

☐ **294:** Aznar J, Santos MT, Valles J, Sala J. Related Articles, L

Serum malondialdehyde-like material (MDA-LM) in acute myocardial infarction.
J Clin Pathol. 1983 Jun;36(6):712-5.
PMID: 6853736 [PubMed - indexed for MEDLINE]

☐ **295:** de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Related Articles, L

Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.
Br Heart J. 1982 Mar;47(3):239-43.
PMID: 7059401 [PubMed - indexed for MEDLINE]

☐ **296:** Martinelli M, Bugiardini R, Vinelli S, Puddu P, Bugiardini G, Capelli M, Cocchi V, Motta R. Related Articles, L

[Critical analysis of the radioimmunological methods of determining creati kinase isoenzyme MB (CK-MB), myoglobin (MG) and of LDH (H4) in ischemic cardiopathy]
Quad Sclavo Diagn. 1980 Jun;16(2):134-48. Italian.
PMID: 7244091 [PubMed - indexed for MEDLINE]

☐ **297:** Fiol Sala M, Fuentespina Vidal E, Abizanda Campos R, Ibanez Juve J, Marse Milla P, Abadal Centellas JM, Coll Solivellas R, Perello J, Garcia Moris S. Related Articles, L

[Usefulness of creatine phosphokinase isoenzyme, CK-MB, in the diagnosi myocardial necrosis (author's transl)]
Med Clin (Barc). 1979 Dec 15;73(10):403-9. Spanish.
PMID: 529861 [PubMed - indexed for MEDLINE]

☐ **298:** Kopp HG, Hess OM, Gautschi K, Baumann PC, Knob M, Rosenmund H. Related Articles, L

[Plasma myoglobin level as a course criterium in patients with acute myocardial infarct]
Schweiz Med Wochenschr. 1979 Nov 10;109(43):1660-3. German.
PMID: 531558 [PubMed - indexed for MEDLINE]

☐ **299:** Marmor A, Kahana L, Alpan G, Grenadier E, Keidar S, Palant A. Related Articles, L

Creatine kinase isoenzyme MB (CK-MB) in acute coronary ischemia.
Am Heart J. 1979 May;97(5):574-7. No abstract available.
PMID: 433731 [PubMed - indexed for MEDLINE]

☐ **300:** Kaiser H, Spaar U, Sold G, Wolfrum DI, Kreuzer H. Related Articles, L

[Radioimmunoassay for human myoglobin: methodology and diagnostic significance in myocardial infarction (author's transl)]
Klin Wochenschr. 1979 Mar 1;57(5):225-35. German.
PMID: 431032 [PubMed - indexed for MEDLINE]

☐ **301:** Marmor A, Keidar S, Grenadir E, Palant A. Related Articles, L

Reliability of CK-MB isoenzyme as a predictor of acute MI.
Am Heart J. 1979 Feb;97(2):269-70. No abstract available.
PMID: 760461 [PubMed - indexed for MEDLINE]

☐ **302:** Strom S. Related Articles, L

Prognostic significance of cardiopulmonary bypass time and postoperative serum enzyme levels in coronary surgery.
Scand J Thorac Cardiovasc Surg. 1979;13(2):133-8.
PMID: 314155 [PubMed - indexed for MEDLINE]

☐ **303:** Chemnitz G, Schmidt E, Schmidt FW, Gahl K, Lobers J. Related Articles, L

[Determination of creatine kinase and CK-MB in heart failure (author's tran
Med Klin. 1978 Dec 22;73(51-52):1809-11. German.
PMID: 723768 [PubMed - indexed for MEDLINE]

☐ **304:** Welman E, Fox KM, Selwyn AP, Carroll BJ. Related Articles, L

The effect of established beta-adrenoreceptor-blocking therapy on the relea of cytosolic and lysosomal enzymes after acute myocardial infarction in ma
Clin Sci Mol Med Suppl. 1978 Dec;55(6):549-53.
PMID: 32987 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

```
Connecting via Winsock to STN
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:33:05 ON 15 OCT 2004

=> File BIOSCIENCE
FILE 'ADISCTI' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 08:33:22 ON 15 OCT 2004

FILE 'AQUALINE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 08:33:22 ON 15 OCT 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 08:33:22 ON 15 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 08:33:22 ON 15 OCT 2004

FILE 'CAPLUS' ENTERED AT 08:33:22 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 08:33:22 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 08:33:22 ON 15 OCT 2004
```

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGB' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'IMSRESEARCH' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 08:33:22 ON 15 OCT 2004

FILE 'FOMAD' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 08:33:22 ON 15 OCT 2004

FILE 'HEALSAFE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 08:33:22 ON 15 OCT 2004

FILE 'NIOSHTIC' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 08:33:22 ON 15 OCT 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 08:33:22 ON 15 OCT 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 08:33:22 ON 15 OCT 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 08:33:22 ON 15 OCT 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 08:33:22 ON 15 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 08:33:22 ON 15 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 08:33:22 ON 15 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 08:33:22 ON 15 OCT 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

```
FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s FGF-1 OR FGF-2 OR VEGF OR aFGF OR bFGF
  14 FILES SEARCHED...
  25 FILES SEARCHED...
  35 FILES SEARCHED...
  50 FILES SEARCHED...
  59 FILES SEARCHED...
  69 FILES SEARCHED...
L1      233217 FGF-1 OR FGF-2 OR VEGF OR AFGF OR BFGF

=> s coronary artery disease OR angina OR myocardial infarct OR myocardial ischemia
  12 FILES SEARCHED...
  25 FILES SEARCHED...
  33 FILES SEARCHED...
  45 FILES SEARCHED...
  52 FILES SEARCHED...
  66 FILES SEARCHED...
L2      656834 CORONARY ARTERY DISEASE OR ANGINA OR MYOCARDIAL INFARCT OR MYOCA
               RDIAL ISCHEMIA

=> S L1 AND L2
  22 FILES SEARCHED...
  38 FILES SEARCHED...
  64 FILES SEARCHED...
L3        4935 L1 AND L2

=> DUP REM L3
FILE 'ADISCTI' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'BIOBUSINESS' ENTERED AT 08:39:35 ON 15 OCT 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 08:39:35 ON 15 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 08:39:35 ON 15 OCT 2004

FILE 'CAPLUS' ENTERED AT 08:39:35 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CIN' ENTERED AT 08:39:35 ON 15 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.
```

FILE 'DGENE' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'IMSDRUGNEWS' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'IMSRESEARCH' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 08:39:35 ON 15 OCT 2004

FILE 'IFIPAT' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'LIFESCI' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 08:39:35 ON 15 OCT 2004

FILE 'PASCAL' ENTERED AT 08:39:35 ON 15 OCT 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PHAR' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 08:39:35 ON 15 OCT 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIN' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'SCISEARCH' ENTERED AT 08:39:35 ON 15 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 08:39:35 ON 15 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 08:39:35 ON 15 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 08:39:35 ON 15 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION
PROCESSING IS APPROXIMATELY 18% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 48% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 78% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 93% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
L4 3487 DUP REM L3 (1448 DUPLICATES REMOVED)

```
=> S L4 AND PY<=2000
'2000' NOT A VALID FIELD CODE
   5 FILES SEARCHED...
   8 FILES SEARCHED...
  10 FILES SEARCHED...
  14 FILES SEARCHED...
  21 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  26 FILES SEARCHED...
  28 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  32 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  35 FILES SEARCHED...
  36 FILES SEARCHED...
L5          931 L4 AND PY<=2000

=> S nasal OR intranasal OR inhale OR inhalation OR olfactory
  28 FILES SEARCHED...
L6      1006005 NASAL OR INTRANASAL OR INHALE OR INHALATION OR OLFACTORY

=> S L5 AND L6
  22 FILES SEARCHED...
L7           78 L5 AND L6

=> D L7 1-78

L7    ANSWER 1 OF 78  PHARMAML  COPYRIGHT 2004 MARKETLETTER on STN
AN    1641161   PHARMAML
TI    Genentech Starts Trials Of Recombinant   ***VEGF***
SO    Marketletter April 3, 1998
DT    Newsletter
WC    750

L7    ANSWER 2 OF 78  PHARMAML  COPYRIGHT 2004 MARKETLETTER on STN
AN    1639493   PHARMAML
TI    Zeneca Allays Fears Of Near-Term Product Gap
SO    Marketletter December 4, 1997
DT    Newsletter
WC    2267

L7   ANSWER 3 OF 78  PHIN COPYRIGHT 2004 PJB on STN

AN   2000:17955  PHIN
DN   B00683182
DED  1 Sep 2000
TI   What's in the Pipeline? - Bioventure-View's Roundup of Biotech Products in
     Phase III - Part B
SO   Bioventure-View (  ***2000***  )  No. 1509 p12
DT   Newsletter
FS   FULL

L7   ANSWER 4 OF 78  PHIN COPYRIGHT 2004 PJB on STN

AN   97:13715  PHIN
DN   S00546366
DED  3 Jul 1997
TI   Genentech earnings down, sales flat
SO   Scrip (  ***1997***  )  No. 2253 p12
DT   Newsletter
FS   FULL

L7   ANSWER 5 OF 78  PHIN COPYRIGHT 2004 PJB on STN

AN   95:11703  PHIN
DN   S00450122
DED  29 Jun 1995
TI   Bristol-Myers Squibb Company Profile (1995)
SO   Scrip-Online-plus (  ***1995***  )
DT   Newsletter
FS   FULL

L7   ANSWER 6 OF 78  PROMT  COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER:   2000:169609  PROMT
TITLE:              Gene genies.
```

AUTHOR(S): Truelove, Christiane
SOURCE: Med Ad News, (***Sept 1999***) Vol. 18, No. 9, pp. 122.
ISSN: 1067-733X.
PUBLISHER: Engel Publishing Partners
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2599
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 7 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:208043 PROMT
TITLE: Best PIPELINES.
AUTHOR(S): Engel, Styli
SOURCE: Med Ad News, (***March 1999***) Vol. 18, No. 3, pp. 1(1).
ISSN: 0745-0907.
PUBLISHER: Engel Communications, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 41331
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 8 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:162782 PROMT
TITLE: Megabios and GeneMedicine Complete Merger.
SOURCE: PR Newswire, (***19 Mar 1999***) pp. 8437.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 636
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 9 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:175708 PROMT
TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :GeneMedicine-Cationic Lipid Gene Delivery System In Two Phase II Gene Therapy Angioplasty Clinical Trials
SOURCE: BioAccess, (***1 Apr 1998***) pp. N/A.
ISSN: 1356-3432.
LANGUAGE: English
WORD COUNT: 712
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 10 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:173353 PROMT
TITLE: Genentech Starts Trials Of Recombinant ***VEGF***
SOURCE: Marketletter, (***13 Apr 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 756
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 11 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:143219 PROMT
TITLE: GENEMEDICINE Proprietary Cationic Lipid Gene Delivery System Is Employed in Two Phase II Gene Therapy Angioplasty Clinical Trials.
SOURCE: Business Wire, (***19 Mar 1998***) pp. 3190068.
LANGUAGE: English
WORD COUNT: 900
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 12 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:41293 PROMT
TITLE: Genentech's Year-End Results Show Growth Plan on Track: Earnings Increase Nine Percent on Revenues Exceeding $1 Billion.
SOURCE: Business Wire, (***22 Jan 1998***) pp. 01220134.
LANGUAGE: English
WORD COUNT: 2029

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 13 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:41215 PROMT
TITLE: ZENECA AIMS TO DOUBLE R & D OUTPUT BY 2002
SOURCE: Pharmaceutical Business News, (***19 Dec 1997***) pp. N/A.
ISSN: 0956-0661.
LANGUAGE: English
WORD COUNT: 1561
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 14 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:629445 PROMT
TITLE: Zeneca Allays Fears of Near-Term Product Gap
SOURCE: Marketletter, (***8 Dec 1997***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 2214
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 15 OF 78 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:97804 PROMT
TITLE: Biotech's Bellwethers
SOURCE: BioVenture View, (***1 Feb 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 4435
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 16 OF 78 USPATFULL on STN
AN 2001:33286 USPATFULL
TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6197789 B1 20010306
WO 9640098 19961219 <--
AI US 1997-973570 19971205 (8)
WO 1996-US10211 19960607
19980908 PCT 371 date
19980908 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, now patented, Pat. No. US 5595722 Continuation-in-part of Ser. No. US 1995-477393, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609
DT Utility
FS Granted
LN.CNT 4577
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000; 514/866.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000; 514/866.000
IC [7]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/319; 514/324; 514/422; 514/428; 514/444; 514/448; 514/651; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 78 USPATFULL on STN
AN 2000:164259 USPATFULL
TI Methods for the treatment and diagnosis of cardiovascular disease
IN Falb, Dean, Wellesley, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6156500 20001205 <--

AI US 1995-386844 19950210 (8)
DT Utility
FS Granted
LN.CNT 4817
INCL INCLM: 435/006.000
INCLS: 436/501.000; 935/077.000
NCL NCLM: 435/006.000
NCLS: 436/501.000
IC [7]
ICM: C12Q001-68
EXF 435/6; 435/810; 435/69.1; 435/7.1; 436/501; 436/63; 530/300; 530/350; 530/387.1; 536/23.1; 536/24.1; 536/24.3-24.33; 935/77.78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 78 USPATFULL on STN
AN 2000:145865 USPATFULL
TI Targeted contrast agents for diagnostic and therapeutic use
IN Unger, Evan C., Tucson, AZ, United States
Fritz, Thomas A., Tucson, AZ, United States
Gertz, Edward W., Paradise Valley, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6139819 20001031 <--
AI US 1997-932273 19970917 (8)
RLI Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-640464, filed on 1 May 1996, now abandoned which is a continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned And a continuation-in-part of Ser. No. US 1996-666129, filed on 19 Jun 1996, now patented, Pat. No. US 6033645
DT Utility
FS Granted
LN.CNT 7523
INCL INCLM: 424/009.520
INCLS: 424/009.510; 424/450.000
NCL NCLM: 424/009.520
NCLS: 424/009.510; 424/450.000
IC [7]
ICM: A61B008-00
ICS: A61K009-127
EXF 424/9.52; 424/9.51; 424/9.5; 424/450; 424/812; 600/441; 600/458; 264/4.1; 427/2.14; 427/213.3; 428/402.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 78 USPATFULL on STN
AN 2000:138360 USPATFULL
TI Hydroxyl-containing bicyclic compounds
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6133274 20001017 <--
AI US 1996-756703 19961126 (8)
RLI Continuation of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1646
INCL INCLM: 514/263.000
INCLS: 544/267.000
NCL NCLM: 514/263.360
NCLS: 544/267.000
IC [7]
ICM: C07D473-04
ICS: A61K031-52
EXF 544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 78 USPATFULL on STN
AN 2000:128465 USPATFULL
TI Compositions and methods for treatment and diagnosis of cardiovascular disease
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.

corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6124433 20000926 <--
AI US 1997-944496 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5924
INCL INCLM: 530/350.000
INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000; 536/023.100; 536/023.500
IC [7]
ICM: C07K016-00
ICS: C12N015-00
EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 935/32; 935/52; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 78 USPATFULL on STN
AN 2000:121539 USPATFULL
TI Methods for regulating transcription factors
IN Qabar, Maher N., Redmond, WA, United States
McMillan, Michael K., Bellevue, WA, United States
Kahn, Michael S., Kirkland, WA, United States
Tulinsky, John E., Seattle, WA, United States
Ogbu, Cyprian O., Bellevue, WA, United States
Mathew, Jessymol, Bellevue, WA, United States
PA Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)
PI US 6117896 20000912 <--
AI US 1998-22934 19980212 (9)
RLI Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997, now abandoned And a continuation-in-part of Ser. No. US 692420
PRAI US 1997-47067P 19970519 (60)
DT Utility
FS Granted
LN.CNT 4501
INCL INCLM: 514/384.000
INCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400
NCL NCLM: 514/384.000
NCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400
IC [7]
ICM: A61K031-41
ICS: C07K005-00; C07K007-00; C07K016-00; C07D249-12
EXF 514/248; 514/384; 530/332; 530/323; 548/263.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 78 USPATFULL on STN
AN 2000:109372 USPATFULL
TI In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
IN Ranney, David F., Dallas, TX, United States
PA Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6106866 20000822 <--
AI US 1995-509338 19950731 (8)
DT Utility
FS Granted
LN.CNT 3913
INCL INCLM: 424/499.000
INCLS: 424/489.000; 424/491.000; 424/493.000; 424/548.000; 514/054.000; 514/062.000; 530/322.000; 536/054.000
NCL NCLM: 424/499.000
NCLS: 424/489.000; 424/491.000; 424/493.000; 424/548.000; 514/054.000; 514/062.000; 530/322.000; 536/054.000
IC [7]
ICM: A61K031-726
EXF 530/322; 424/548; 424/489; 424/491; 424/493; 424/499; 536/54; 514/54;

514/62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 78 USPATFULL on STN
AN 2000:105913 USPATFULL
TI Amine substituted compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6103730 20000815 <--
AI US 1995-486264 19950607 (8)
RLI Continuation of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1702
INCL INCLM: 514/263.000
INCLS: 514/265.000; 544/268.000; 544/269.000; 544/270.000; 544/271.000; 544/272.000
NCL NCLM: 514/263.200
NCLS: 514/151.000; 514/210.210; 514/263.210; 514/263.220; 514/263.230; 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/270.000; 544/271.000; 544/272.000
IC [7]
ICM: A61K031-522
ICS: C07D473-10
EXF 544/268; 544/269; 544/220; 544/271; 544/272; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 78 USPATFULL on STN
AN 2000:102304 USPATFULL
TI Therapeutic compounds containing xanthinyl
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6100271 20000808 <--
AI US 1995-483871 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1986
INCL INCLM: 514/263.000
INCLS: 514/265.000; 544/268.000; 544/269.000; 544/271.000
NCL NCLM: 514/263.200
NCLS: 514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/271.000
IC [7]
ICM: A61K031-522
ICS: C07D473-10
EXF 544/271; 544/268; 544/269; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 78 USPATFULL on STN
AN 2000:101856 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease
IN Falb, Dean A., Wellesley, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6099823 20000808 <--
AI US 1998-126640 19980730 (9)
RLI Continuation-in-part of Ser. No. US 1997-870434, filed on 6 Jun 1997 which is a continuation-in-part of Ser. No. US 1997-799910, filed on 13 Feb 1997
PRAI US 1996-11787P 19960216 (60)
DT Utility
FS Granted
LN.CNT 5987
INCL INCLM: 424/009.100
INCLS: 536/023.100; 424/009.200; 435/006.000; 435/325.000
NCL NCLM: 424/009.100

NCLS: 424/009.200; 435/006.000; 435/325.000; 536/023.100
IC [7]
ICM: C12Q001-68
ICS: C12N015-85; C12N015-86; C07H021-02; C07H021-04; A61K049-00
EXF 435/70.1; 435/325; 435/69.1; 435/6; 435/91.1; 435/91.3; 435/320.1; 435/4; 536/23.1; 536/24.5; 424/9.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 78 USPATFULL on STN
AN 2000:95042 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox Inc., San Diego, CA, United States (U.S. corporation)
PI US 6093743 20000725 <--
AI US 1998-103639 19980623 (9)
DT Utility
FS Granted
LN.CNT 2691
INCL INCLM: 514/599.000
INCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000; 514/866.000; 514/909.000; 514/912.000
NCL NCLM: 514/599.000
NCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000; 514/866.000; 514/909.000; 514/912.000
IC [7]
ICM: A61K031-16
ICS: A61K031-095; A61K031-105
EXF 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909; 514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 78 USPATFULL on STN
AN 2000:91735 USPATFULL
TI Interferon responsive transcript (IRT-1)
IN Autieri, Michael V., Blue Bell, PA, United States
PA Temple University of the Commonwealth System of Higher Education, Philadelphia, PA, United States (U.S. corporation)
PI US 6090580 20000718 <--
AI US 1998-4171 19980102 (9)
DT Utility
FS Granted
LN.CNT 1142
INCL INCLM: 435/069.100
INCLS: 435/252.330; 435/325.000; 435/320.100; 530/350.000; 536/023.100; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/252.330; 435/320.100; 435/325.000; 530/350.000; 536/023.100; 536/023.500
IC [7]
ICM: C12P021-06
ICS: C07H021-04
EXF 530/350; 536/23.5; 435/69.1; 435/252.3; 435/252.33; 435/320.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 78 USPATFULL on STN
AN 2000:88304 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6087477 20000711 <--
AI US 1997-944495 19971006 (8)
RLI Division of Ser. No. US 1997-799910, filed on 13 Feb 1997
PRAI US 1996-11787P 19960216 (60)
DT Utility
FS Granted
LN.CNT 5589
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/325.000; 536/023.100
NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/325.000; 536/023.100
IC [7]
ICM: C07K016-00
ICS: C12N015-00
EXF 435/325; 435/69.1; 435/6; 536/23.1; 424/185.1; 530/388.24; 530/389.2; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 78 USPATFULL on STN
AN 2000:53742 USPATFULL
TI Method of treatment of arterial and venous thromboembolic disorders
IN Mousa, Shaker Ahmed, Lincoln University, PA, United States
PA Dupont Pharmaceuticals, Wilmington, DE, United States (U.S. corporation)
PI US 6056958 20000502 <--
AI US 1997-901344 19970728 (8)
RLI Continuation of Ser. No. US 1994-353419, filed on 9 Dec 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2186
INCL INCLM: 424/145.100
INCLS: 424/141.100; 424/130.100; 514/002.000
NCL NCLM: 424/145.100
NCLS: 424/130.100; 424/141.100; 514/002.000
IC [7]
ICM: A61K039-395
EXF 360/32; 360/64; 360/33.1; 360/72.2; 514/2; 386/27; 386/33; 386/37; 386/40-41; 386/109; 386/123; 424/145.1; 424/141.1; 424/130.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 78 USPATFULL on STN
AN 2000:50808 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd534 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Brigham and Womens's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6054558 20000425 <--
AI US 1997-925743 19970909 (8)
RLI Division of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5141
INCL INCLM: 530/350.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100; 536/024.100; 536/024.300
IC [7]
ICM: C07K016-00
ICS: C12N015-00
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/810; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 435/350; 435/34; 435/52; 435/77; 436/301; 436/63; 514/2; 530/388.24; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 31 OF 78 USPATFULL on STN
AN 2000:43949 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease
IN Falb, Dean A., Wellesley, MA, United States
PA Millennium Pharmaceuticals Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6048709 20000411 <--
AI US 1997-826246 19970328 (8)
RLI Division of Ser. No. US 1997-799910, filed on 13 Feb 1997
PRAI US 1996-11787P 19960216 (60)
DT Utility
FS Granted
LN.CNT 5855
INCL INCLM: 435/069.100

INCLS: 435/172.300; 435/252.300; 435/325.000; 435/320.100; 536/023.500; 536/024.310
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.500; 536/024.310
IC [7]
ICM: C12N015-85
ICS: C12N015-63; C12N015-70; C12N015-12
EXF 435/6; 435/69.1; 435/71.2; 435/91.1; 435/172.1; 435/172.3; 435/325; 435/375; 435/320.1; 530/350; 536/23.5; 536/25.32
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 32 OF 78 USPATFULL on STN
AN 2000:43938 USPATFULL
TI Parallel SELEX.TM.
IN Eaton, Bruce, Boulder, CO, United States
Tarasow, Theodore M., Boulder, CO, United States
PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6048698 20000411 <--
AI US 1998-157601 19980921 (9)
RLI Continuation-in-part of Ser. No. US 1996-618700, filed on 20 Mar 1996, now patented, Pat. No. US 5858660 which is a continuation-in-part of Ser. No. US 1994-309245, filed on 20 Sep 1994, now patented, Pat. No. US 5723289
DT Utility
FS Granted
LN.CNT 3339
INCL INCLM: 435/006.000
INCLS: 536/025.400
NCL NCLM: 435/006.000
NCLS: 536/025.400
IC [7]
ICM: C12Q001-68
ICS: C07H021-02; C07H021-04
EXF 435/6; 536/25.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 78 USPATFULL on STN
AN 2000:37806 USPATFULL
TI Methods for using therapeutic compounds containing xanthinyl
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6043250 20000328 <--
AI US 1995-472296 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2052
INCL INCLM: 514/263.000
NCL NCLM: 514/234.200
NCLS: 514/210.210; 514/263.200; 514/263.220; 514/263.230; 514/263.350
IC [7]
ICM: A61K003-52
EXF 514/263

L7 ANSWER 34 OF 78 USPATFULL on STN
AN 2000:34403 USPATFULL
TI Vascular endothelial growth factor 2
IN Hu, Jing-Shan, Sunnyvale, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
Cao, Liang, South Horizons, Hong Kong
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6040157 20000321 <--
AI US 1998-42105 19980313 (9)
RLI Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997, now patented, Pat. No. US 5932540 which is a continuation-in-part of Ser. No. US 1997-824996, filed on 27 Mar 1997 And a continuation-in-part of Ser. No. US 1995-465968, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994
DT Utility

FS Granted
LN.CNT 5292
INCL INCLM: 435/069.400
INCLS: 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510; 530/399.000
NCL NCLM: 435/069.400
NCLS: 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000; 536/023.510
IC [7]
ICM: C12N015-18
ICS: C12N015-63; C12N001-21; C12N005-00
EXF 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 78 USPATFULL on STN
AN 2000:12926 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6020463 20000201 <--
AI US 1997-944423 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995, now patented, Pat. No. US 5968770 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5972
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
IC [6]
ICM: C07K016-00
ICS: C12N015-00
EXF 435/320.1; 435/325; 435/69.1; 435/6; 536/23.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 78 USPATFULL on STN
AN 2000:12800 USPATFULL
TI Electronegative-substituted long chain xanthine compounds
IN Leigh, Alistair J., Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil M., Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Underiner, Gail, Malvern, PA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6020337 20000201 <--
AI US 1997-950810 19970916 (8)
RLI Continuation-in-part of Ser. No. US 1993-42946, filed on 5 Apr 1993, now patented, Pat. No. US 5670506 And a continuation-in-part of Ser. No. US 1997-910579, filed on 26 Jul 1997
DT Utility
FS Granted
LN.CNT 1376
INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/263.340
NCLS: 514/210.210; 514/263.360; 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 514/258; 544/267; 544/272; 544/277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 78 USPATFULL on STN
AN 2000:10014 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target
IN Falb, Dean A., Wellesley, MA, United States

Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6018025 20000125 <--
AI US 1997-944868 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 6133
INCL INCLM: 530/350.000
INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000; 536/023.100; 536/023.500
IC [6]
ICM: C07K016-00
ICS: C12N015-00
EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/810; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 436/501; 436/63; 935/32; 935/52; 935/77; 530/350; 530/325; 530/326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 78 USPATFULL on STN
AN 2000:4941 USPATFULL
TI ***VEGF*** .sub.145 expression vectors
IN Neufeld, Gera, Haifa, Israel
Keshet, Eli, Kiryat Yam, Israel
Vlodavsky, Israel, Mevaseret Zion, Israel
Poltorak, Zoya, Jerusalem, Israel
PA Technion Research & Development Co. Ltd., Haifa, Israel (non-U.S. corporation)
PI US 6013780 20000111 <--
AI US 1997-784551 19970121 (8)
PRAI US 1996-25537P 19960906 (60)
DT Utility
FS Granted
LN.CNT 2158
INCL INCLM: 536/023.100
INCLS: 435/320.100
NCL NCLM: 536/023.100
NCLS: 435/320.100
IC [6]
ICM: C07H021-04
ICS: C12N015-11; C12N015-63
EXF 514/44; 435/172.3; 435/320.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 39 OF 78 USPATFULL on STN
AN 1999:151195 USPATFULL
TI GATA-6 transcription factor: compositions and methods
IN Walsh, Kenneth, Carlisle, MA, United States
PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S. corporation)
PI US 5990092 19991123 <--
AI US 1997-927394 19970827 (8)
DT Utility
FS Granted
LN.CNT 2449
INCL INCLM: 514/044.000
INCLS: 435/320.100; 536/023.500
NCL NCLM: 514/044.000
NCLS: 435/320.100; 536/023.500
IC [6]
ICM: A61K048-00
ICS: C12N015-12; C12N015-85
EXF 435/320.1; 435/375; 435/377; 514/44; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 40 OF 78 USPATFULL on STN
AN 1999:128386 USPATFULL

TI Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5968770 19991019 <--
AI US 1995-485573 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5019
INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/007.100; 435/320.100; 435/325.000; 435/455.000; 514/044.000; 536/023.100; 536/024.100; 536/024.300
NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/007.100; 435/320.100; 435/325.000; 435/455.000; 514/044.000; 536/023.100; 536/024.100; 536/024.300
IC [6]
ICM: C12N001-21
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/7.1; 435/320.1; 435/325; 435/455; 514/44; 436/501; 436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 41 OF 78 USPATFULL on STN
AN 1999:96407 USPATFULL
TI Pulsed administration of compositions for the treatment of blood disorders
IN Perrine, Susan P., 27 Harding Ave., Braintree, MA, United States 02184
PI US 5939456 19990817 <--
AI US 1996-687670 19960726 (8)
DT Utility
FS Granted
LN.CNT 2147
INCL INCLM: 514/554.000
INCLS: 514/538.000; 514/546.000; 514/563.000; 514/568.000; 514/576.000; 514/578.000; 514/629.000
NCL NCLM: 514/554.000
NCLS: 514/538.000; 514/546.000; 514/563.000; 514/568.000; 514/576.000; 514/578.000; 514/629.000
IC [6]
ICM: A61K031-205
ICS: A61K031-19; A61K031-22
EXF 514/576; 514/578; 514/563; 514/568; 514/538; 514/629; 514/546; 514/554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 42 OF 78 USPATFULL on STN
AN 1999:92656 USPATFULL
TI Compositions and methods for modulating growth of a tissue in a mammal
IN Weisz, Paul B., State College, PA, United States
PA Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5935940 19990810 <--
AI US 1997-906500 19970805 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1497
INCL INCLM: 514/058.000
INCLS: 514/021.000; 530/810.000; 530/812.000; 530/813.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 530/810.000; 530/812.000; 530/813.000
IC [6]
ICM: A61K031-715
ICS: A61K038-00
EXF 514/58; 514/21; 530/810; 530/812; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 43 OF 78 USPATFULL on STN
AN 1999:89116 USPATFULL
TI Vascular endothelial growth factor 2
IN Hu, Jing-Shan, Sunnyvale, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
Cao, Liang, Hong Kong, Hong Kong
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5932540 19990803 <--
AI US 1997-999811 19971224 (8)
RLI Continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994, now abandoned And Ser. No. US 1995-465968, filed on 6 Jun 1995
DT Utility
FS Granted
LN.CNT 2605
INCL INCLM: 514/002.000
INCLS: 530/326.000; 530/399.000; 530/402.000
NCL NCLM: 514/002.000
NCLS: 530/326.000; 530/399.000; 530/402.000
IC [6]
ICM: A61K038-14
ICS: C07K014-475
EXF 514/2; 514/12; 530/399; 530/326; 530/402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 44 OF 78 USPATFULL on STN
AN 1999:56471 USPATFULL
TI Methods of modulating tissue growth and regeneration
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5902799 19990511 <--
AI US 1997-906501 19970805 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1703
INCL INCLM: 514/058.000
INCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
IC [6]
ICM: A61K031-715
ICS: A61K031-735
EXF 514/58; 514/21; 514/56; 530/810; 530/812; 530/813; 530/817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 45 OF 78 USPATFULL on STN
AN 1999:40428 USPATFULL
TI Substituted amino alkyl compounds
IN Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5889011 19990330 <--
AI US 1997-884037 19970627 (8)
RLI Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9 Nov 1992, now patented, Pat. No. US 5340813
DT Utility
FS Granted
LN.CNT 1351
INCL INCLM: 514/263.000
INCLS: 514/261.000; 544/267.000; 544/264.000; 544/265.000
NCL NCLM: 514/263.350
NCLS: 544/264.000; 544/265.000; 544/267.000

IC [6]
ICM: C07D473-00
ICS: A61K031-52
EXF 544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 46 OF 78 USPATFULL on STN
AN 1999:33831 USPATFULL
TI Compositions and method for the treatment and diagnosis of cardiovascular disease using rchd502 as a target
IN Falb, Dean A., Wellesley, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5882925 19990316 <--
AI US 1996-599654 19960209 (8)
RLI Continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5758
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100; 435/320.100; 435/455.000
NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100; 536/024.100; 536/024.300
IC [6]
ICM: C12N015-12
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/325; 435/320.1; 435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 47 OF 78 USPATFULL on STN
AN 1999:24638 USPATFULL
TI Compositions and methods for modulating growth of a tissue in a mammal
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5874419 19990223 <--
AI US 1997-905612 19970804 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 20 -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted
LN.CNT 1482
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000; 424/652.000; 424/682.000; 424/617.000; 536/103.000
NCL NCLM: 514/058.000
NCLS: 424/617.000; 424/652.000; 424/682.000; 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: A61K047-02; C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 514/769; 536/103; 424/652; 424/682; 424/617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 48 OF 78 USPATFULL on STN
AN 1999:18711 USPATFULL
TI Adenoviral-mediated gene transfer to adipocytes
IN Crystal, Ronald G., Potomac, MD, United States
Magovern, Christopher J., New York, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 5869037 19990209 <--

AI US 1996-672461 19960626 (8)
DT Utility
FS Granted
LN.CNT 1452
INCL INCLM: 424/093.200
INCLS: 424/093.700; 424/093.210; 435/325.000; 435/320.100; 435/172.300; 514/044.000
NCL NCLM: 424/093.200
NCLS: 424/093.210; 424/093.700; 435/320.100; 435/325.000; 435/456.000; 514/044.000
IC [6]
ICM: A61K035-12
ICS: A61K048-00; C12N015-09; C12N015-86
EXF 514/2; 514/44; 435/172.3; 435/320.1; 435/252.3; 435/325.1; 424/93.21; 424/93.7; 424/93.2; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 49 OF 78 USPATFULL on STN
AN 1999:4647 USPATFULL
TI Fas ligand compositions for treatment of proliferative disorders
IN Walsh, Kenneth, Carlisle, MA, United States
PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S. corporation)
PI US 5858990 19990112 <--
AI US 1997-810453 19970304 (8)
DT Utility
FS Granted
LN.CNT 3038
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/172.100; 435/320.100; 435/069.100; 435/375.000; 435/377.000
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/375.000; 435/377.000
IC [6]
ICM: A61K048-00
ICS: C12N015-11
EXF 435/6; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/69.1; 435/31.1; 435/375; 435/377; 536/23.1; 536/23.5; 514/2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 50 OF 78 USPATFULL on STN
AN 1999:4328 USPATFULL
TI Parallel selex
IN Eaton, Bruce, Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
PA NeXstar Pharmaceuticlas, Inc., Boulder, CO, United States (U.S. corporation)
PI US 5858660 19990112 <--
AI US 1996-618700 19960320 (8)
RLI Continuation-in-part of Ser. No. US 1994-309245, filed on 20 Sep 1994, now patented, Pat. No. US 5723289
DT Utility
FS Granted
LN.CNT 3236
INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/025.400; 536/022.100; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/022.100; 536/025.400
IC [6]
ICM: C12Q001-68
ICS: C12Q019-34; C07H021-02; C07H021-04
EXF 435/6; 435/91.2; 536/22.1; 536/25.4; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 51 OF 78 USPATFULL on STN
AN 1998:157185 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular using RCHD528 as a target
IN Falb, Dean A., Massachusetts, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5849578 19981215 <--
AI US 1996-616844 19960315 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-458873, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10

Feb 1995
DT Utility
FS Granted
LN.CNT 5753
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100; 435/320.100; 435/455.000
NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100; 536/024.100; 536/024.300
IC [6]
ICM: C12N015-12
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/7.1; 435/325; 435/320.1; 435/455; 436/201; 436/63; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 52 OF 78 USPATFULL on STN
AN 1998:144102 USPATFULL
TI Amino-alcohol substituted cyclic compounds
IN Kumar, Anil M., Seattle, WA, United States
Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5837703 19981117 <--
AI US 1993-152650 19931112 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2596
INCL INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000; 514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000; 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000; 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
NCL NCLM: 514/183.000
NCLS: 514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000; 514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000; 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000; 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
IC [6]
ICM: A61K031-55
ICS: A61K031-515; A61K031-445; A61K031-52
EXF 544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311; 544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242; 514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315; 514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467; 540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334; 548/215; 548/340.1; 548/485; 548/546; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 53 OF 78 USPATFULL on STN
AN 1998:138691 USPATFULL
TI Compositions and methods using rchd534, a gene uregulated by shear stress
IN Falb, Dean, Wellesley, MA, United States
PA Millennium Pharmaceuticals Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5834248 19981110 <--
AI US 1995-480994 19950607 (8)
RLI Division of Ser. No. US 1995-485573, filed on 7 Jun 1995 And a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 4877
INCL INCLM: 435/070.100

INCLS: 435/325.000; 435/172.300; 435/320.100; 536/023.100; 536/023.500
NCL NCLM: 435/070.100
NCLS: 435/320.100; 435/325.000; 536/023.100; 536/023.500
IC [6]
ICM: C12N015-00
ICS: C07H021-00
EXF 514/44; 424/93.1; 536/23.1; 536/23.5; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 54 OF 78 USPATFULL on STN
AN 1998:128265 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5824677 19981020 <--
AI US 1995-474816 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 , said Ser. No. US -152650 And Ser. No. US -164081 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3136
INCL INCLM: 514/222.500
INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000; 514/249.000; 514/255.000; 514/258.000; 514/274.000; 514/301.000; 514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000; 514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/433.000; 514/452.000; 514/432.000; 514/438.000; 346/113.000; 346/114.000; 346/164.000; 346/300.000; 549/014.000; 549/050.000; 549/075.000; 549/367.000; 549/368.000; 544/002.000; 544/003.000; 544/005.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000; 544/127.000; 544/128.000; 544/162.000; 544/215.000; 544/219.000; 544/229.000; 544/235.000; 544/237.000; 544/255.000; 544/278.000; 544/311.000; 544/353.000; 544/385.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000; 548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000; 548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000; 548/486.000; 548/543.000; 548/546.000
NCL NCLM: 514/222.500
NCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000; 514/249.000; 514/255.020; 514/260.100; 514/274.000; 514/301.000; 514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000; 514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/432.000; 514/433.000; 514/438.000; 514/452.000; 544/002.000; 544/003.000; 544/005.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000; 544/127.000; 544/128.000; 544/162.000; 544/215.000; 544/219.000; 544/229.000; 544/235.000; 544/237.000; 544/255.000; 544/278.000; 544/311.000; 544/353.000; 544/385.000; 546/113.000; 546/114.000; 546/164.000; 546/300.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000; 548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000; 548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000; 548/486.000; 548/543.000; 548/546.000; 549/014.000; 549/050.000; 549/075.000; 549/367.000; 549/368.000
IC [6]
ICM: A61K031-385
ICS: A61K031-445; A61K031-47; A61K031-505
EXF 549/75; 549/50; 549/14; 549/367; 549/368; 514/432; 514/438; 514/222.5;

514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8; 514/229.2;
514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258;
514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362;
514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;
514/376; 514/378; 514/379; 514/380; 514/387; 514/395; 514/415; 514/418;
514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/8; 544/53;
544/63; 544/65; 544/66; 544/67; 544/90; 544/91; 544/127; 544/128;
544/162; 544/215; 544/219; 544/229; 544/235; 544/237; 544/255; 544/278;
544/311; 544/353; 544/385; 546/113; 546/114; 546/164; 546/300; 548/123;
548/125; 548/131; 548/134; 548/145; 548/146; 548/153; 548/174; 548/207;
548/214; 548/215; 548/217; 548/221; 548/228; 548/229; 548/237; 548/240;
548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453;
548/486; 548/543; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 55 OF 78 USPATFULL on STN
AN 1998:122413 USPATFULL
TI Substituted amino alkyl compounds
IN Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5817662 19981006 <--
AI US 1995-468656 19950606 (8)
RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9
Nov 1992, now patented, Pat. No. US 5340813
DT Utility
FS Granted
LN.CNT 1358
INCL INCLM: 514/263.000
INCLS: 424/824.000; 424/825.000; 424/885.000; 424/921.000
NCL NCLM: 514/263.350
NCLS: 424/824.000; 424/825.000
IC [6]
ICM: A61K031-52
EXF 514/397; 514/263; 424/824; 424/825; 424/885; 424/921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 56 OF 78 USPATFULL on STN
AN 1998:111942 USPATFULL
TI Therapeutic compounds containing pyrimidinyl moieties
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5807862 19980915 <--
AI US 1995-478112 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 2190
INCL INCLM: 514/269.000
INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
NCL NCLM: 514/269.000
NCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-54
EXF 514/269; 514/274; 544/309; 544/310; 544/311; 544/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 57 OF 78 USPATFULL on STN
AN 1998:111941 USPATFULL
TI Amine substituted xanthinyl compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Rice, Glenn C., Seattle, WA, United States
Leung, David W., Mercer Island, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5807861 19980915 <--
AI US 1995-476911 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1713
INCL INCLM: 514/263.000
NCL NCLM: 514/263.350
NCLS: 514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220; 514/263.230
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 58 OF 78 USPATFULL on STN
AN 1998:108415 USPATFULL
TI Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5804584 19980908 <--
AI US 1995-468659 19950606 (8)
RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1554
INCL INCLM: 514/269.000
INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000
NCL NCLM: 514/269.000
NCLS: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000
IC [6]
ICM: C07D239-54
ICS: A61K031-52
EXF 514/242; 514/243; 514/269; 544/298; 544/299
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 59 OF 78 USPATFULL on STN
AN 1998:104752 USPATFULL
TI Amine substituted compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801182 19980901 <--
AI US 1995-485777 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1706
INCL INCLM: 514/269.000
INCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
NCL NCLM: 514/269.000
NCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-02
EXF 544/312; 514/269; 514/274; 514/310; 514/311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 60 OF 78 USPATFULL on STN
AN 1998:104751 USPATFULL
TI Amino alcohol substituted cyclic compounds
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801181 19980901 <--
AI US 1995-474820 19950607 (8)

RLI Division of Ser. No. US 1993-152650, filed on 12 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993
DT Utility
FS Granted
LN.CNT 2822
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000; 514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000; 514/626.000; 514/668.000; 514/669.000
NCL NCLM: 514/263.350
NCLS: 514/183.000; 514/249.000; 514/266.300; 514/274.000; 514/309.000; 514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000; 514/626.000; 514/668.000; 514/669.000
IC [6]
ICM: A01N043-00
ICS: A01N043-90; A01N043-58; A01N043-42
EXF 514/263; 514/249; 514/259; 514/265; 514/274; 514/309; 514/315; 514/418; 514/425; 514/617; 514/619; 514/626; 514/668; 514/669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 61 OF 78 USPATFULL on STN
AN 1998:98932 USPATFULL
TI DHA-pharmaceutical agent conjugates of taxanes
IN Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5795909 19980818 <--
AI US 1996-651312 19960522 (8)
DT Utility
FS Granted
LN.CNT 2451
INCL INCLM: 514/449.000
INCLS: 514/549.000
NCL NCLM: 514/449.000
NCLS: 514/549.000
IC [6]
ICM: A61K031-335
ICS: A61K031-22
EXF 514/449; 514/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 62 OF 78 USPATFULL on STN
AN 1998:88470 USPATFULL
TI ***VEGF*** gene transfer into endothelial cells for vascular prosthesis
IN Pratt, Richard E., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
PA The Board of Trustees of the Leland Stanford Junior Univ., Palo Alto, CA, United States (U.S. corporation)
PI US 5785965 19980728 <--
AI US 1996-647821 19960515 (8)
DT Utility
FS Granted
LN.CNT 905
INCL INCLM: 424/093.210
INCLS: 424/093.100; 424/093.200; 435/172.300; 435/325.000
NCL NCLM: 424/093.210
NCLS: 424/093.100; 424/093.200; 435/325.000; 435/455.000; 435/456.000
IC [6]
ICM: A01N063-00
ICS: C12N015-00
EXF 600/36; 623/1; 623/11; 623/12; 435/172.3; 435/240.2; 435/320.1; 435/325; 424/93.21; 424/93.1; 424/93.2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 63 OF 78 USPATFULL on STN
AN 1998:82763 USPATFULL
TI Hydroxyl-containing xanthine compounds
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5780476 19980714 <--
AI US 1995-468660 19950606 (8)
RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1672
INCL INCLM: 514/263.000
INCLS: 544/267.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
ICS: C07D473-04
EXF 514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 64 OF 78 USPATFULL on STN
AN 1998:79344 USPATFULL
TI Method for preparing substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5777117 19980707 <--
AI US 1995-472569 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned , said Ser. No. US -152650 which is a continuation-in-part of Ser. No. US -40820
DT Utility
FS Granted
LN.CNT 3153
INCL INCLM: 544/267.000
INCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000; 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
NCL NCLM: 544/267.000
NCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000; 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
IC [6]
ICM: C07D473-10
ICS: C07D239-80; C07D211-94; C07D209-48
EXF 544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243; 546/246; 548/477; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 65 OF 78 USPATFULL on STN
AN 1998:79342 USPATFULL
TI Acetal-and ketal-substituted pyrimidine compounds
IN Leigh, Alistair, Brier, WA, United States
Underiner, Gail, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5777115 19980707 <--
AI US 1994-193331 19940207 (8)
RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1632
INCL INCLM: 544/242.000
INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
NCL NCLM: 544/242.000
NCLS: 544/267.000
IC [6]
ICM: C07D239-26
ICS: A61K031-505
EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 66 OF 78 USPATFULL on STN
AN 1998:72634 USPATFULL
TI Prevention and treatment of cardiovascular pathologies
IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England

Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
Weissberg, Peter L., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5770609 19980623 <--
AI US 1995-486334 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 4318
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
IC [6]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/651; 514/324; 514/212; 514/422; 514/428; 514/444; 514/448; 514/319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 67 OF 78 USPATFULL on STN
AN 1998:72620 USPATFULL
TI Oxime substituted therapeutic compounds
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5770595 19980623 <--
AI US 1994-193344 19940207 (8)
RLI Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2183
INCL INCLM: 514/263.000
INCLS: 544/271.000; 544/273.000
NCL NCLM: 514/263.350
NCLS: 514/151.000; 544/271.000; 544/273.000
IC [6]
ICM: M61K031-52
EXF 514/263; 544/271; 544/273

L7 ANSWER 68 OF 78 USPATFULL on STN
AN 1998:51651 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5750575 19980512 <--
AI US 1995-475721 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3115
INCL INCLM: 514/617.000
INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
NCL NCLM: 514/617.000
NCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
IC [6]
ICM: A61K031-165
ICS: A61K031-135; C07C233-35; C07C215-20
EXF 564/355; 564/182; 564/361; 514/617; 514/653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 69 OF 78 USPATFULL on STN
AN 97:114932 USPATFULL
TI Suppression of nitric oxide production by osteopontin
IN Denhardt, David T., Bridgewater, NJ, United States
Hwang, Shiaw-Min, Piscataway, NJ, United States
Heck, Diane Elaine, Rumson, NJ, United States
Lopez, Cecilia Ang, North Brunswick, NJ, United States
Laskin, Debra L., Basking Ridge, NJ, United States
Laskin, Jeffrey D., Piscataway, NJ, United States
PA Rutgers University, Piscataway, NJ, United States (U.S. corporation)
University of Medicine & Dentistry of NJ, Newark, NJ, United States
(U.S. corporation)
PI US 5695761 19971209 <--
AI US 1993-173116 19931223 (8)
DT Utility
FS Granted
LN.CNT 1552
INCL INCLM: 424/184.100
INCLS: 424/085.500; 424/278.100; 530/351.000; 530/330.000; 530/326.000;
530/300.000; 514/002.000; 514/012.000
NCL NCLM: 424/184.100
NCLS: 424/085.500; 424/278.100; 514/002.000; 514/012.000; 530/300.000;
530/326.000; 530/330.000; 530/351.000
IC [6]
ICM: A01N037-18
ICS: A61K038-00; A61K039-38; C07K002-00
EXF 424/88; 424/85.5; 424/278.1; 424/184.1; 530/351; 530/330; 530/326;
530/300; 514/2; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 70 OF 78 USPATFULL on STN
AN 97:86614 USPATFULL
TI Halogen, isothiocyanate or azide substituted xanthines
IN Leigh, Alistair, Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil, Seattle, WA, United States
Underiner, Gail, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5670506 19970923 <--
AI US 1993-42946 19930405 (8)
DT Utility
FS Granted
LN.CNT 1994
INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/141.000
NCLS: 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 544/267; 544/276; 544/272; 544/277; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 71 OF 78 USPATFULL on STN
AN 97:73601 USPATFULL
TI Compositions for inhibiting restenosis
IN Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadephia, PA, United
States (U.S. corporation)
PI US 5658894 19970819 <--
AI US 1994-345011 19941123 (8)
RLI Continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now
abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed
on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser.
No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a
continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now
abandoned , said Ser. No. US -900592 which is a continuation-in-part
of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No.
US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted
LN.CNT 1449
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 536/103.000;
530/810.000; 530/812.000; 530/813.000

NCL NCLM: 514/058.000
NCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 530/810.000; 530/812.000; 530/813.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 536/103; 530/810; 530/812; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 72 OF 78 USPATFULL on STN
AN 97:54233 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5641783 19970624 <--
AI US 1994-303842 19940908 (8)
RLI Continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
DT Utility
FS Granted
LN.CNT 3206
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000; 514/247.000; 514/248.000; 514/249.000; 514/255.000; 514/256.000; 514/258.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000; 514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000; 514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/383.000; 514/389.000; 514/394.000; 514/395.000; 514/398.000; 514/399.000; 514/401.000; 514/404.000; 514/406.000; 514/413.000; 514/415.000; 514/416.000; 514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000; 514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000; 544/162.000; 544/215.000; 544/216.000; 544/219.000; 544/220.000; 544/224.000; 544/235.000; 544/239.000; 544/254.000; 544/255.000; 544/257.000; 544/262.000; 544/272.000; 544/277.000; 544/278.000; 544/280.000; 544/283.000; 544/286.000; 544/301.000; 544/311.000; 544/335.000; 544/336.000; 544/350.000; 544/353.000; 544/385.000; 544/401.000; 546/102.000; 546/113.000; 546/114.000; 546/115.000; 546/117.000; 546/118.000; 546/119.000; 546/122.000; 546/138.000; 546/139.000; 546/150.000; 546/153.000; 546/157.000; 546/164.000; 546/176.000; 546/178.000; 546/242.000; 546/243.000; 546/246.000; 546/264.000; 546/300.000; 546/334.000; 548/100.000; 548/123.000; 548/125.000; 548/127.000; 548/128.000; 548/131.000; 548/134.000; 548/146.000; 548/153.000; 548/179.000; 548/186.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/225.000; 548/228.000; 548/229.000; 548/235.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000; 548/252.000; 548/267.200; 548/267.800; 548/303.700; 548/306.400; 548/307.100; 548/309.700; 548/319.100; 548/323.500; 548/340.100; 548/348.100; 548/349.100; 548/356.100; 548/370.100; 548/375.100; 548/379.400; 548/452.000; 548/453.000; 548/470.000; 548/482.000; 548/485.000; 548/486.000; 548/491.000; 548/503.000; 548/532.000; 548/543.000; 548/546.000; 548/550.000; 548/565.000; 548/566.000
NCL NCLM: 514/263.350
NCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000; 514/247.000; 514/248.000; 514/249.000; 514/252.160; 514/256.000; 514/259.500; 514/264.100; 514/266.300; 514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000; 514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000;

514/381.000; 514/383.000; 514/389.000; 514/394.000; 514/395.000;
514/398.000; 514/399.000; 514/401.000; 514/404.000; 514/406.000;
514/413.000; 514/415.000; 514/416.000; 514/418.000; 514/423.000;
514/424.000; 514/425.000; 514/427.000; 514/428.000; 544/001.000;
544/002.000; 544/003.000; 544/008.000; 544/053.000; 544/063.000;
544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000;
544/162.000; 544/215.000; 544/216.000; 544/219.000; 544/220.000;
544/224.000; 544/235.000; 544/239.000; 544/254.000; 544/255.000;
544/257.000; 544/262.000; 544/272.000; 544/277.000; 544/278.000;
544/280.000; 544/283.000; 544/286.000; 544/301.000; 544/311.000;
544/335.000; 544/336.000; 544/350.000; 544/353.000; 544/385.000;
544/401.000; 546/102.000; 546/113.000; 546/114.000; 546/115.000;
546/117.000; 546/118.000; 546/119.000; 546/122.000; 546/138.000;
546/139.000; 546/150.000; 546/153.000; 546/157.000; 546/164.000;
546/176.000; 546/178.000; 546/242.000; 546/243.000; 546/246.000;
546/264.000; 546/300.000; 546/334.000; 548/100.000; 548/123.000;
548/125.000; 548/127.000; 548/128.000; 548/131.000; 548/134.000;
548/146.000; 548/153.000; 548/179.000; 548/186.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/225.000;
548/228.000; 548/229.000; 548/235.000; 548/237.000; 548/240.000;
548/241.000; 548/243.000; 548/247.000; 548/252.000; 548/267.200;
548/267.800; 548/303.700; 548/306.400; 548/307.100; 548/309.700;
548/319.100; 548/323.500; 548/340.100; 548/348.100; 548/349.100;
548/356.100; 548/370.100; 548/375.100; 548/379.400; 548/452.000;
548/453.000; 548/470.000; 548/482.000; 548/485.000; 548/486.000;
548/491.000; 548/503.000; 548/532.000; 548/543.000; 548/546.000;
548/550.000; 548/565.000; 548/566.000

IC [6]
ICM: A61K031-415
ICS: A61K031-42; A61K031-425; A61K031-52
EXF 544/272; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 73 OF 78 USPATFULL on STN
AN 97:5708 USPATFULL
TI Method for identifying an agent which increases TGF-beta levels
IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5595722 19970121 <--
AI US 1995-476735 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned And Ser. No. US 1994-241844, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 4090
INCL INCLM: 424/009.200
NCL NCLM: 424/009.200
IC [6]
ICM: A61K049-00
EXF 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 74 OF 78 USPATFULL on STN
AN 96:53051 USPATFULL
TI Extraluminal regulation of the growth and repair of tubular structures in vivo
IN Edelman, Elazer R., Brookline, MA, United States
Adams, David H., Boston, MA, United States
Karnovsky, Morris J., Newton Centre, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5527532 19960618 <--
AI US 1993-105903 19930902 (8)
RLI Continuation-in-part of Ser. No. US 1991-656182, filed on 27 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-436337, filed on 13 Nov 1989, now abandoned
DT Utility
FS Granted
LN.CNT 940
INCL INCLM: 424/422.000
INCLS: 424/423.000; 424/426.000; 424/430.000

NCL NCLM: 424/422.000
NCLS: 424/423.000; 424/426.000; 424/430.000
IC [6]
ICM: A61K009-12
EXF 424/422; 424/423; 424/426; 424/430; 514/56; 514/423; 514/12

L7 ANSWER 75 OF 78 USPATFULL on STN
AN 95:105868 USPATFULL
TI Cell signaling inhibitors
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5470878 19951128 <--
AI US 1993-164081 19931208 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2665
INCL INCLM: 514/558.000
INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000; 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000; 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
NCL NCLM: 514/558.000
NCLS: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000
IC [6]
ICM: A61K031-20
ICS: C07C233-00
EXF 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198; 564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552; 514/529; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 76 OF 78 USPATFULL on STN
AN 94:93338 USPATFULL
TI Methods for treating arteriosclerosis
IN Halperin, Jose, Brookline, MA, United States
Brugnara, Carlo, Newton Highlands, MA, United States
PA President and Fellows of Harvard University, Cambridge, MA, United States (U.S. corporation)
PI US 5358959 19941025 <--
AI US 1993-18835 19930218 (8)
DT Utility
FS Granted
LN.CNT 539
INCL INCLM: 514/396.000
INCLS: 514/399.000; 514/824.000
NCL NCLM: 514/396.000
NCLS: 514/399.000; 514/824.000
IC [5]
ICM: A61K031-415
EXF 514/396; 514/399; 514/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 77 OF 78 USPATFULL on STN
AN 91:84437 USPATFULL
TI Method for preventing tissue damage after an ischemic episode
IN Sheffield, Warren D., Lebanon, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 5057494 19911015 <--
AI US 1988-227579 19880803 (7)
DT Utility
FS Granted
LN.CNT 487
INCL INCLM: 514/012.000
INCLS: 514/021.000
NCL NCLM: 514/012.000

NCLS: 514/021.000
IC [5]
ICM: A61K037-02
ICS: A61K037-36
EXF 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 78 OF 78 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2000-256866 [22] WPIDS
DNC C2000-078440
TI Hydrogel compositions useful for controlled delivery of growth factors e.g. in treatment of ischemia and in wound healing.
DC A11 A25 A96 B04 B07
IN JENNINGS, R N; PROTTER, A A; WANG, Y J; YANG, B
PA (SCIO-N) SCIOS INC
CYC 87
PI WO 2000013710 A2 20000316 (200022)* EN 27 A61K047-10 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW
AU 9959095 A 20000327 (200032) <--
EP 1107791 A2 20010620 (200135) EN A61K047-10
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
US 6331309 B1 20011218 (200205) A61F013-00
JP 2002524425 W 20020806 (200266) 33 A61K038-22
AU 758178 B 20030320 (200329) A61K047-10
ADT WO 2000013710 A2 WO 1999-US20382 19990903; AU 9959095 A AU 1999-59095 19990903; EP 1107791 A2 EP 1999-946759 19990903, WO 1999-US20382 19990903; US 6331309 B1 Provisional US 1998-99168P 19980904, US 1999-390164 19990903; JP 2002524425 W WO 1999-US20382 19990903, JP 2000-568516 19990903; AU 758178 B AU 1999-59095 19990903
FDT AU 9959095 A Based on WO 2000013710; EP 1107791 A2 Based on WO 2000013710; JP 2002524425 W Based on WO 2000013710; AU 758178 B Previous Publ. AU 9959095, Based on WO 2000013710
PRAI US 1998-99168P 19980904; US 1999-390164 19990903
IC ICM A61F013-00; A61K038-22; A61K047-10
ICS A61K009-10; A61K009-70; A61K038-18; A61K047-26; A61K047-32; A61K047-34; A61K047-36; A61P009-10; A61P017-02
STN INTERNATIONAL LOGOFF AT 08:59:43 ON 15 OCT 2004